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Abstract 
Circulating	 tumour	 cells	 (CTCs)	 –	 cancer	 cells	 which	 have	 shed	 from	 the	primary	cancer	into	the	bloodstream	–	can	be	enriched	from	whole	blood	and	serve	as	a	non-invasive	and	economical	 ‘liquid	biopsy’.	The	cell	phenotype	switch	 from	 epithelial	 to	 mesenchymal	 –	 called	 epithelial-mesenchymal	transition	 (EMT)	 –	 plays	 an	 important	 role	 in	 metastasis	 and	 has	 more	recently	been	proposed	to	play	an	important	role	in	developing	resistance	to	chemotherapy.	Enriched	CTCs	may	then	be	characterised	to	provide	clinical	insight	 into	the	patient’s	cancer	to	identify	biomarkers	of	drug	response	in	real-time.	 The	 conventional	 strategy	 for	 isolating	 CTCs	 relies	 upon	 the	immunomagnetic	targeting	of	cell	surface	marker	EpCAM.	However,	EpCAM	heterogeneity	 and	 downregulation	 is	 a	 hallmark	 of	 EMT,	 suggesting	 the	conventional	 CTC	 isolation	 strategies	may	miss	 EMT-CTC	populations	 that	contribute	to	drug	resistance.	Thus,	there	is	an	inherent	necessity	to	capture	more	 representative	 populations	 of	 CTCs	 in	 order	 to	 understand	 to	 what	extent	EMT	contributes	to	CTC	formation,	metastasis	and	resistance.	
In	this	study,	we	demonstrated	that	the	combined	immunomagnetic	targeting	of	epithelial	marker	EpCAM	and	mesenchymal	marker	N-cadherin	improved	CTC	 isolation	 in	 advanced	 ovarian	 cancer	 patients	 meanwhile	 enriching	epithelial-mesenchymal	 transition	 (EMT)	 CTC	 populations.	 We	 then	expanded	 our	 EMT-CTC	 detection	 methods	 to	 include	 other	 cancer	 types	including	non-small	cell	lung	cancer	(NSCLC),	and	metastatic	prostate	cancers.	By	expanding	the	improved	CTC	isolation	assay	we	developed	to	a	range	of	epithelium-derived	 cancer	 types,	 we	 demonstrated	 that	 the	 combined	
		
	xvi		
EpCAM	 and	N-cadherin	 targeting	 improved	 CTC	 isolation	 in	 the	 advanced	cancer	 setting	 as	 well.	 Additionally,	 isolated	 CTCs	 were	 for	 the	 first	 time	observed	 at	 the	 ultrastructural	 level,	 identifying	 key	 structures	 indicating	tumour	cell	origin.	Following	this	we	investigated	other	cancer	types	that	are	void	of	EpCAM	expression,	in	this	case	melanoma.	We	developed	a	method	to	isolate	and	detect	melanoma	patient	CTCs	using	combined	MCAM	and	MCSP	immunomagnetic	targeting	and	subsequent	detection	by	utilising	a	panel	of	melanoma-specific	markers.		We	additionally	probed	melanoma	patient	CTCs	for	the	clinically	relevant	biomarker	PD-L1	–	which	to	our	knowledge	is	also	a	 world	 first	 –	 that	 may	 serve	 as	 a	 diagnostic	 tool	 to	 determine	 patient	response	to	PD-1	inhibitor	therapy.		
Collectively,	 these	 data	 provide	 a	 framework	 for	 EMT-CTC	 detection	 and	analysis	in	ovarian,	prostate	and	NSCLC	cancer	patients	that	may	improve	the	robustness	of	CTC	analyses	leading	to	the	improvement	of	our	understanding	of	the	translational	value	of	patient	CTCs.	These	data	may	also	contribute	to	future	research	into	understanding	the	biological	role	EMT-CTC	populations	play	in	seeding	metastasis	and	developing	resistance	to	therapy.	Finally,	the	melanoma	CTC	isolation	and	PD-L1	detection	assay	established	here	set	the	foundations	for	an	ongoing	longitudinal	study	investigating	the	utility	of	PD-L1	biomarker	detection	 in	melanoma	patient	CTCs	 in	determining	 therapy	response.	
	  
1		
Chapter 1  Literature Review 
Parts	of	this	chapter	were	published	in	InTech,	Tumour	Metastasis	as	part	of	an	invited	book	chapter	(1)	(see	Appendix	2)	
1.1 Introduction The	spread	of	cancer	cells	from	the	primary	tumour	to	surrounding	tissues	and	distant	organs	–	the	process	also	known	as	metastasis	–	is	the	main	cause	of	death,	accounting	for	~90%	of	cancer	patient	deaths	(2-4).	For	cancer	cells	to	metastasize,	a	multi-step	sequence	of	events	must	occur:	 initial	 invasion	into	 the	 surrounding	 tissues,	 intravasation	 into	 the	 microvasculature	 and	eventually	 larger	 blood	 vessels,	 survival	 during	 haematogenous	 transit,	adherence	to	blood	vessels	at	distant	sites,	and	finally,	extravasation,	where	they	may	form	secondary	tumours	or	metastases	(5,	6).		
For	cancer	cells	to	enter	or	initiate	the	metastatic	cascade,	they	must	acquire	migratory	and	invasive	capabilities	that	enable	them	to	degrade	or	migrate	through	the	surrounding	extracellular	matrix	and	tissues	to	ultimately	enter	the	circulation	(5,	6).	One	proposed	mechanism	enabling	the	acquisition	of	invasive	and	migratory	characteristics	is	a	phenotype	switch	when	a	cancer	cell	 that	 normally	 expresses	 epithelial	 characteristics	 acquires	 more	mesenchymal	 characteristics,	 also	 called	 the	 epithelial-mesenchymal	transition	(EMT).	EMT	is	a	biological	mechanism	that	normally	occurs	during	physiological	 organ	 formation	 in	 embryogenesis	 (7-9).	 Cancer	 cells	 hijack	these	EMT	processes	in	the	early	stages	of	the	metastatic	cascade	that	enable	them	 to	 shed	 from	 the	 original	 tumour	 and	 invade	 into	 the	 surrounding	tissues	or	bloodstream	(10).	Following	intravasation	into	the	blood	vessels,	
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these	 cells	 persist	 as	 circulating	 tumour	 cells	 (CTCs)	 for	 a	 time	 and	 may	subsequently	go	on	to	extravasate	at	distant	sites	and	seed	metastases.		
In	addition	to	the	acquisition	of	 invasiveness	and	mobility,	 the	presence	of	EMT,	as	determined	from	histological	tissues	from	biopsies	or	the	resection	specimen,	 is	 associated	 with	 chemotherapeutic	 resistance	 (11-16).	 While	EMT	characteristics	have	been	detected	 in	CTCs	 in	 recent	years	 (hereafter	called	EMT-CTCs),	 the	clinical	significance	of	EMT-CTCs	has	not	yet	clearly	been	established	(17-19).	
A	number	of	studies	have	demonstrated	that	CTCs	have	prognostic	utility;	the	presence	of	>5	CTCs	per	volume	of	blood	is	indicative	of	poor	overall	survival,	cancer	progression	or	poor	therapeutic	response	(20-22).	In	breast	cancer,	high	CTC	counts	are	associated	with	poor	prognosis;	patients	with	³5	CTCs	per	7.5	mL	of	blood	have	a	median	survival	of	10.1	months	in	comparison	to	those	with	<5	CTCs	per	7.5	mL	of	blood,	where	the	median	survival	 is	>18	months	 (23).	 In	 prostate	 cancer,	 the	 utility	 of	 CTCs	 is	 just	 as	 impressive;	patients	with	a	CTC	count	>5	have	a	median	survival	of	19.5	months,	whereas	those	with	 <5	 CTCs	 have	 a	median	 survival	 of	 >30	months	 (24).	 In	 other	cancers,	CTC	counts	 also	 seem	 to	have	prognostic	power	 (25-32).	 It	 is	not	clear	 whether	 CTC	 counts	 also	 have	 predictive	 power	 (i.e.	 the	 ability	 to	predict	 response	 to	 a	 therapeutic	 agent),	 and	 studies	 are	 ongoing.	Nevertheless,	the	appearance	of	CTCs	some	time	after	definitive	therapy	for	localised	 cancer	 seems	 to	 portend	 recurrence	 (33-36).	 At	 present,	 studies	based	on	CTC	positivity	 (patients	with	CTCs	detected	 from	 liquid	biopsies,	compared	to	no	CTCs	detected)	to	stratify	for	selected	patient	populations	are	
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being	conducted.	Emerging	data	suggest	that	CTCs	have	great	potential	to	be	used	as	a	standard	test	in	the	clinic,	though	key	data	from	pivotal	trials	are	yet	to	be	presented.	
	Given	the	range	of	methodologies	available	to	detect	CTCs,	it	is	not	clear	that	any	one	approach	is	ideal.	The	main	issue	appears	to	be	too	much	sensitivity	(thereby	 detecting	 false	 positive	 cancer	 cells	 in	 the	 blood),	 or	 too	 little	specificity	(thereby	missing	true	CTCs	 in	 the	blood),	regardless	of	whether	the	method	 used	 is	 physical	 (e.g.	 size-based	 exclusion)	 or	 antibody-based	capture	(e.g.	Epithelial	cell	adhesion	molecule	(EpCAM)).	Recently,	there	has	been	 increasing	 focus	 on	 investigation	 of	 the	 role	 that	 EMT	 plays	 in	 CTC	formation	and	the	metastatic	process	(19,	37-39).	The	ability	to	detect	EMT-CTCs	 may	 aid	 in	 detecting	 a	 higher	 (true)	 count	 that	 could	 increase	 the	sensitivity	of	CTC	tests	generally	and	show	CTCs	to	be	more	prevalent	than	current	 evidence	 shows.	 Moreover,	 EMT-CTCS	 may	 be	 an	 important	assessable	biomarker	of	chemoresistance	in	epithelium-derived	cancers	that	can	be	readily	translated	into	clinical	practice.	
	
1.2 Circulating tumour cells (CTCs) CTCs	are	tumour	cells	that	intravasate	into	the	bloodstream	and	are	thought	to	 form	 metastases	 after	 resettling	 in	 distant	 tissue	 (40).	 It	 is	 commonly	understood	that	EMT	is	one	of	the	primary	mechanisms	which	cancers	cells	use	to	dissociate	from	the	original	tumour	and	enter	the	bloodstream	(41).	The	most	common	platform	used	for	CTC	isolation,	called	CellSearch	(Silicon	Biosystems),	 relies	 upon	 the	 immunomagnetic	 targeting	 of	 cell	 surface	
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marker	 EpCAM,	 a	 common	 protein	 expressed	 in	 carcinomas.	 Critically,	following	enrichment,	CTCs	must	be	distinguished	from	residual	white	blood	cells	by	immunofluorescence	identification	staining	positive	for	cytoplasmic	cytokeratin	and	negative	for	white	blood	cell	marker	CD45.	CellSearch	is	the	only	platform	to	have	been	granted	FDA	approval	for	CTC	enumeration	and	subsequent	 patient	 prognostication.	 The	 potentially	 powerful	 clinical	application	of	a	simple	and	economical	blood	test	to	acquire	tumour-derived	material	 (also	 called	 “liquid	 biopsies”)	 has	 brought	 CTC	 analysis	 to	 the	forefront	 of	 translational	 research.	 Since	 the	 approval	 of	 the	 CellSearch	platform,	many	alternative	methods	of	CTC	isolation	have	been	explored	to	improve	isolation	efficiencies,	with	the	aim	of	enriching	the	CTC	population	within	liquid	biopsies	based	on	biological	or	physical	properties	(42,	43).		
	
1.3 Current approaches to CTC isolation CTCs	were	 first	 discovered	 in	 1869	when	 the	Australian	 scientist	 Thomas	Ashworth	noticed	during	an	autopsy	that	cells	in	circulation	appeared	similar	in	morphology	to	the	cells	from	the	patient’s	tumour	(44).	However,	it	wasn't	until	 2008	 that	 the	 first	 CTC	 isolation	 and	 identification	 platform	 was	approved	for	clinical	use,	stratifying	patients	with	³5	CTCs	/	7.5mL	with	an	unfavourable	prognosis	in	metastatic	breast,	prostate	and	colorectal	patients	(45).	 The	 CellSearch	 system	 positively	 selects	 out	 CTCs	 through	immunomagnetic	 targeting	 of	 the	 cell	 surface	 marker	 EpCAM	 and	intracellular	expression	of	cytokeratin	(46).	Notably,	this	relies	on	epithelial	characteristics	alone,	limiting	detection	of	non-epithelial	marker	expressing	
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CTCs,	as	 found	 in	sarcoma,	glioblastoma	multiforme	(GBM)	and	melanoma	patients	for	example	(47).	Accordingly,	CTC	isolation	methods	have	expanded	to	 try	 to	 account	 for	 cancer	 cell	 heterogeneity,	 using	 an	 array	 of	 different	methods	 to	 enrich	 CTCs	 from	patient	 blood	 samples	 (42,	 43,	 45,	 48).	 CTC	enrichment	 is	 achieved	 by	 discriminating	 cells	 based	 on	 their	 biological	properties	–	particularly	antigenicity	–	or	their	physical	properties	including	density,	dielectric	properties	or	size	and	deformability	(see	Figure	1.1).	
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Figure	 1.1	 CTC	 isolation	 from	 whole	 blood	 based	 on	 biological	 or	
physical	 properties.	CTC	 isolation	 based	 on	 biological	 (A,	 B)	 or	 physical	properties	(C-F),	including	antigenicity	by	either	(A)	positive-selection	or	(B)	negative-depletion;	 or	 (C)	 density	 gradient	 centrifugation,	 (D)	 dielectrical	charge,	(E)	size	and	deformability	or	(F)	size	and	inertia.		
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1.3.1 Antigenicity-based CTC isolation 
Isolating	CTCs	based	on	antigenicity	is	achieved	by	either	positively	selecting	cancer-specific	 cell	 surface	 markers	 such	 as	 the	 conventional	 epithelial	marker	 EpCAM,	 or	 as	 a	 polarising	 example,	 EMT-marker	 vimentin	 (49).	Alternatively,	 some	 studies	 report	 the	 immunomagnetic	 targeting	 of	 cell	surface	markers	EGFR,	HER2,	TROP-2	and	MUC-1	(48).	Samples	may	also	be	subject	to	immunomagnetic	depletion	by	targeting	cell	surface	markers	such	as	CD45,	CD66b	or	CD144	on	white	blood	cells/endothelial	cells	(50).		
	
1.3.2 Density centrifugation CTC isolation 
Layering	blood	over	a	dense	gradient	solution	–	such	as	Ficoll	or	Lymphoprep	–	 followed	by	 centrifugation	 allows	 for	 separation	 of	 the	 peripheral	 blood	mononuclear	 cells	 (PBMCs)	 based	 on	 differential	 densities	 between	haematopoietic	 cells	 while	 removing	 high	 density	 red	 blood	 cells	 and	granulocytes.	 This	 often	 precedes	 positive/negative	 immunomagnetic	enrichment,	 and	 offers	 a	 relatively	 quick	 method	 of	 enriching	 CTCs	 from	blood	samples,	but	some	CTCs	may	be	lost	in	the	plasma	or	through	clusters	settling	in	lower	gradients	(51,	52).	
	
1.3.3 Size-based CTC isolation - filtration 
Size-based	cell	separation	relies	on	the	fundamental	size	differences	between	white	 blood	 cells	 and	 CTCs,	 utilising	 porous	 membrane	 filters	 ranging	
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between	8-12	micron	to	‘catch’	CTCs	while	allowing	red	blood	cells	and	white	blood	cells	to	pass	freely	through.	The	primary	advantage	of	this	methodology	is	the	label-free	enrichment	of	patient	CTCs	and	potential	application	to	any	cancer	type,	since	no	specific	cell	surface	recognition	is	required.	However,	CTC	size	variability	means	inevitable	loss	of	CTCs	smaller	than	the	filter	pore	size	(53,	54).	
	
1.3.4 Size-based CTC isolation - inertia 
Similar	 to	 filter-based	 isolation,	 inertia-based	 platforms	 achieve	 cell	separation	by	passively	separating	cells	based	on	size,	exerting	inertial	forces	on	cells	and	manipulating	their	position	within	a	microfluidic	channel.	That	is,	smaller	cells	will	migrate	along	the	outer	wall	of	the	microfluidic	channel	while	the	theoretically	larger	and	heavier	CTCs	will	travel	along	the	inner	wall.	This	method	allows	for	label-free	isolation	and	high	throughput	processing,	but	results	can	be	affected	by	the	cell	concentration	within	the	sample	and	cell	size	heterogeneity	(55,	56).	
	
1.3.5 Dielectrophoresis 
CTC	 isolation	 based	 on	 dielectrical	 properties	 relies	 on	 the	 interaction	between	the	electric	field	spatial	gradient	and	the	CTCs	dipole.	The	variable	dielectrical	 properties	 of	 biological	 cells	 allows	 dielectrophoresis	 to	manipulate	CTCs	and	separate	them	from	peripheral	blood	cells	by	applying	
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an	 electric	 field.	 	 The	 low	 fluid	 velocity	 required	 for	 dielectrophoresis	separation	limits	the	speed	of	sample	processing	(57).	
Not	surprisingly,	the	potential	for	utilisation	of	CTC	analysis	in	the	clinic	has	garnered	attention	from	commercial	entities,	subsequently	driving	platform	development	encompassing	many	possible	methods	for	CTC	enrichment	(see	Table	1.1	for	summary	of	commercial	CTC	isolation	platforms	[adapted	from	(48)]).		
	
1.4 Downstream analysis of patient CTCs After	 enrichment	 or	 single	 cell	 isolation,	 CTCs	 can	 be	 successfully	 further	analysed	 to	 provide	 information	 regarding	 protein	 expression,	 point	mutations,	 gene	 amplifications	 and	 expression	 as	 well	 as	 the	 presence	 of	fusion	genes	(reviewed	by	(58-60)).	More	recently,	efforts	are	moving	 into	high	 resolution	 structural	 imaging	 of	 CTCs.	While	 some	 success	 has	 been	made	 to	 detect	 CTCs	 by	 confocal	 and	 high-resolution	microscopy	 –	which	illustrated	structures	such	as	cytoskeletal	bridges	and	microtentacles	–	initial	steps	have	been	made	to	investigate	CTCs	using	electron	microscopy	imaging	(61,	62).	These	studies	revealed	cell	surface	structures	such	as	microvilli	and	pseudopodia	 using	 scanning	 electron	microscopy	 (SEM)	 (63,	 64).	 Notably,	one	 recent	 study	 showed	 cytokeratin-positive	 spherical	 vesicles	 spanning	across	 the	 cell	 membrane	 of	 patient	 CTCs	 using	 SEM	 imaging,	 indicating	cytoskeletal	 organisation	 and	 early	 apoptosis	 (65).	 Electron	 microscopy,	broadly	 speaking,	 has	 been	 hampered	 by	 time	 consuming	 and	meticulous	sample	 processing,	 but	 nevertheless	 offers	 the	 ability	 to	 identify	 subtle	
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morphological	 changes	 that	 contribute	 to	 the	 modification	 of	 cellular	phenotype	and	behaviour.	Further	steps	into	analysing	CTC	ultrastructures	will	provide	clues	regarding	their	biology.		
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Table	1.1	Comparison	of	commercial	platforms	for	CTC	isolation	based	
on	physical	and	biological	properties	
  Technology	 Selection	criteria	
Positive	Selection	 	  
Antibodies	targeting	
tumour-associated	
antigens	are	bound	
to	immunomagnetic	
beads	or	device	
components	to	
capture	CTCs.	
CellSearch®	 EpCAM	AdnaTest	 Antibody	Cocktail	MACS	 EpCAM	MagSweeper	 EpCAM	CTC-Chip	 EpCAM	Isoflux™	 Customisable	to	any	cell	surface	marker	GILUPI	CellCollector™	 EpCAM	CSV	(84-1)	 Vimentin	
Negative	Depletion	   Antibodies	targeting	white	blood	cell	or	endothelial	cell	antigens	are	bound	to	immunomagnetic	beads	or	the	device	components	to	deplete	unwanted	residual	cells.	
EasySep™	Human	CD45	Depletion	Kit	 CD45	
CTC-iChip	 CD45,	CD66b,	Size	
Density	Gradient	
Centrifugation	
	  
Blood	layered	over	a	
dense	separation	
medium	and	
centrifuged.		Cell	
populations	will	
separate	based	on	
their	relative	
densities.	
Ficoll-Paque®	 Density	Density,	Size	 Porous	membrane	in	addition	to	separation	media	RosetteSep™	CTC	 Density,	Antibody	Cocktail	Accucyte	Enrichment	and	CyteSealer™	 Density	
Dielectric	
Properties	
  
Separates	cells	
based	on	their	
dielectrical	
properties	by	
applying	an	electric	
field.	
ApoStream®	 Electrical	Signature	
DEPArray™	 Requires	pre-enrichment,	allows	recovery	and	manipulation	of	viable,	single	cells	through	DEP	cages	
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Size	and	
Deformability:	
Filter-Based	
	 	
Size-based	cell	
separation	using	
porous	membranes	
ISET®	 Size,	Deformability	CanPatrol	 Size,	Deformability	Cell	Sieve	 Size,	Deformability	
Physical	–	Size	and	
Deformability:	
Inertia-Based	
  
Cells	are	passively	
separated	based	on	
cell	size.	Inertial	
forces	affect	
positioning	within	
the	microfluidic	
channel.	
Vortex	 Size	
ClearCell®	FX	 Size	
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1.5 EMT – a physiological process adapted by cancer cells Epithelial	 cancer	 cells	 are	 highly	 polarised	 and	 anchored	 to	 both	 the	basement	membrane	and	surrounding	epithelial	cells,	these	are	properties	of	normal	cells	that	enable	stabilisation	of	the	microenvironment	of	a	tissue	or	an	 organ.	 One	 major	 hallmark	 of	 cancer	 cells	 however,	 is	 their	 ability	 to	migrate	 and	 eventually	 establish	 metastases	 in	 distant	 organs.	 Epithelial-mesenchymal	transition	(EMT)	is	a	normal	biological	process	which	enables	epithelial	cells	to	undergo	morphologic	changes	and	attain	mesenchymal-like	characteristics	(66,	67).	This	mechanism	was	first	coined	by	Elizabeth	Hay	in	1982	as	 ‘epithelial-mesenchymal	transformation’	following	the	observation	that	epithelial	cells	suspended	in	3D	collagen	were	capable	of	transforming	into	mesenchymal	cells	(68,	69).	At	the	first	meeting	of	The	EMT	International	Association	 in	 2003,	 the	 term	 ‘transition’,	 rather	 than	 ‘transformation’	 or	‘transdifferentiation’,	was	established	(70,	71).		
EMT	 is	 broadly	 classified	 into	 three	 distinct	 categories	 that	 result	 in	 very	different	functional	endpoints:	Type	1	is	the	critical	mechanism	driving	organ	formation	during	embryogenesis,	for	example	playing	a	key	role	in	generating	the	primary	mesenchyme	which	may	 then	 further	develop	 into	connective	and	skeletal	 tissues;	Type	2	 is	 the	primary	driver	of	wound	healing	and	 is	associated	with	 inflammation	and	 in	some	cases	organ	 fibrosis;	and	 finally	Type	 3	 describes	 the	 scenario	 where	 cancer	 cells	 have	 adapted	 these	processes	 for	 their	 own	 benefit	 to	 allow	 invasiveness,	 cell	 migration,	 and	increased	expression	of	extracellular	matrix	(ECM)	components	(72).		
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The	 complex	 physiological	 changes	 that	 occur	 during	 the	 EMT	 program	require	 co-operation	 of	 a	 number	 of	 cell	 signaling	 pathways	 and	 key	regulators,	 and	 can	 be	 broadly	 categorised	 into	 effector	 molecules,	 core	regulators	and	inducers	that	activate	EMT	(72).	A	summary	of	common	EMT-associated	markers	is	listed	in	Table	1.2.	
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Table	1.2	EMT-associated	markers	
Marker	 Function	 High	Expression	Phenotype	 Reference	
Cell	Adhesion	/	Migration	
E-cadherin	 Transmembrane	protein,	cell-cell	adhesion,	adherent	junctions	 Epithelial	 (72,	73)	
Mucin-1	 Epithelial	cell	surface	glycoprotein,	adhesion,	signaling	 Epithelial	 (72)	
Syndecan-1	 Transmembrane	heparan	sulfate	proteoglycan,	adhesion,	signaling	 Epithelial	 (74)	
EpCAM	 Cell-cell	adhesion	molecule	 Epithelial	 (17)	
Cytokeratin	 Filamentous,	cytoskeletal	protein	 Epithelial	 (17)	
N-cadherin	 Transmembrane	protein,	cell-cell	adhesion,	adherent	junctions	 Mesenchymal	 (75)	
Vimentin	 Filamentous,	cytoskeletal	protein	 Mesenchymal	 (75)	
Fibronectin	 Excreted	extracellular	matrix	glycoprotein,	adhesion,	migration	 Mesenchymal	 (75)	
Cell	Signaling	
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TGF-β	 Transforming	growth	factor	beta	(TGF-β)	signaling:	proliferation,	differentiation	 Mesenchymal	 (72,	73)	
EGF/EGFR	 Epithelial	growth	factor	(EGF)	signaling:	proliferation,	survival	 Mesenchymal	 (72)	
HGF/MET	 Hepatocyte	growth	factor	(HGF)	signaling:	proliferation,	survival	 Mesenchymal	 (76)	
HER2	 Proliferation,	survival	 Mesenchymal	 (75)	
MAPK	 Mitogen	activated	phosphorylation	kinase	pathway:	proliferation,	survival	 Mesenchymal	 (73,	75,	76)	
Wnt/β-catenin	 Proliferation,	survival,	migration	 Mesenchymal	 (73,	75,	76)	
STAT3	 Proliferation,	survival,	migration	 Mesenchymal	 (73)	
Transcriptional	Regulators	
SNAI1	 Zinc-finger	E-box	transcription	factor,	cell	survival,	repressor	of	E-cadherin	 Mesenchymal	 (72,	73,	75)	
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SLUG	
Zinc-finger	E-box	transcription	factor,	cytoskeletal	regulator,	repressor	of	E-cadherin	
Mesenchymal	 (73,	75,	76)	
TWIST	 Nuclear	E-box	inhibitory	factor,	repressor	of	E-cadherin	 Mesenchymal	 (75,	76)	
ZEB1	
Zinc-finger	E-box	transcription	factor,	cell	migration	regulator,	repressor	of	E-cadherin	
Mesenchymal	 (75,	76)	
ZEB2	
Zinc-finger	E-box	transcription	factor,	cell	migration	&	proliferation	regulator,	repressor	of	E-cadherin	
Mesenchymal	 (76)	
FOXC1	 Regulator	of	developmental	processes,	activator	of	SNAI1	 Mesenchymal	 (75)	
FOXC2	 Regulator	of	developmental	processes,	activator	of	SNAI1	 Mesenchymal	 (76)	
NFkb	 Stress	response	transcription	factor,	activator	of	TWIST	 Mesenchymal	 (73,	75)	
Other/Various	Functions	
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Endothelin-1	 Activator	of	β-catenin	and	SNAI1	 Mesenchymal	 (77)	
CD133	 Physiological	regulator	of	stem	cells,	activator	of	MAPK	signaling	 Mesenchymal	 (17)	
CD44	 Transmembrane	glyco-adhesion	protein	linked	to	TGF-β	signaling	 Mesenchymal	 (73)	
CXCR4	 G	protein-coupled	transmembrane	receptor,	MAPK	and	ZEB1	activator	 Mesenchymal	 (78)	
EMT	markers	are	generally	detected	at	 the	protein	and/or	gene	expression	 level	or	transcriptome	signature	of	EMT	associated	signaling	pathways	are	defined.	
	
Effector	molecules	are	structural	proteins	that	are	typically	either	present	in	only	 epithelial	 or	 mesenchymal	 phenotypes.	 A	 feature	 of	 EMT	 is	 the	downregulation	of	effector	molecules	such	as	epithelial	proteins	E-cadherin,	
b-catenin,	 EpCAM,	 MUC1	 and	 cytokeratin,	 followed	 by	 subsequent	upregulation	of	mesenchymal	structural	and	cell	surface	proteins	such	as	N-cadherin,	vimentin,	CD44	and	 integrin	beta6	 (10,	70,	79-83).	Other	critical	effector	 molecules	 promoting	 cell	 migration	 and	 invasion	 include	 the	extracellular	protein	fibronectin,	as	well	as	autocrine	activation	of	PDGF	and	its	 receptor	 which	 in	 turn	 promotes	 migration	 through	 the	 extracellular	matrix	(84).	
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EMT	core	regulators	drive	transcriptional	alterations	in	genes	that	regulate	critical	 EMT	 characteristics	 including	 cell	 adhesion,	 mesenchymal	differentiation,	 cell	 migration	 and	 invasion.	 SNAI1	 and	 SNAI2	 of	 the	 zinc	finger	box	family	suppress	E-cadherin	transcription	by	directly	binding	to	the	E-box	in	the	promotor	region	(85-87).	Similarly,	the	E-box	binding	homeobox	family	 protein	 proteins	 ZEB1	 and	 ZEB2	 suppress	 E-cadherin	 transcription	through	 a	 double-negative	 feedback	 loop	 involving	 interactions	 between	ZEB1/2	proteins	and	microRNA-200	expression	(88,	89)	.	Both	SNAI1/2	and	ZEB1/2	 families	 have	 been	 shown	 to	 also	 repress	 epithelial	 cell	 junction	proteins,	 such	 as	 claudin	 and	 ZO-1	 (90,	 91).	 Finally,	 basic	 helix-loop-helix	family	of	transcription	factors	–	TWIST1/2	and	E12/47	–	induce	EMT	through	both	 suppression	 of	 epithelial	 protein	 expression	 as	 well	 as	 activating	signaling	pathways	associated	with	tumour	invasion	either	independently	or	synergistically	(84)	(92-94).		
Cancer	cells	are	subject	to	a	combination	of	extracellular	events	within	the	tumour	 microenvironment	 that	 are	 considered	 core	 inducers	 of	 EMT	including	 critical	 developmental	 cell	 signaling	 pathways	 including	transforming	growth	factor-beta	(TGF-b),	Wnt,	Notch,	Ras	and	growth	factor	receptor	 signaling	 pathways	 (10).	 TGF-b	 plays	 an	 important	 role	 in	 EMT,	known	to	be	a	potent	inducer	of	EMT	in	the	presence	of	Ras	signaling	(95,	96)	inducing	the	core	EMT	transcription		factors	SNAI1/2,	ZEB1/2	and	TWIST1	(84,	97).	Additionally,	inflammatory	cytokines	and	hypoxic	conditions	within	the	tumour	microenvironment	may	induce	EMT	characteristics.	It	has	been	shown	that	TNF-a,	an	inflammatory	cytokine,	prevents	the	ubiquination	and	
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degradation	of	 SNAIL1	via	 activation	of	 the	NF-	kb	 pathway	 and	may	 also	drive	TWIST1	expression	via	activation	of	the	IKK-B	and	NF-kB	p65	pathways	(98,	99).		
	
1.5.1 EMT and cell motility 
As	 outlined	 above,	 EMT	 is	 a	 complex	multi-step	 process	 involving	 various	molecular	 and	 cellular	 changes	 that	 contribute	 to	 cells	 acquiring	 EMT	phenotypes.	In	the	context	of	cancer,	EMT	has	been	reported	as	playing	an	important	 role	 in	 contributing	 to	 CTC	 formation	 by	 increasing	 the	invasiveness	 of	 cells,	 promoting	 intravasation	 into	 the	 bloodstream	 and	finally	survival	within	the	bloodstream	(see	Figure	1.2;	(1))	(10,	19,	37).	This	is	further	supported	by	decades	of	research	with	in	vitro	and	in	vivo	models,	and	more	recently,	EMT	phenotype	detection	in	CTCs	showing	an	association	between	 EMT	 phenotypes	 and	 increased	 metastatic	 potential	 as	 well	 as	tumour	 progression	 (19,	 100).	 However,	 the	 precise	 role	 EMT	 plays	 in	seeding	metastases	is	not	yet	clearly	understood.		
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Figure	1.2	EMT	involvement	 in	CTC	formation.	Simplified	 illustration	of	cells	 in	 a	 primary	 tumour	 undergoing	 EMT.	 	 Cancer	 cells	 are	 then	 able	 to	disseminate	from	the	primary	tumour,	intravasate	into	the	bloodstream	and	travel	as	CTCs	before	extravasating	the	vascular	system	and,	by	undergoing	MET,	regain	the	ability	to	settle	and	form	a	metastatic	tumour	(1).	
	
Some	studies	question	the	indispensability	of	EMT	in	the	metastatic	cascade.	One	author	noted	 that	complete	EMT	has	never	been	observed	 in	vivo	and	that	carcinoma	cells	are	intrinsically	epithelial	and	thus	never	fully	undergo	EMT	(101).	EMT	phenotypes	can	also	be	detected	 in	primary	tumours	and	CTCs,	yet	histological	examination	of	metastases	that	resemble	the	primary	tumour	 paradoxically	 show	 epithelial	 phenotypes	 (10).	 To	 reconcile	 the	seemingly	 contradictory	 studies,	 a	model	 acknowledging	 the	 dynamic	 and	reversible	 nature	 of	 EMT	 into	 a	 model	 of	 cancer	 cell	 dissemination	 and	metastatic	seeding	was	proposed	called	the	‘EMT-MET	model’	(102).	Initially,	
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cancer	cells	undergo	EMT	to	acquire	invasive	properties	and	intravasate	into	circulation,	disseminate	to	distant	sites	and	finally	the	reverse	process	called	mesenchymal-epithelial	 transition	 (MET),	 allowing	 CTCs	 to	 re-establish	epithelial	 characteristics	 such	as	 adherent	 and	proliferative	 characteristics	and	ultimately	seed	metastases	(see	Figure	1.2;	(1))(10,	37).		
Despite	 some	 controversies,	 the	 complexity	 of	 biology	 and	 dynamic	regulation	of	 EMT	make	 it	 difficult	 to	 pinpoint	 experimentally	 the	 state	 of	EMT	representative	of	the	tumour	or	metastasis,	and	the	degree	to	which	this	contributes	 to	 metastatic	 formation.	 Ultimately	 though,	 the	 acquisition	 of	EMT	characteristics	indicate	a	shift	towards	the	invasion-metastatic	cascade	–	a	fundamental	necessity	to	acquire	migratory	and	invasive	capabilities	-	and	remains	a	 critical	 step	 in	 the	 cascade	 that	 can	be	potentially	detected	as	a	biomarker	identifying	the	‘bad	actors’	in	metastatic	formation.	
	
1.5.2 EMT and therapeutic resistance 
The	effectiveness	of	therapy	is	a	major	determinant	of	patient	survival	and	is	limited	by	the	development	of	drug	resistance.	EMT	has	been	linked	to	up-regulation	 of	 anti-apoptotic	 pathways,	 and	 the	 acquisition	 of	 the	 EMT	phenotype	 is	 also	 associated	 with	 resistance	 against	 various	 therapies.	Importantly,	 EMT	phenotype	 changes	have	been	proposed	as	downstream	events	 of	 various	 oncogenic	 signaling	pathways	 and	 thus,	 EMT	expression	profiles	 are	 linked	 strongly	 to	 expression	 of	 anti-apoptotic	 pathways	 that	promote	 cell	 survival	 and	 drug	 resistance	 (75,	 103).	 More	 recently,	 EMT-
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associated	 molecular	 and	 phenotype	 changes	 following	 therapy	 have	garnered	 attention	 as	 a	 major	 driver	 of	 resistance	 (16,	 75,	 104-108).	 For	example,	 activation	 of	 notch	 signaling	 –	 a	 recognised	 key	 regulator	 and	inducer	 of	 the	 EMT	pathway	 –	 in	 the	 prostate	 cancer	 cell	 line	 LNCaP	was	associated	 with	 resistance	 to	 gemcitabine	 (109).	 One	 study	 showed	 an	increase	 in	 expression	 of	 EMT-related	 transcription	 factors	 SNAIL,	 SLUG,	TWIST2	 and	 ZEB2	 when	 comparing	 chemoresistant	 and	 sensitive	subpopulations	 derived	 from	 the	 A2780	 ovarian	 cancer	 cell	 line	 (110).	 In	MCF-7	and	MDA-MB	breast	cancer	cell	lines,	paclitaxel	treatment	resulted	in	increased	 expression	 of	 EMT-associated	 markers	 TWIST,	 vimentin,	fibronectin	and	fibronectin	as	well	as	increase	in	invasiveness	(111).	In	one	other	 study	comparing	epithelial	 and	EMT	NSCLC	cell	 lines,	EMT	cell	 lines	showed	 significantly	 greater	 resistance	 to	 EGFR	 and	 PI3K/AKt	 pathway	inhibitors	(112).		Interestingly,	suppression	of	EMT	via	knockdown	of	SNAIL	or	TWIST	in	pancreatic	mouse	models	enhanced	sensitivity	to	gemcitabine	and	increased	overall	survival	(113).	Notably,	one	study	suggests	that	EMT	is	not	 indispensable	 for	 cells	 developing	 therapy	 resistance;	 knockdown	 of	EMT-associated	markers	such	as	TWIST	in	H3122	lung	cancer	cell	line	did	not	restore	sensitivity	to	ALK	inhibitors	(114).	
Taken	together,	there	is	good	evidence	that	EMT	is	associated	with	treatment	resistance	in	many	cancers.	What	is	not	clear	is	whether	EMT	is	the	primary	driver	 of	 resistance	 or	 the	 downstream	 event	 of	 resistance.	 Clearly,	more	work	needs	to	be	done	to	understand	these	aspects.	
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1.6 CTC isolation and analysis - considerations for EMT-CTC 
isolation and detection The	 inability	of	EpCAM-based	CTC	 isolation	 to	optimally	account	 for	EMT-CTCs	with	 EpCAM	 loss	 has	 led	 to	 the	 development	 of	 platforms	 targeting	alternative	EMT-associated	 cell-surface	markers	 such	 as	 vimentin,	 for	CTC	detection,	or	instead	by	focusing	on	CTC	enrichment	due	to	physical	cancer	cell	 properties,	 mainly	 size	 exclusion	 (see	 Figure	 1.3).	 More	 importantly,	targeting	EpCAM	alone	is	limited	in	that	it	may	‘miss’	CTC	populations	that	have	 low	 or	 null	 EpCAM	 expression.	 Essentially,	 this	 may	 result	 in	underestimating	CTC	counts	and	potentially	missing	critical	subpopulations	including	EMT-CTCs	that	might	otherwise	provide	important	clinical	insights	into	the	patient’s	disease	status	(115-119).	Thus,	it	is	important	to	consider	CTC	isolation	strategies	in	order	to	enable	detection	of	EMT-CTCs	as	well	as	epithelial	 CTCs,	 to	 ensure	 that	 a	 more	 holistic	 approach	 to	 isolating	 CTC	populations	 is	 achieved,	 thereby	allowing	a	more	accurate	 insight	 into	 the	patient’s	 cancer,	 including	 for	 example,	 early	 detection	 of	 treatment	resistance.	
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Figure	 1.3	 Comparison	 of	 immunomagnetic-targeting	 CTC	 isolation	
platforms	 with	 differential	 EpCAM	 dependency.	 Representative	 CTC	isolation	platforms	detailing	the	advantages	and	pitfalls	relative	to	EpCAM-dependency.	 (A)	 CellSearch	 platform	 entirely	 dependent	 upon	 EpCAM-targeted	CTC	isolation.	(B)	Isoflux	platform	semi-dependent	of	EpCAM,	using	combination	 epithelial	 EpCAM	 and	mesenchymal	N-cadherin	 targeted	 CTC	isolation.	(C)	CSV	[84-1]	kit	entirely	independent	of	EpCAM	expression,	using	EMT	marker	cell-surface	vimentin	targeted	CTC	isolation.	
	
In	 one	 study	 directly	 comparing	 EpCAM-based	 immunomagnetic	 CTC	isolation	with	size	exclusion	CTC	enrichment	of	parallel	blood	samples	from	40	NSCLC	patients,	CTCs	were	isolated	from	a	higher	proportion	of	patients	(80%	 vs	 23%)	 by	 size	 exclusion.	 The	 isolated	 cells	 tended	 to	 lack	 EpCAM	expression,	but	they	expressed	cytokeratin	(CK)	and	had	elevated	 levels	of	
Chapter 1 Literature Review 
	26		
the	EMT-associated	epithelial	growth	factor	receptor	(EGFR)	and	thus	likely	were	tumour	cells	(120).		
Similarly,	in	another	study,	CTCs	were	enriched	from	29	breast	cancer	patient	samples	using	EpCAM-based	CTC	enrichment	with	the	CellSearch	platform.	The	 EpCAM	 based	 CTC	 capture	 was	 followed	 by	 another	 round	 of	immunomagnetic	 cell	 enrichment,	 this	 time	 targeting	 different	 cancer-associated	 cell	 surface	 markers:	 Trop2,	 CD49f,	 c-Met,	 CK8	 and	 HA.	 This	strategy	enriched	further	cells	that	were	defined	as	CTCs	due	to	cytokeratin	and	DAPI	staining	but	lack	of	CD45,	indicating	that	EpCAM	alone	based	CTC	isolation	may	miss	cells.	(47).	
An	 elegant	 approach	 to	 account	 for	 the	CTCs	missed	during	EpCAM-based	capture	 in	 HER2-	 positive	 breast	 cancer	 patients	 utilised	 CD45	immunomagnetic	depletion	of	blood	cells	after	an	initial	EpCAM-based	CTC	capture,	 to	 further	 enrich	 the	 remaining	 EpCAM-negative	 CTCs.	 The	 EMT-linked	transcription	factors	SNAI1	and	ZEB1	were	more	commonly	expressed	in	these	EpCAM-negative	cells	compared	to	the	EpCAM	isolated	counterparts	(121).	Vimentin,	best	known	for	its	function	as	a	cytoskeletal	support	protein,	can	also	be	present	on	 the	cell	 surface	of	mesenchymal	cells	and	has	been	successfully	 targeted	 in	 immunomagnetic	 isolation	of	CTCs	 from	colorectal	cancer	 patients	 and	 breast	 cancer	 patients.	 After	 CD45	 immunodepletion,	CTCs	were	positively	selected	with	cell-surface	vimentin	(CSV)	targeting.	The	authors	 suggest	 that	 CSV	 expression	 is	 restricted	 to	 cancer	 cells,	 and	 CSV	targeting	 isolates	 significantly	 more	 CTCs	 from	 colorectal	 cancer	 patients	with	progressive	disease	 than	 those	with	 stable	disease;	moreover,	 higher	
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CSV-CTC	counts	were	more	commonly	found	in	therapy-resistant	patients.	In	a	direct	comparison	of	CSV-	and	EpCAM-based	CTC	isolation	(CellSearch	CTC	platform)	in	breast	cancer	patients,	CTCs	isolated	with	CSV	targeting	were	a	more	reliable	marker	for	progressive	disease	compared	to	stable	disease.	In	both	CSV-isolated	breast	and	colorectal	cancer	CTCs,	the	EMT	markers	FOXC2,	SNAIL,	TWIST1	and	SLUG	tended	to	be	highly	expressed	while	E-cadherin	and	EpCAM	levels	were	low	(122,	123).	A	study	that	investigated	gene	expression	in	ovarian	cancer	CTCs	showed	the	expression	 of	 EMT	 markers	 in	 most	 individual	 CTCs	 from	 three	 patients,	while	only	30%	of	these	cells	also	expressed	epithelial	CK5	or	CK7.	However,	all	CTCs	expressed	the	epithelial	antigen	MUC1	[28].	In	a	patient	with	non-small	 cell	 lung	 cancer	 who	 was	 CTC-negative	 according	 to	 EpCAM-based	(CellSearch)	 enrichment,	 it	 is	 worth	 noting	 that	 CTCs	 enriched	 by	 CD45	depletion	were	tumourigenic	in	mice	and	CTCs	isolated	from	the	same	patient	by	 size	 exclusion	 showed	 predominant	 EMT	 or	 intermittent	 phenotypes	(124).			
1.6.1 Clinical significance of EMT-CTCs 
Circumstantial	 evidence	 linking	 EMT	 changes	 to	 advanced	 disease	 and	increased	metastasis	 is	 strong.	EMT	phenotype	 in	patient	 tumour	 tissue	 is	often	 prognostic	 and	 correlates	 negatively	 to	 overall	 survival	 and	 disease	progression.	Most	notably,	the	switch	from	the	expression	of	the	epithelial	E-cadherin	 to	 mesenchymal	 N-cadherin	 is	 thought	 to	 be	 central	 to	 EMT	(described	 above),	 and	 is	 commonly	 found	 in	 association	 with	 disease	
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progression	in	various	cancer	including	melanoma,	pancreatic,	bladder	and	colorectal	 cancer	 (reviewed	 by	 (125)).	 Other	 studies	 found	 elevated	expression	 of	 a	 number	 of	 E-cadherin	 transcriptional	 repressors	 such	 as	TWIST,	SLUG,	ZEB1/2	and	SNAIL	linked	to	poorer	prognosis	in	endometrial,	colorectal,	hepatocellular,	bladder,	gastric	and	lung	cancer	(126-132).	Equally,	increased	expression	of	vimentin	was	associated	with	poorer	outcomes	for	patients	with	gastric,	colorectal,	bladder	and	breast	cancer	(127,	133-135).	However,	the	association	of	EMT	with	poorer	overall	or	disease-free	survival	is	not	universal.	A	recent	study,	which	established	a	comprehensive	EMT	gene	expression	 signature	 in	 tumour	 tissue,	 found	 that	 poorer	 disease-free	survival	was	associated	with	an	EMT	gene	expression	pattern	in	ovarian	and	colorectal	cancer	but	not	in	breast	cancer;	therefore,	it	will	be	important	to	better	 define	 the	 context	 in	 which	 EMT	 gives	 cancer	 cells	 a	 selective	advantage	(136).	As	detailed	above,	EMT	marker	gene	or	protein	expression	has	also	been	studied	 in	CTCs,	and	the	overall	emerging	evidence	suggests	that	 increased	 EMT-phenotype	 detection	 in	 CTCs	 correlates	 with	 more	advanced	 disease	 stages	 and	 is	 the	 predominant	 phenotype	 found	 in	 the	blood	of	patients	with	metastatic	disease.	
Techniques	employing	EMT-CTC	targeting	methods	may	then	be	a	powerful	tool	 in	 epithelial-derived	 cancers	 that	 are	 known	 to	 overexpress	 EMT	markers	as	well	as	those	often	diagnosed	in	later	stages	such	as	in	the	ovarian	cancer	setting.	Ovarian	cancer	patients	are	often	diagnosed	in	the	later	stages	of	 disease	 due	 to	 the	 relatively	 asymptomatic	 condition	 (137).	 Evidence	indicates	that	expression	of	EpCAM	and	cytokeratin	—	the	conventional	CTC	
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isolation	 and	 detection	 markers	 —	 is	 variable,	 suggesting	 conventional	methods	of	CTC	 isolation	may	be	 suboptimal	 in	 the	ovarian	 cancer	 setting	(119,	 138,	 139).	 This	 is	 in	 line	with	 a	 report	 analysing	CTCs	 in	 a	 range	 of	cancer	patients	that	found	ovarian	cancer	had	the	lowest	average	detection	of	CTCs	with	an	average	of	1	CTC	 ,	 compared	with	prostate	and	colorectal	cancer	with	2	and	4	CTCs	detectable	per	mL	of	blood	respectively,	although	patient	numbers	were	limited	in	that	study	(140).	
One	 study	 enriched	 CTCs	 from	 blood	 of	 epithelial	 ovarian	 cancer	 patients	using	gradient	centrifugation	and	analysed	the	CTC	containing	cell	fraction	by	gene	expression	arrays	and	RT-qPCR	in	comparison	to	blood	samples	from	healthy	donors	processed	the	same	way.	Expression	profiles	of	a	cohort	of	eleven	genes	 that	were	considered	CTC	specific	were	determined	and	CTC	presence	was	defined	by	beyond	baseline	expression	of	at	least	one	of	these	eleven	CTC	specific	genes.	Approximately	25%	of	200	patients	were	defined	as	CTC	positive	with	that	approach.	Notably,	EpCAM	expression	was	seldom	detected,	while	cyclophilin	C	(PPIC)	–	a	gene	family	associated	with	resistance	to	cisplatinum	–	was	highly	expressed	in	samples	of	two	thirds	of	all	patients	considered	to	have	CTCs.	PPIC	expression	correlated	with	poor	prognosis	and	importantly	was	detected	significantly	more	frequent	 in	platinum	resistant	than	 platinum	 sensitive	 patients	 (141).	 It	 would	 be	 relevant	 to	 further	validate	whether	detected	expression	of	PPIC	was	indeed	produced	by	CTCs	in	 the	 investigated	 cell	 fractions,	 enriched	by	 gradient	 centrifugation	only,	and	 to	 substantiate	 its	 robustness	 as	 CTC-based	 marker	 of	 platinum-resistance.		
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A	 recent	 study	 was	 able	 to	 investigate	 Excision	 Repair	 Cross-Complementation	 Repair	 Group	 1	 (ERCC1)	 expression	 in	 ovarian	 CTCs.	ERCC1	is	a	proposed	predictor	of	overall	survival,	progression-free	survival	and	platinum-based	 therapy	 resistance	 in	 primary	 ovarian	 cancer.	 14%	of	143	patients	presented	with	CTCs	at	primary	diagnosis	which	was	a	predictor	of	 poor	 overall	 survival.	 Furthermore	 8%	 of	 patients	 had	 ERCC1-positive	CTCs	which	 independently	predicted	overall	and	progression-free	survival.	The	 investigators	 proposed	 that	 ERCC1-postive	CTCs	 at	 primary	diagnosis	are	 a	 better	 predictor	 of	 resistance	 than	 ERCC1	 analysis	 of	 the	 primary	tumour	(142).	Importantly,	the	mentioned	studies	highlight	an	opportunity	to	improve	the	current	CTC	isolation	methods	in	the	ovarian	cancer	setting	by	 inclusion	of	EMT	marker	 targeting,	as	well	as	potentially	bolstering	 the	CTC	analysis	as	a	complementary	assay	to	guide	patient	therapy.	Both	are	the	rationale	for	the	study	presented	in	Chapter	3.	
Data	are	also	starting	to	emerge	suggesting	these	changes	might	be	detectable	by	 CTC	 subpopulation	 analysis:	 subtyping	 CTCs	 as	 possessing	 epithelial,	intermittent	or	mesenchymal	characteristics	showed	that	gastric	cancer	CTCs	of	 a	 patient	 progressing	 on	 therapy	 were	 all	 of	 EMT	 phenotype	 (143).	Interestingly,	 any	 remaining	 CTCs	 detected	 in	 gastric	 cancer	 patients	 that	responded	to	therapy	were	more	epithelial	in	nature	(143),	suggesting	that	once	the	stress	had	passed,	cells	were	able	to	undergo	MET	to	return	to	the	epithelial	 state,	 or	 alternately,	 these	 epithelial	 CTCs	 were	 due	 to	 a	 fresh	release	of	EMT	unaffected	cancer	cells	from	a	tumour	mass.	Presumably,	the	process	 of	 EMT	 allows	 the	 cancer	 cells	 to	 separate	 into	 different	
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subpopulations	and	support	tumour	heterogeneity,	and	may	be	one	reason	explaining	different	clinical	outcomes	 in	a	 range	of	patients	with	 the	same	tumour	type.	
Regardless,	it	is	possible	that	therapy	inadvertently	induces	cells	that	survive	drug	exposure	to	change	into	more	mobile,	viable	and	aggressive	clones.	Due	to	 their	 EMT	 phenotype,	 these	 cells	may	 be	 ideally	 equipped	 to	 leave	 the	primary	tumour,	become	CTCs,	prevent	anoikis	and	potentially	form	distant	metastasis	 sites.	 Additionally,	 the	 survival	 advantage	 of	 EMT	 cancer	 cells	might	 allow	 time	 to	 acquire	 alternative	 resistance	 mechanisms	 such	 as	mutations.	 In	 turn,	 that	 would	 allow	 EMT-CTCs	 to	 undergo	 MET	 after	extravasation	 to	 enable	 the	 resettling	 and	 formation	 of	 proliferating	metastases.	 The	 underlying	 mechanisms	 need	 to	 be	 more	 thoroughly	investigated,	and	the	ability	to	accurately	isolate	EMT-CTCs	will	prove	central	to	 clarifying	 the	 role	 of	 EMT	 in	 therapy	 resistance,	 disease	 relapse	 and	metastatic	processes.	Efficient	EMT-CTC	isolation	and	identification	may	also	allow	the	development	of	diagnostic	tests	that	monitor	escape	into	EMT	as	part	of	therapy	response	to	inform	improved	patient	management.	
	
1.6.2 Non-epithelium derived cancer CTCs 
The	 isolation	of	 non-epithelium	derived	 cancer	CTCs	has	been	 challenging	due	to	tumour	heterogeneity	and	their	lack	of	EpCAM	expression.	Canonical	CTC	 isolation	 methods	 targeting	 epithelial	 markers	 therefore	 cannot	 be	applied	 to	 these	 cancers.	 Alternative	 methods	 independent	 of	 epithelial	
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markers	have	been	developed	and	demonstrated	success	 in	 isolating	CTCs	from	cancers	such	as	melanoma,	GBM	and	sarcoma	patients		(49,	50,	55,	144-153).	The	main	methods	for	CTC	isolation	in	non-epithelium	cancers	include	the	immunomagnetic	targeting	of	multiple	cell	surface	markers	specific	to	the	cancer	 itself	 and	 size-based	 filtration.	Compared	 to	CTC	 isolation	 from	 the	more	 common	 epithelial	 cancers,	 the	 research	 field	 of	 non-epithelium	derived	CTC	 isolation	 is	 relatively	novel	and	research	 is	 in	 its	 infancy,	and	therefore,	 conclusions	 are	 largely	 preliminary.	 Nevertheless,	 the	 trend	 of	prognostic	value	and	clinical	 relevance	of	CTC	detection	 in	non-epithelium	derived	cancers	appears	to	be	similar	to	that	seen	in	epithelial	cancer	patients	(50,	55,	144,	154).	
With	slight	modifications	to	the	CellSearch	platform	to	target	the	melanoma	specific	 cell	 surface	 marker	 MCAM	 instead	 of	 EpCAM,	 followed	 by	immunostaining	 identification	 using	 antibodies	 targeting	 MCSP,	 CTC	detection	was	possible	in	40%	of	melanoma	patients	with	1	or	more	CTCs	/	10mL	(154).	Setting	a	threshold	of	2	or	more	CTCs	/	10mL	resulted	in	a	clear	separation	 between	 favourable	 and	 unfavourable	 prognosis	 patients,	irrespective	of	whether	the	patient	had	received	first	or	second	line	therapy	prior	 (154).	 One	 study	 relied	 on	 size-based	 separation	 with	 a	 spiral	microfluidic	 system	 to	 isolate	 melanoma	 patient	 CTCs,	 using	 inertia	 to	separate	out	 larger	CTCs	on	the	outer	edge	of	 the	channel	 tubing	 from	the	smaller	residual	white	blood	cells	on	the	inside	of	the	channel.	The	enriched	CTC	sample	output	was	subject	to	multiple	marker	flow	cytometry	analysis	–	staining	 for	melanoma	markers	MCAM,	MCSP,	ABCB5,	 CD271	 and	RANK	–	
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resulting	in	the	detection	of	CTCs	in	7/10	patients	(median	5	CTCs	/	8mL).	(55,	 151).	 Using	 a	 similar	 panel	 of	 markers	 in	 another	 study,	 CTCs	 were	detected	in	17/22	melanoma	patients	using	immunomagnetic	targeting	of	the	melanoma	markers	MCSP,	MCAM,	ABCB5	and	CD271	following	red	blood	cell	lysis	 (155).	 One	 other	 study	 identified	melanoma	 CTCs	 following	 negative	depletion	 of	 CD45,	 CD66b	 and	 CD16	 by	 screening	 for	 19	 melanoma-associated	RNA	 transcripts.	 In	48/49	patients,	 at	 least	 one	RNA	 transcript	was	detectable	from	at	least	one	time	point	throughout	therapy.	Importantly,	a	 reduction	 in	 CTC	 detection	 throughout	 treatment	 was	 associated	 with	longer	progression	free	survival	and	response	to	therapy	(50).	
The	presence	of	CTCs	in	GBM	patients	was	viewed	with	great	skepticism	due	to	 the	 presence	 of	 the	 blood-brain	 barrier	 physically	 blocking	 CTCs	 from	entering	the	circulation	and	that	metastatic	dissemination	is	exceedingly	rare.	In	fact,	CTC	isolation	from	GBM	patients	seemed	impossible	until	a	seminal	study	 published	 in	 2014.	 Bloods	 from	 141	 GBM	 patients	 were	 subject	 to	density	 gradient	 centrifugation,	 the	 mononuclear	 cell	 layer	 collected	 and	centrifuged	 onto	 slides	 followed	 by	 immunofluorescence	 staining	 with	antibodies	 targeting	 glial	 fibrillary	 acidic	protein	 (GFAP)	 and	EGFR.	GFAP-positive	CTCs	were	identified	in	29/141	(21%;	range	1-22	CTCs	/	10mL)	of	GBM	patient	samples.	Importantly,	individual	GBM	CTCs	were	isolated	from	two	patients	and	showed	shared	mutations	and	genomic	aberrations	with	the	primary	tumour,	confirming	that	isolated	CTCs	were	indeed	cancer	cells	and	derived	from	the	GBM	primary	tumour	(145).	This	paper	dispelled	the	dogma	that	 CTCs	 could	 not	 be	 detected	 in	 GBM	 patients,	 and	 studies	 have	 since	
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emerged	exploring	a	variety	of	methods	and	immunofluorescent	markers	to	identify	CTCs	from	GBM	patients.		
In	one	study,	blood	samples	were	processed	for	GBM	CTC	detection	using	a	combination	of	size-based	depletion	of	red	blood	cells,	followed	by	negative	immunomagnetic	 depletion	 of	 CD45	 /	 CD66b-positive	 white	 blood	 cells.	Following	 this,	 samples	 were	 centrifuged	 onto	 slides	 and	 probed	 using	 a	cocktail	of	antibodies	detecting	SOX-2,	Tubulin	beta-3,	EGFR,	A2B5	and	c-Met	(STEAM)	expression,	with	a	CTC	declared	as	positive	for	any	of	the	STEAM	markers.	Using	a	cutoff	of	7	CTCs	/	mL,	CTCs	were	identified	in	13/33	(39%)	of	patient	samples	at	any	time	throughout	therapy.	Importantly,	median	CTC	counts	 were	 significantly	 higher	 in	 patients	 with	 disease	 progression	compared	with	stable	patients	(11.8	CTCs	/	mL	vs	2.1	CTCs	/	mL;	p<0.001)	(144).	
Glioma	 patient	 blood	 samples	 were	 separated	 by	 density	 gradient	centrifugation,	followed	by	immunomagnetic	depletion	of	white	blood	cells	and	endothelial	cells,	then	finally	spun	onto	slides	for	immunostaining	CTC	identification	 and	 fluorescent	 in	 situ	 hybridization	 staining	 (FISH)	 for	chromosome	8	polyploidy	(CEP8).	Here,	CTCs	–	identified	as	DAPI	positive,	CEP8	positive	and	CD45	negative	–	were	detected	in	24/31	(77%)	of	glioma	patient	samples	(range	1-10	CTCs	/	7.5mL	blood).	No	statistical	association	was	observed	between	CTC	incidence	and	grade	of	glioma	(146).	The	most	recent	study	-	using	a	size-based	platform	called	Parsortix	–	detected	CTCs	as	well	as	CTC	clusters	in	7/13	GBM	patients,	indicated	as	>2	CTCs	/	10mL	blood	positive	 for	EGFR,	Ki67	and/or	EB1	 immunostaining	at	any	 time	point.	No	
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obvious	 trend	 appeared	 between	 CTC	 or	 CTC	 clusters	 with	 response	 to	therapy	or	tumour	volume	determined	by	functional	MRI	(147).	
As	 the	 route	 of	 metastasis	 in	 sarcoma	 patients	 is	 predominantly	haematogenous,	 there	 have	 been	 recent	 studies	 investigating	 CTCs	 as	 a	window	into	 therapy	response	and	metastatic	relapse	 in	sarcoma	patients.	Despite	being	limited	by	the	heterogeneity	of	sarcoma	cancer	cells	and	low	incidence	 rates,	 studies	 have	 demonstrated	 a	 clear	 link	 between	 CTC	presence	 and	 clinical	 utility	 (reviewed	by	 (148)).	One	 study	 isolated	CTCs	from	sarcoma	patients	by	first	depleting	blood	samples	of	CD45-positive	cells	using	negative	immunomagnetic	depletion,	followed	by	positive	targeting	of	cell-surface	vimentin	(CSV),	detecting	CTCs	in	22/24	(92%;	range	1-10	CTCs	/	 mL)	 sarcoma	 patient	 samples.	 A	 trend	 of	 higher	 CTCs	 in	 patients	 with	metastatic	 disease	 compared	with	 localised	 disease,	 as	 well	 as	 lower	 CTC	counts	 in	 chemotherapy-treated	 patients	 was	 observed	 (49).	 Using	 size-based	 exclusion	 by	 filtering	 whole	 blood	 through	 a	 7-micron	 porous	membrane,	 one	 study	 reported	 CTC	 detection	 –	 defined	 as	 DAPI-positive,	vimentin-positive	and	CD45-negative	–	 in	35/54	(65%)	of	sarcoma	patient	samples	(range	0-514	cells/	7.5mL).	Here,	CTCs	were	reported	as	more	often	detected	 at	 diagnosis,	 decreased	 following	 successful	 treatment	 and	 were	importantly	 detectable	 with	 no	 radiographic	 evidence	 of	 disease	 prior	 to	development	of	metastases	(150).		
While	investigation	of	CTCs	in	non-epithelium	derived	cancers	is	in	its	infancy,	the	 broad	 trend	 seems	 to	 suggest	 presence	 of	 CTCs	 as	 an	 indication	 of	
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unfavourable	prognosis	and	poor	response	to	therapy,	and	shows	promise	for	the	use	of	CTC	isolation	within	the	clinical	setting.	
	
1.7 Specific hypotheses in this thesis 1) A	wider	spectrum	of	ovarian	cancer	CTC	phenotypes	can	be	detected	using	 an	 antibody-based	 cell	 capture	 system.	 Additionally,	 probing	CTCs	for	a	specific	EMT	marker	allows	identification	of	EMT-CTCs	2) This	EMT-CTC	capture	and	analysis	strategy	can	be	used	in	a	range	of	epithelium-derived	 cancers.	 Important	 phenotypes	 including	 EMT	characteristics	 can	 be	 detected	 from	 EM	 ultrastructure	 analysis	 of	CTCs	3) Specific	 antibody-based	 isolation	 can	 also	 target	 CTCs	 from	 non-epithelial	origin	cancers	and	these	CTCs	can	be	screened	for	clinically	relevant	biomarkers	
	
1.8 Aims and organisation of thesis The	study	of	CTCs	is	emerging	as	a	promising	clinical	adjunct	for	diagnosis,	monitoring	 and	 prediction	 of	 treatment	 resistance	 in	 many	 cancers.	 The	technologies	 for	 detecting	 CTCs	 are	 variable,	 and	 beyond	 prognostication	there	is	no	clinically	accepted	CTC	assay.	Our	laboratory	is	investigating	the	utility	of	antibody-based	cell	capture,	as	this	offers	the	ability	to	test	a	large	variety	 of	 antibodies	 targeting	 cell	 surface	 characteristics	 of	 cancer	 cells.	Traditionally,	this	approach	is	largely	based	on	epithelial	markers	–	EpCAM	
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in	 particular	 –	 but	 this	 implies	 that	many	 circulating	 cancer	 cells	may	 be	missed	if	they	do	not	express	EpCAM.	This	is	a	fundamental	limitation	of	an	antibody-based	 capture	 system.	 Our	 general	 aim	 was	 to	 develop	 novel	methods	 using	 novel	 antibodies	 and	 combinations	 to	 isolate	 and	 identify	CTCs	from	epithelial	cancers	and	melanoma	and	to	investigate	whether	it	was	possible	to	further	analyse	them	for	the	expression	of	important	biomarkers,	such	 as	 vimentin	 to	 characterise	 EMT,	 and	 PD-L1	 which	 may	 indicate	response	to	immunotherapies.	To	answer	the	specific	project	hypotheses,	the	below	aims	were	developed:	
	
Aim	 1:	 Establishing	 a	 method	 to	 enrich	 and	 characterise	 EMT-CTCs	 and	epithelial-phenotype	CTCs	from	ovarian	cancer	patients	
Chapter	 3	 aims	 to	 find	 cell	 surface	 proteins	 that	 can	 be	 targeted	 for	immunomagnetic	 isolation	 of	 EMT	 and	 epithelial	 phenotype	 CTCs	 from	ovarian	 cancer	 patients.	 It	 compares	 CTC	 isolation	 using	 conventional	EpCAM-targeting	while	also	targeting	the	EMT	marker	N-cadherin	for	ovarian	cancer	 CTC	 capture.	 Presence	 of	 EMT	 phenotype	 CTCs	 is	 confirmed	 by	detection	of	the	EMT	marker	vimentin.		
	
Aim	 2:	 Enrich	 EMT-CTC	 and	 epithelial	 phenotypes	 in	 other	 carcinomas,	combined	with	ultrastructure	CTC	analysis	
Chapter	4	explores	whether	the	methods	developed	for	EMT-CTC	detection	are	applicable	to	other	advanced	epithelium-derived	cancers	including	non-
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small	cell	lung	cancer	and	metastatic	prostate	cancer.	Additionally,	electron	microscopy	 is	used	to	 investigate	CTCs	 to	detect	cancer	associated	cellular	ultrastructures	and	 further	characterise	subcellular	phenotypes	 in	some	of	the	same	CTC	samples.	
	
Aim	3:	Non-EpCAM-based	enrichment	of	melanoma	CTCs	and	determination	of	PD-L1	expression	
Chapter	5	determines	cell	 surface	 targets	 to	 isolate	non-epithelial	derived	cancer	CTCs	 from	a	a	cancer	 typically	devoid	of	EpCAM	expression,	 in	 this	case	 from	 cutaneous	 melanoma,	 and	 further	 analyses	 these	 CTCs	 for	 a	clinically	relevant	biomarker,	PD-L1.	
	
The	work	 described	 in	 this	 thesis	 established	 a	 variety	 of	 novel	 antibody-based	 CTC	 capture	 and	 identification	 techniques	 and	 showed	 that	 CTCs	isolated	 with	 these	 methods	 can	 be	 further	 characterised	 for	 important	biomarkers.	 Moreover,	 the	 findings	 may	 further	 guide	 future	 studies	 in	elucidating	the	role	that	EMT	plays	in	CTCs	in	driving	therapeutic	resistance	and	the	metastatic	cascade.	
	 	
39		
Chapter 2  Materials and Methods 
2.1 Chemicals and research consumables with suppliers 8	mm	micromoulds	(Proscitech,	Kirwan,	Australia)	
Acetone	(ThermoFisher,	Scoresby,	Australia)	
Agar	automatic	carbon	coater	(Emgrid	Australia,	Pooraka,	Australia)		
BX53	microscope	(Olympus,	Notting	Hill,	Australia)	
CellCelector	(Automated	Lab	Solutions,	GmbH,	Jena,	Germany)	
Cell	scraper	(Sigma,	Castle	Hill,	Australia)	
Coverslips	13	mm	(Menzel-Glaser,	Braunschweig,	Germany)	
Cryovials	(Interpath,	Melbourne,	Australia)	
DER	732	(Proscitech,	Kirwan,	Australia)	
Dimethyl	sulfoxide	(DMSO;	Sigma,	Castle	Hill,	Australia)	
DMAE	(Proscitech,	Kirwan,	Australia)	
Dulbecco’s	modified	eagle	media	(DMEM;	Lonza,	Basel,	Switzerland)	
DRAQ5	nuclear	stain	(Abcam,	Melbourne,	Australia)	
EDTA	vacutubes	(Greiner-Bio-One,	Frickenhausen,	Germany)	
Endogenous	biotin	blocking	kit	(ThermoFisher,	Scoresby,	Australia)	
ERL	4221	(Proscitech,	Kirwan,	Australia)	
Ethanol	100%	(ThermoFisher,	Scoresby,	Australia)	
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Ethylenediaminetetraacetic	acid	(EDTA;	Sigma,	Castle	Hill,	Australia)	
FACS	 Canto	 II	 Cell	 Analyzer	 (Becton	 Dickinson	 Biosciences,	 North	 Ryde,	Australia)	
Fetal	bovine	serum	(FBS;	Interpath,	Melbourne,	Australia)	
Formaldehyde	(VMR	International,	Tingalpa,	Australia)	
Gluteraldhyde	(EMS,	Thuringowa	Central,	Australia)	
Haemocytometer	(Sigma,	Castle	Hill,	Australia)	
HEPES	(Lonza,	Basel,	Switzerland)	
Heraeus	Pico	21	Microcentrifuge	(ThermoFisher,	Scoresby,	Australia)	
Isoflux	Rare	Cell	Isolation	Kit	(Fluxion,	San	Francisco,	USA)	containing:	
Binding	buffer	 	
	 Fc	blocker	buffer	
Immunomagnetic	beads	
	 Microfluidic	CTC	enrichment	cartridge	
	 Mounting	media	
IX71	microscope	(Olympus,	Notting	Hill,	Australia)	
L-glutamine	(Sigma,	Castle	Hill,	Australia)		
LSM-800	confocal	microscope	(Zeiss,	Jena,	Germany)	
Lymphoprep	(Stemcell	Technologies,	Vancouver,	Canada)	
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Megaview	MegaView	III	digital	monochrome	camera	(Olympus,	Notting	Hill,	Australia)	
Merlin	GEMINI	 II	 field	emission	 scanning	electron	microscope	 (Zeiss,	 Jena,	Germany)	
Morgagnia	 268D	 transmission	 electron	 microscope	 (FEI	 Company,	Eindhoven,	Netherlands)	
Mr.	Frosty	freezing	container	(ThermoFisher,	Scoresby,	Australia)	
NanoDropTM	2000	spectrophotometer	(ThermoFisher,	Scoresby,	Australia)	
NSA	(Proscitech,	Kirwan,	Australia)	
Osmium	tetroxide	(Proscitech,	Kirwan,	Australia)	
QuBit	dsDNA	HS	Assay	Kit	(Invitrogen,	Life	Technologies,	CA,	USA)	
Roswell	 Park	 Memorial	 Institute	 1640	 media	 (RPMI;	 Lonza,	 Basel,	Switzerland)	
SepMate	tubes	(Stemcell	Technologies,	Vancouver,	Canada)	
Sodium	acetate	(Proscitech,	Kirwan,	Australia)	
Sodium	cacodylate	(Proscitech,	Kirwan,	Australia)	
Spurr	low	viscosity	embedding	kit	(Sigma,	Castle	Hill,	Australia)	
Superfrost	glass	slides	(Menzel-Glaser,	Braunschweig,	Germany)	
Phosphate	buffered	saline	(PBS;	Life	Technologies,	Mulgrave,	Australia)	
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ProLong	gold	anti-fade	mountant	with	4’,6-diamidino-2-phenylindole	(DAPI;	Life	Technologies,	Melbourne,	Australia)	
RMC	Powertome	X	ultramicrotome	(Boeckeler	Instruments,	Tucson,	Arizon,	USA)	
T	25	cm2	and	T	75cm2	tissue	culture	flasks	(Corning,	Massachusetts,	USA)	
Transmission	 electron	 microscope	 camera	 control	 software	 (Soft	 Imaging	System,	Muenster,	Germany)	
Triton	X-100	(Sigma,	Castle	Hill,	Australia)	
Ultra	45	diamond	knife	(Emgrid	Australia,	Pooraka,	Australia)		
Uranyl	acetate	(ThermoFisher,	Scoresby,	Australia)	
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2.2 Common methods The	methods	below	are	commonly	used	throughout	Chapters	3,	4	and	5	and	have	 been	 described	 here	 in	 detail.	 These	 are	 then	 briefly	 described	 in	Chapters	3,	4	and	5,	with	any	minor	changes/deviations	noted.	
	
2.2.1 Patient recruitment 
Patients	were	recruited	from	Liverpool	Cancer	Therapy	Centre,	The	Crown	Princess	 Mary	 Cancer	 Centre	 Westmead,	 Wollongong	 Hospital,	 Prince	 of	Wales	Private	Hospital	and	St	George	Private	Hospital.	Clinical	 information	was	 sourced	 from	 patient	medical	 records.	 Clinical	 information	 at	 time	 of	blood	sampling	was	collected	including	age,	sex,	primary	cancer	site	and	stage.	Treatment	 information	 was	 collected	 including	 chemotherapy	 regimen,	previous	lines	of	therapy	prior	to	CTC	isolation,	serum	biomarker	levels	and	radiological	assessments.	Disease	status	was	defined	by	overseeing	physician	as	patient	response	to	chemotherapy	prior	to	CTC	sampling	by	assessing	CA-125	levels,	radiological	imaging	data	and	clinical	notes.	Blood	samples	from	healthy	individuals	were	collected	as	controls	for	initial	optimization	studies	(See	Chapter	3).	All	 studies	were	undertaken	with	written	patient	 consent	and	 approval	 from	 the	 South	 Western	 Sydney	 Biosafety	 Committee,	 and	managed	by	CONCERT	Biobank	(HREC/13/LPOOL/158)	(see	Appendix	1).	
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2.2.2 Tissue culture 
Ovarian	 cancer	 cell	 lines	 A2780,	 COLO-316,	 ES-2,	 OVCAR-3,	 PEO1,	 PEO4,	PEO14,	SKOV-3,	CAOV-3	and	the	WME-099	EBV	transformed	lymphocyte	cell	line	(the	latter	kindly	provided	by	Prof.	Graham	Mann;	Westmead	Institute	for	 Medical	 Research,	 NSW,	 Australia)	 were	 maintained	 in	 RPMI	 media	supplemented	 with	 10%	 fetal	 bovine	 serum	 (FBS),	 4nM	 L-glutamine	 and	HEPES	in	a	humidified	atmosphere	with	5%	CO2	at	37°C.	Similarly,	NSCLC	cell	lines	 HCC827,	 H3255	 and	 H1975	 (kindly	 provided	 by	 Dr.	 Tara	 Roberts;	Ingham	 Institute	 for	 Applied	Medical	 Research,	NSW,	Australia)	were	 also	maintained	 in	 RPMI,	 supplemented	 as	 above,	 in	 a	 humidified	 atmosphere	with	5%	CO2	at	37°C.	Melanoma	cell	lines	SkMel28,	501mel,	A375,	WMM1175,	MelRM,	NM176,	MelMS	and	M230	were	maintained	in	DMEM	with	10%	FBS,	4nM	L-glutamine	and	HEPES	in	a	humidified	atmosphere	with	5%	CO2	at	37°C.	Melanoma	cell	lines	were	kindly	provided	by	Prof	G.	Mann	and	Prof.	Antoni	Ribas.	 All	 cell	 lines	 were	 grown	 from	 frozen	 stocks	 that	 were	 STR	authenticated	 and	 confirmed	 to	 be	 free	 of	Mycoplasma	 at	 time	 of	 freezing	(Australian	 Genome	 Research	 Facility	 Ltd,	 Melbourne,	 Australia)	 and	maintained	 for	 no	 more	 than	 25	 passages.	 Cells	 were	 seeded	 at	 15-20%	confluency	and	cultured	for	three	to	four	days	before	passaging.	In	order	to	preserve	 cell	 surface	 marker	 integrity,	 adhered	 cells	 were	 harvested	 by	incubation	with	0.2mM	EDTA	in	PBS	for	10	minutes.	If	adhered	cells	were	not	detached	within	10	minutes	of	37°C	EDTA/PBS	incubation,	cell	scrapers	were	used	to	aid	cell	detachment.	
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2.2.3 Flow cytometry 
Cells	were	seeded	into	T75	cm2	flasks	and	cultured	for	72	hours.	EDTA/PBS-detached	cells	were	pelleted	via	centrifugation	at	300	x	g	for	3	minutes	and	resuspended	in	PBS.	Cell	suspensions	were	aliquoted	into	samples	of	~1	x	105	and	blocked	with	10%	FBS	in	PBS	for	20	minutes	(see	Chapters	3	and	5	for	details).	 Cells	 were	 then	 incubated	 with	 relevant	 primary	 antibodies	 or	matched	IgG	controls	diluted	in	10%	FBS	for	30	minutes,	washed	again	with	PBS	and	then	incubated	with	secondary	antibody	for	30	minutes,	diluted	in	10%	FBS	for	30	minutes.	After	a	final	wash,	cells	were	resuspended	in	300	µL	of	PBS	for	FACS	analysis	measuring	the	proportion	of	AlexaFluor488	positive	cells	 using	 a	 FACS	 Canto	 II	 Cell	 Analyzer	 (BD	Biosciences).	 The	 data	were	analysed	 using	 Flowing	 Software	 2.5.1	 (Perttu	 Terho,	 Turku	 Centre	 for	Biotechnology,	Turku,	Finland).	
	
2.2.4 Immunocytostaining and fluorescence microscopy 
Ovarian	cancer,	NSCLC	and	melanoma	cells	were	seeded	at	~2	x	104	cells	onto	sterile	coverslips	 in	12-well	plates.	Non-fixed	cells	were	blocked	with	10%	FBS	in	PBS	for	15	minutes,	and	then	incubated	with	primary	antibody	diluted	in	10%	FBS	in	PBS,	before	washing	with	PBS	and	incubation	with	secondary	antibody	 (1:2000,	 Life	 Technologies)	 diluted	 in	 10%	 FBS	 in	 PBS	 for	 30	minutes.	Coverslips	were	washed	thrice	with	PBS	followed	by	a	MilliQ	water	rinse	 and	 mounted	 onto	 glass	 slides	 (Menzel-Glaser)	 with	 ProLong	 Gold	Antifade	 reagent	 containing	 a	 DAPI	 stain	 (Life	 Technologies).	 Cells	 were	
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visualised	with	BX53	or	IX71	fluorescent	microscope	(Olympus)	and	images	captured	with	the	20	X	objective	with	CellSens	Dimension	imaging	software.	
	
2.2.5 Immunomagnetic bead preparation 
Immunomagnetic	beads	from	the	Rare	Cell	Isolation	Kit	are	pre-coupled	with	anti-mouse	antibodies	by	the	manufacturer.	Briefly,	a	specific	volume	of	bead	suspension	was	prepared	as	 follows:	beads	were	pulled	down	by	magnetic	force,	supernatant	discarded,	washed	in	5	times	the	original	bead	suspension	volume,	 then	 resuspended	 in	 the	original	 suspension	volume	with	binding	buffer.	Appropriate	 concentrations	of	 selected	anti-mouse	antibodies	were	incubated	with	the	Isoflux	Rare	Cell	magnetic	beads	(Fluxion)	on	a	rotating	platform	for	90	minutes	at	room	temperature.	Beads	were	stored	at	4°C	until	use	within	4	weeks.	
	
2.2.6 CTC isolation from patient blood 
Patient	bloods	were	drawn	into	9	mL	EDTA	vacutubes	(Greiner	Bio-One)	and	processed	within	24	hours.	 Lymphoprep	 and	 SepMate	 tubes	were	used	 to	separate	the	peripheral	blood	mononuclear	cells	(PBMCs),	containing	CTCs,	according	to	the	manufacturer’s	 instructions.	Briefly,	13.5	mL	Lymphoprep	was	transferred	to	SepMate	tubes	directly	through	centre	filter,	then	blood	gently	 layered	ontop.	Blood	collection	 tube	was	rinsed	with	9	mL	PBS	and	transferred	to	SepMate	tube	before	centrifugation	at	1200	x	g	for	10	minutes	with	brakes	on.	Supernatant	was	gently	but	quickly	poured	into	a	fresh	50	mL	
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falcon	 tube	 and	 centrifuged	 at	 280	 x	 g	 for	 10	 minutes	 with	 brakes	 on.	Supernatant	was	discarded	and	PBMC	cell	pellet	was	washed	in	10	mL	PBS.	Sample	was	again	centrifuged	at	280	x	g	for	10	minutes,	supernatant	removed	and	the	PBMC	cell	pellet	derived	from	9	mL	blood	was	resuspended	in	binding	buffer,	FC	buffer	and	pre-prepared	immunomagnetic	beads	(as	above).	
Cells	were	incubated	for	90	minutes	at	4°C	on	a	rotating	platform	and	then	loaded	 into	 binding	 buffer-primed	 IsoFlux	 cartridges	 for	 CTC	 enrichment	using	the	Fluxion	Standard	Isolation	Protocol	Rev2	with	collection	into	200	µl	 recovery	 tubes.	 Enriched	 CTCs	 samples	 were	 fixed	 with	 3.7%	formaldehyde	in	PBS	for	10	minutes,	washed	in	binding	buffer	before	storage	in	100	µl	of	PBS	at	4°C	before	immunocytostaining.	
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Chapter 3  Isolation of EMT-CTCs in ovarian cancer 
patients 
The	key	findings	of	this	chapter	were	published	in	the	Journal	of	Circulating	Biomarkers	(52)	(see	Appendix	3).		
3.1 Introduction Ovarian	cancer	 is	 the	 leading	cause	of	gynecological	 cancer	death.	Ovarian	cancer	is	often	diagnosed	in	the	later	stages	of	disease	due	to	the	relatively	asymptomatic	nature	which	is	further	compounded	by	the	limited	availability	of	screening	tests	in	the	clinic	(137).	Diagnosis	and	monitoring	ovarian	cancer	patient	disease	involves	pelvic	and	vaginal	examinations,	diagnostic	imaging	such	as	ultrasound	and	CT	scans	as	well	as	serum	biomarker	detection	(156).	Radiological	imaging	as	well	as	serum	biomarker	testing	are	routinely	used	in	 the	 clinic	 to	 assess	 tumour	 burden	 and	 response	 (see	 RECIST	 criteria	(157)),	 with	 imaging	 more	 suitable	 for	 patients	 with	 measurable	 disease.	Many	serum	biomarkers	over	the	previous	decades	have	been	utilized	in	the	clinic	in	the	ovarian	cancer	setting	including	carcinoembryonic	antigen	(CEA),	human	epididymis	protein	(HE4)	and	mesothelin,	however	CA-125	remains	to	be	the	most	ubiquitously	used	serum	biomarker	(137,	156,	158).		
More	recently,	the	use	of	‘liquid	biopsies’	in	the	clinic	has	gained	popularity	as	a	proxy	to	tumour	tissue	in	a	range	of	cancers	including	ovarian	cancer.	As	outlined	 in	 Chapter	 1,	 Section	 1.1,	 the	 most	 commonly	 employed	 CTC	isolation	and	identification	strategies	currently	rely	on	detection	of	epithelial	markers	 (EpCAM	 and	 cytokeratin),	 with	 isolation	 of	 CTCs	 predominantly	
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performed	using	EpCAM	targeted	immunomagnetic	enrichment.	Therefore,	CTCs	undergoing	epithelial-mesenchymal	transition	(EMT)	may	be	missed	by	these	methods,	due	to	low	or	no	EpCAM	expression.	The	process	of	EMT	is	thought	to	favour	the	dissemination	of	cancer	cells	and	their	entry	into	the	bloodstream	and	thus	metastatic	disease.	More	importantly,	it	has	also	been	suggested	 that	 cancer	 cells	 that	 undergo	 EMT	 develop	 resistance	 against	therapeutic	drugs	and	radiation	therapy	(see	Chapter	1,	Section	1.3).	Since	part	 of	 the	 focus	 of	 this	 project	 was	 to	 investigate	 EMT-CTCs	 and	 their	relationship	to	treatment	resistance	in	ovarian	cancer,	we	aimed	to	establish	a	 method	 that	 accounts	 appropriately	 for	 EMT-CTCs,	 focusing	 on	 ovarian	cancer	CTCs.		
The	aim	of	the	work	presented	in	this	chapter	was	to	establish	an	improved	method	to	account	for	not	only	epithelial	antigen	expressing	CTCs,	but	also	CTCs	 undergoing	 EMT	 by	 identifying	 alternate	 or	 additional	 cell	 surface	markers	 as	 candidate	 targets	 for	 immunomagnetic	 CTC	 isolation.	We	 also	aimed	to	evaluate	a	commonly	screened	ovarian	cancer	biomarker,	CA-125	(159)	 as	 a	 potential	 alternative	 detection	 method,	 to	 better	 distinguish	ovarian	cancer	CTCs,	including	EMT-CTCs,	from	residual	blood	cells.	In	this	chapter,	one	EMT-CTC	isolation	candidate	marker,	N-cadherin,	was	validated.	We	show	that	 it	 improved	isolation	of	a	more	representative	population	of	CTCs	 from	 ovarian	 cancer	 patients.	 Importantly,	 the	 newly	 established	method	is	the	basis	for	further	analysis	of	EMT-CTCs	from	a	range	of	cancers	(see	Chapter	4).		
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3.2 Methods 
3.2.1 Patients 
Patients	were	recruited	from	Liverpool	Cancer	Therapy	Centre,	The	Crown	Princess	 Mary	 Cancer	 Centre	 Westmead	 (facilitated	 by	 Gynaecological	Oncology	 Biobank,	 Westmead).	 Clinical	 information	 was	 sourced	 from	patient	medical	records.	Information	at	time	of	blood	sampling	was	collected,	including	patient	 age	 and	primary	 cancer	 site.	 Treatment	 information	was	also	 collected	 including	 chemotherapy	 regimen,	 previous	 lines	 of	 therapy	prior	to	CTC	isolation,	serum	CA-125	levels	and	radiological	assessments	(see	Table	3.1).	Blood	samples	from	healthy	individuals	with	no	history	of	cancer	or	Crohn’s	disease	were	used	as	controls.		
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Table	3.1	Clinical	characteristics	of	ovarian	cancer	patient	cohort	
Clinical	Data	 Patients,	n	(%)	
Age	Mean	(range)	 65	(54-78)	 		
Primary	 Tumour	
Location	#	
Ovary	 16	(73%)	Fallopian	Tube	 1	(5%)	
Primary	Peritoneal	 1	(5%)	N/A	 4	(18%)	
FIGO	Stage	#	
III	 11	(50%)	IV	 5	(23%)	N/A	 6	(27%)	
CA-125	
<35	U/mL	 2	(9%)	≥35	U/mL	 13	(59%)	N/A	 7	(32%)	
CA-125	*	
Rising	 8	(36%)	Stable	 2	(9%)	Falling	 5	(23%)	N/A	 7	(32%)	
Disease	Status	**	
Progressing	 12	(55%)	Stable	 1	(5%)	Responding	 4	(18%)	N/A	 5	(23%)		Patients	had	up	to	six	previous	chemotherapies	and	time	to	progression	median	was	161	days	(38-654).	#	at	time	of	diagnosis;	*	at	time	of	CTC	collection,	first	collection	if	several;	rising/falling	 indicates	 increase	or	decrease	≥25%	from	CA-125	at	CTC	collection;	**Disease	status	was	defined	by	overseeing	physician	as	patient	response	to	 chemotherapy	 prior	 to	 CTC	 sampling	 by	 assessing	 CA-125	 levels,	 radiological	imaging	data	and	clinical	notes;	N/A	no	data	available	in	electronic	medical	records 
	  
Chapter 3 Isolation of EMT-CTCs in ovarian cancer patients 
	52		
3.2.2 Cell lines 
A2780,	 COLO-316,	 ES-2,	 OVCAR-3,	 PEO1,	 PEO4,	 PEO14,	 SKOV-3,	 CAOV-3	ovarian	cancer	cells	and	the	WME-099	EBV	transformed	lymphocyte	cell	line	were	maintained	as	described	previously	(see	Section	2.2.2).	All	cells	were	authenticated	by	 small	 tandem	repeat	 (STR)	 (AGRF,	Melbourne,	Australia)	and	 confirmed	 Mycoplasma	 free	 (Lonza,	 Basel,	 Switzerland	 MycoAlertTM	Assay	Control	Kit).	
	
3.2.3 Flow cytometry analysis 
Samples	were	processed	for	flow	cytometry	analysis	as	described	previously	(see	Section	2.2.3).	Briefly,	cultured	cells	were	EDTA/PBS-detached,	pelleted	via	centrifugation	at	300	x	g	for	3	minutes	and	blocked	in	10%	FBS	in	PBS	for	20	 minutes.	 Following	 this,	 samples	 were	 probed	 with	 relevant	 primary	antibodies	 diluted	 in	 10%	 FBS	 for	 30	minutes,	washed,	 then	 probed	with	appropriate	secondary	antibodies	diluted	in	10%	FBS	for	30	minutes	again	(see	table	3.2	below	for	antibody	dilution	details).	Cells	were	detected	using	a	 FACS-Canto	 II	 (Becton	 Dickinson)	 and	 analysed	 using	 Flowing	 Software	2.5.1	(Turku,	Finland).	
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Table	3.2	Antibodies	and	working	dilutions		
α-human	antibody	 Dilution	 Company	(host);	[clone];	{conjugate}	 FACS/IF;	*beads	 		CA-125	(rabbit)	 0.1ng	/	μl	 Millipore	CD45	(rabbit)	 1:100	 Fluxion	Biosciences	E-cadherin	(mouse)	[HECD1]	 1:200	 Abcam	EGFR	(mouse)	[LA1]	 5ng	/	μl;	25ng	/	μl*	 Millipore	EpCAM	(mouse)	[BER-EP4]	 1:200;	1:40*	 Abcam	Her-2	(mouse)	[24D2]	 1:200;	1:40*	 Biolegend	MUC-1	(mouse)	[VU4H5]	 0.8ng	/	μl	 Santa	Cruz	N-cadherin	(mouse)	[GC-4]	 9.2ng	/	μl;	46ng	/	μl*	 Sigma	Pan-Cytokeratin	 (mouse)	 [C-11]	{FITC}	 7.2ng	/	μl	 Sigma	VE-cadherin	 (recombinant	human)	[REA199]	{VioBlue}	 1:10	 Miltenyi	Biotec	Vimentin	 (mouse)	 [V9]	{AlexaFluor647}	 0.57ng	/	μl	 Abcam	
Secondary	antibodies:	Goat	 anti-mouse	 IgG	{AlexaFluor488}	 1ng	/	μl	 LifeTech	Goat	anti-rabbit	IgG	 1ng	/	μl	 LifeTech	Donkey	anti-rabbit	IgG	{Cy3}	 1:200	 Fluxion	Biosciences	*	concentration	for	immunomagnetic	bead	coupling;	IF	=	immunofluorescence		
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3.2.4 Immunocytostaining and fluorescence microscopy 
Cells	were	prepared	and	imaged	as	described	previously	(see	Section	2.2.4).	Briefly,	 ovarian	 cancer	 cells	 were	 cultured	 in	 12-well	 plates	 on	 sterile	coverslips	 for	 72	 hours,	 blocked	with	 10%	 FBS	 and	 probed	with	 relevant	primary	antibodies	(see	Table	3.2	for	antibody	dilutions).	Cells	were	washed	and	 probed	 with	 appropriate	 secondary	 antibodies	 (see	 Table	 3.2	 for	antibody	dilutions).	Following	a	PBS	wash	thrice,	coverslips	were	mounted,	and	 images	 captured	 using	 the	 BX53	 Olympus	 fluorescent	 microscope	(Olympus).	
 
3.2.5 Immunomagnetic bead conjugation to isolation antibodies 
Immunomagnetic	beads	were	prepared	as	previously	described	(see	Section	2.2.5).	 Following	 this,	 appropriate	 concentrations	 of	 antibodies	 against	human	EpCAM,	N-cadherin,	EGFR	or	Her-2	 (see	Table	3.2)	were	 incubated	with	the	beads	on	a	rotating	platform	for	90	minutes	at	room	temperature.	Beads	were	stored	at	4°C	until	use	within	4	weeks.	
	
3.2.6 Immunomagnetic isolation of cultured ovarian cancer cells 
Cells	were	seeded	at	2	x	105	cells	into	T25	cm2	flasks	(Sigma)	and	cultured	for	72	hours.	After	cell	detachment	with	EDTA/PBS	cells	were	spun	at	300	x	g	for	3	minutes	and	resuspended	in	1	mL	PBS.	After	hemocytometer	cell	counts	the	cell	 suspension	was	 then	diluted	 in	PBS	to	achieve	a	 final	concentration	of	
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approximately	4000	cells	/	mL.	Triplicate	5	µL	aliquots	of	that	cell	suspension	were	transferred	onto	slides	and	cells	in	each	5	µL	counted	using	brightfield	microscopy	to	validate	cell	counts.	100	cells	(usually	in	20-25	µl)	were	then	added	 into	800	µL	PBS,	40	µL	FC	buffer	and	30	µL	of	beads	coupled	 to	 the	either	EpCAM,	N-cadherin,	EGFR	or	Her-2	antibodies.	For	combined	targeted	isolation,	30	µL	of	beads	for	each	of	the	various	antibodies	were	used.	Before	(pre)	and	after	(post)	transfer	of	cells	into	binding	buffer,	the	same	volume	of	cell	suspension,	containing	an	average	of	100	cells,	were	spotted	on	slides	as	input	controls.	Pre	and	post	input	control	cells	were	dried	onto	the	slides	and	stained	with	DAPI	to	count	actual	cell	numbers	(nucleus	positive	events).	For	cell	 isolation,	 recovery	 rates	 were	 calculated	 as	 proportion	 of	 cells	immunomagnetically	recovered	from	PBS	compared	to	the	average	of	the	pre	and	post	input	control	cells.	
 
3.2.7 CTC isolation from patient blood 
At	each	peripheral	blood	collection,	9	mL	of	blood	per	tube	were	drawn	into	3	EDTA	vacutubes	per	patient	 (Greiner	Bio-One)	 and	processed	within	24	hours.	A	total	of	26	blood	collections	from	22	patients	were	analysed.	
Lymphoprep	and	Sepmate	tubes	were	used	to	separate	the	peripheral	blood	mononuclear	 cells	 (PBMCs),	 containing	 CTCs,	 according	 to	 the	manufacturer’s	 instructions	 (see	 Section	2.2.6).	 PBMCs	derived	 from	9	mL	blood	 each	were	washed	 once	 in	 PBS	 and	 resuspended	 in	 800	 µl	 binding	buffer,	40	µl	FC	buffer	and	either	30	µl	anti-EpCAM	antibody	coupled	beads	or	
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30	µl	anti-N-cadherin	antibody	coupled	beads	or	30	µl	of	each	were	added.	Cells	were	incubated	for	90	minutes	at	4°C	on	a	rotating	platform	and	then	loaded	 into	 binding	 buffer-primed	 IsoFlux	 cartridges	 for	 CTC	 enrichment	using	the	Fluxion	Standard	Isolation	Protocol	Rev2	with	collection	into	200	µl	 recovery	 tubes.	 Enriched	 CTCs	 samples	 were	 fixed	 with	 3.7%	formaldehyde	in	PBS	for	10	minutes	and	then	washed	in	binding	buffer	before	storage	in	binding	buffer	at	4°C	before	immunocytostaining.	
 
3.2.8 Immunocytostaining of CTCs 
The	sample	was	washed	once	in	binding	buffer	and	then	blocked	in	25	µL	10%	FBS	in	PBS	for	15	minutes	before	incubation	with	25	µL	anti-CD45	primary	antibody	(Fluxion)	diluted	1:100	in	10%	FBS	binding	buffer	for	30	minutes.	After	 a	 binding	 buffer	 wash,	 the	 sample	 was	 incubated	 with	 25	 µL	 CY3-conjugated	donkey	anti-rabbit	secondary	antibody	(Fluxion)	diluted	1:200	in	10%	 FBS	 /	 binding	 buffer	 for	 15	 minutes,	 then	 briefly	 washed	 and	permeabilized	in	0.2%	Triton	X-100	(Sigma)	in	PBS	for	10	minutes	followed	by	incubation	with	FITC-conjugated	anti-cytokeratin	(Sigma)	diluted	1:250	in	10%	FBS	/	binding	buffer	for	30	minutes.	After	two	washes	the	sample	was	loaded	 onto	 slides	 and	 mounted	 with	 ProLong	 Gold	 AntiFade	 reagent	containing	 DAPI	 (Thermo	 Fisher	 Scientific).	 Samples	 were	 visualised	 and	CTCs	enumerated	defined	as	DNA-positive,	 cytokeratin-positive	and	CD45-negative	 (Nuc+/CK+/CD45-).	 Images	 were	 captured	 by	 fluorescent	microscopy	 (Olympus	 BX53)	 with	 the	 20	 X	 objective	 using	 CellSens	Dimension	imaging	software.	
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3.2.9 VE-cadherin quadruple immunocytostaining 
For	quadruple	staining,	enriched	CTC	samples	were	pre-blocked	with	mouse	immunoglobulins	 as	 above.	 Subsequently,	 the	 CTC	 immunocytostaining	protocol	was	followed	to	the	Cy3-conjugated	donkey	anti-rabbit	IgG	antibody	probing,	 before	 one	 binding	 buffer	 wash	 and	 incubation	 with	 VioBlue	conjugated	anti-human	VE-cadherin	antibody	for	30	minutes	(see	Table	3.2),	followed	by	cytokeratin	probing	as	above.	Sample	mounting	media	included	DRAQ5	nuclear	dye	(Thermo	Fisher	Scientific,	Brendale,	Australia)	instead	of	DAPI.	 Imaging	 was	 performed	 as	 outlined	 above.	 VioBlue	 VE-cadherin	staining	 was	 scored	 immediately	 in	 Nuc+/CK+/CD45-	 cells	 to	 avoid	background	associated	with	slide	storage.		
 
3.2.10 Vimentin quadruple immunocytostaining 
For	quadruple	CTC	and	vimentin	staining,	enriched	CTC	samples	were	pre-blocked	in	25	µl	mouse	immunoglobulins	(Abacus)	at	a	final	concentration	of	1.2	µg	/	µl	 in	binding	buffer	 for	20	minutes	to	saturate	any	remaining	free	anti-mouse	 antibodies	 present	 on	magnetic	 beads,	 before	 a	 binding	 buffer	wash	 and	 fixing	 in	 3.7%	 formaldehyde	 for	 10	 minutes.	 Then	 the	 CTC	immunocytostaining	 protocol	 was	 followed	 until	 after	 the	 cytokeratin	probing.	Samples	were	washed	 in	binding	buffer	and	 incubated	with	Alexa	Fluor	647	conjugated	mouse	anti-human	vimentin	antibody	 (Abcam)	 for	1	hour	at	room	temperature	(see	Table	3.2).	After	three	washes	(2xPBS,	1xH2O),	samples	 were	 mounted	 onto	 slides	 with	 mounting	 media	 including	 DAPI	
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nuclear	 staining,	 cells	 were	 observed,	 and	 images	 captured	 as	 above.	Nuc+/CK+/CD45-	 cells	 were	 scored	 as	 EMT-CTCs	 when	 showing	 strong	vimentin	reactivity	(Vim+).		
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3.3 Results 
3.3.1 Identification markers in ovarian cancer cell lines 
A	literature	search	indicated	CA-125	as	a	potential	alternative	ovarian	cancer	CTC	 identification	marker.	CA-125	overexpression	has	been	reported	 in	all	six	ovarian	cancer	cell	lines	used	in	this	study,	and	is	present	in	up	to	90%	of	ovarian	cancer	tissues	as	determined	by	immunohistochemistry	(160-163).	Measuring	 changes	 in	 CA-125	 serum	 levels	 is	 the	 current	 standard	 serum	biomarker	to	monitor	treatment	response	or	progression	of	ovarian	cancer	patients	(162,	164,	165).	It	should	be	noted	though	that	discordance	between	CA-125	response	and	radiological	response	is	relatively	common	in	epithelial	ovarian	cancer	patients.	
In	this	study,	representative	epithelial	and	mesenchymal	ovarian	cancer	cell	lines	SKOV-3	and	ES-2,	respectively,	as	well	as	healthy	donor	PBMCs	(166)	were	 analysed	 for	 expression	 of	 the	 common	 CTC	 identification	 marker	cytokeratin	 in	 comparison	 to	 CA-125	 by	 immunofluorescence	 staining.	Cytokeratin	was	found	at	heterogeneous	levels	in	SKOV-3	and	ES-2	ovarian	cancer	cells,	with	ES-2,	despite	their	EMT	phenotype	being	known	to	(167,	168)	express	cytokeratin,	although,	at	overall	much	lower	levels.	Importantly,	cytokeratin	 was	 undetectable	 in	 PBMCs,	 supporting	 its	 utility	 as	 a	 CTC	identification	 marker.	 In	 contrast,	 CA-125	 was	 consistently,	 albeit	 at	heterogeneous	levels,	expressed	in	both	SKOV-3	and	ES-2	cells.	However,	CA-125	was	also	readily	detectable	in	healthy	donor	PMBCs,	making	it	unsuitable	to	distinguish	CTCs	from	residual	lymphocytes	(Figure	3.1).		
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Figure	3.1	Cytokeratin	and	CA-125	immunostaining	in	cultured	ovarian	
cancer	cells	and	healthy	donor	PBMCs.	The	indicated	ovarian	cancer	cell	lines	 SKOV-3,	 ES-2	 and	 healthy	 donor	 PBMCs	 were	 probed	 for	 the	 CTC	identification	 marker	 cytokeratin	 and	 the	 candidate	 CTC	 identification	marker	CA-125	(green).	DAPI	staining	(blue)	indicates	nuclei.	
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3.3.2 Screening ovarian cancer cell lines for cell isolation candidate cell 
surface markers 
We	 screened	 the	 literature	 for	 ovarian	 cancer	 cell	 surface	 markers,	 and	generated	a	panel	of	six	candidate	markers.	E-cadherin,	EpCAM,	MUC-1,	EGFR,	Her-2	 and	 N-cadherin	 were	 included	 due	 to	 their	 association	 with	 the	progression	and	metastasis	of	ovarian	cancer,	their	association	with	the	EMT	pathway,	or	because	they	had	previously	been	used	for	CTC	detection	(169-177).	The	presence	of	candidate	markers	was	evaluated	in	a	cohort	of	nine	different	ovarian	cancer	cell	lines	by	flow	cytometry	and	immunocytostaining.	This	 large	 cell	 line	 cohort	was	 employed	 to	 ensure	 better	 coverage	 of	 the	heterogeneity	of	ovarian	cancer	cells.	Inclusion	of	the	human	lymphoblastoid	cell	line	WME-099	as	a	control	confirmed	lack	of	expression	of	all	the	tested	cell	surface	markers	on	common	lymphocytes,	which	is	a	prerequisite	for	any	immunomagnetic	CTC	isolation	target	(Figure	3.2.1,	3.2.2).	
As	expected,	EpCAM	was	heterogeneously	expressed;	 further,	 it	was	never	found	on	the	entire	cell	population	of	any	ovarian	cancer	cell	line.	Generally,	60-80%	of	cells	from	each	of	the	tested	cell	lines	expressed	detectable	levels	of	 epithelial	 EpCAM,	 while	 two	 lines,	 ES-2	 and	 A2780,	 lacked	 detectable	EpCAM.	As	expected,	the	classic	epithelial	marker,	E-cadherin,	was	found	on	the	same	cell	 lines	 that	expressed	EpCAM,	although	the	proportion	of	cells	expressing	detectable	E-cadherin	tended	to	be	slightly	 lower,	ranging	from	25-80%,	 while	 ES-2	 and	 A2780	 did	 not	 express	 epithelial	 E-cadherin.	 N-cadherin	 expression,	 on	 the	 other	 hand,	 tended	 to	 be	 inversely	 related	 to	EpCAM	 expression.	 PEO1	 and	 ES-2	 are	 polarising	 examples.	 80%	of	 PEO1	
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cells	expressed	EpCAM	and	lacked	N-cadherin	expression,	while	80%	of	ES-2	cells	 expressed	 N-cadherin	 and	 lacked	 EpCAM	 expression	 (Figure	 3.2.1).	There	were	two	exceptions:	A2780	cells,	while	lacking	EpCAM	and	E-cadherin	expression,	also	lacked	detectable	N-cadherin	expression	in	the	majority	of	cells	 (>60%),	 while	 approximately	 65%	 of	 PEO14	 cells	 expressed	 EpCAM	despite	80%	of	cells	being	N-cadherin	positive,	clearly	indicating	overlap	of	expression	of	the	epithelial	and	mesenchymal	markers	in	these	cells.	MUC-1,	which	 is	 also	 considered	 an	 epithelial	 protein,	was	 undetectable	 in	 7	 of	 9	tested	cell	lines,	but	only	poorly	expressed	in	CAOV3	and	COLO316	cells	(less	than	15%	of	cells	from	both	cell	lines	stained	positive).	EGFR	expression	was	not	detected	on	A2780	cells,	but	was	strongly	expressed	on	about	80-100%	of	 cells	 from	 all	 the	 other	 ovarian	 cancer	 cell	 lines.	 Her-2	 expression	was	heterogeneous	 across	 the	 cohort	 of	 ovarian	 cancer	 cell	 lines,	 with	 a	proportion	of	10-65%	expressing	detectable	Her-2	in	most	lines.	Strong	Her-2	expression	was	detected	in	nearly	100%	of	SKOV-3	cells	(Figure	3.2.2).		
These	 data	warranted	 further	 testing	 of	 the	 possible	 cell	 isolation	 targets	EpCAM,	N-cadherin,	EGFR	and	Her-2	in	combination.		
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Figure	 3.2.1	 Screening	 for	 ovarian	 cancer	 cell	 surface	 proteins.	Expression	of	cell	surface	markers	was	determined	by	immunocytostaining	and	flow	cytometry.	Representative	ovarian	cancer	cell	lines	PEO-1	and	ES-2	were	probed	with	antibodies	against	the	indicated	proteins	and	detected	with	AlexaFluor	 488	 secondary	 antibodies	 (green),	 cell	 nuclei	 are	 stained	with	DAPI	(blue).	Proportion	of	cells	expressing	the	indicated	cell	surface	marker	is	 shown	 (%)	 with	 standard	 deviation	 from	 at	 least	 two	 independent	experiments.	
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Figure	3.2.2	Quantitative	flow	cytometry	analysis	of	cell	surface	marker	
expression	in	ovarian	cancer	cells.	The	indicated	ovarian	cancer	cell	lines	were	 tested	 for	 expression	 of	 the	 shown	 cell	 surface	 proteins	 by	 flow	cytometry.	The	proportion	of	 cells	 expressing	 the	 cell	 surface	markers	are	shown.	 The	 average	 mean	 fluorescence	 intensities	 indicating	 the	 protein	expression	levels	per	cell	are	marked	with	a	red	bar.	The	lymphocyte	cell	line	WME099	was	included	as	a	negative	control.	
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3.3.3 Suitability of candidate antibodies as immunomagnetic isolation 
targets 
As	an	initial	evaluation	of	whether	the	remaining	candidate	antibodies	were	suitable	 for	 immunomagnetic	 cell	 capture,	 antibodies	 against	 EpCAM,	 N-cadherin,	EGFR	and	Her-2	were	coupled	to	immunomagnetic	beads.	Defined	numbers	of	cultured	cells	were	initially	suspended	in	PBS.	A2780,	ES-2,	PEO1	and	SKOV-3	cells	were	chosen	as	the	most	informative	cell	lines	according	to	their	 flow	 cytometry	 expression	 profiles	 of	 the	 candidate	markers	 (Figure	3.2.2).	 Magnetic	 beads	 coupled	 to	 the	 various	 antibodies	 alone	 or	 in	combination	were	used	to	recover	the	cells	immunomagnetically.	
Among	 all	 antibody	 combinations	 and	 cell	 lines,	 the	use	 of	 EpCAM	and	N-cadherin	 targeted	 immunomagnetic	 isolation	 recovered	 the	 highest	proportion	of	cells	in	PEO1	cells	(35%).	For	ES-2	cells,	N-cadherin	targeted	isolation	captured	approximately	40%	of	cells,	and	as	expected,	these	EpCAM	negative	cells	were	not	isolated	by	EpCAM	targeting	alone.	The	combination	of	EpCAM	and	N-cadherin	recovered	approximately 35%	of	PEO1	cells,	thus	improving	 cell	 recovery	 compared	 with	 EpCAM	 and	 N-cadherin	 targeting	alone,	 with	 approximately	 20%	 and	 5%	 recovery,	 respectively.	 While	 no	improvement	 of	 cell	 recovery	 was	 observed	 for	 SKOV-3	 cells	 when	 using	EpCAM	and	N-cadherin	 together,	combined	targeting	did	achieve	 the	same	SKOV-3	cell	recovery	as	EpCAM	alone	targeting	(in	both	cases	around	50%),	while	N-cadherin	alone-based	isolation	captured	less	than	10%	of	cells.		
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EGFR	 and	 N-cadherin	 based	 isolation	 performed	 similarly	 well	 when	combined	with	EpCAM	targeting	for	three	tested	cell	lines	(ES-2,	PEO-1	and	SKOV-3).	
When	 cell	 capture	was	 evaluated	 by	 immunomagnetically	 targeting	Her-2,	less	than	5%	of	PEO1	cells	were	recovered	by	Her-2	alone-based	isolation.	The	combined	targeting	of	EpCAM	and	Her-2	recovered	25%,	five-fold	more	PEO1	cells,	which	is	nearly	identical	to	cell	recovery	when	targeting	EpCAM	alone,	highlighting	that	although	about	60%	of	PEO1	cells	do	express	Her-2	according	to	FACS	analysis	(Figure	3.2.2),	targeting	it	for	isolation	does	not	improve	cell	 recovery.	 In	SKOV-3	cells,	 a	known	Her-2	overexpressing	 cell	line,	about	50%	of	cells	could	be	captured	when	targeting	Her-2	alone;	this	recovery	was	similar	when	targeting	the	combination	of	EpCAM	and	Her-2,	and	a	slight	improvement	on	EpCAM	alone	(Figure	3.3).	
We	chose	to	focus	on	N-cadherin	over	EGFR	targeting	for	EMT-CTC	isolation	because	N-cadherin	is	more	established	as	a	central	protein	during	the	EMT	process	 (75).	 We	 disregarded	 Her-2	 based	 isolation	 as	 the	 cell	 line	 data	indicate	 that	 it	 only	 augments	 cell	 isolation	when	Her-2	 is	 over	 expressed	(SKOV-3	cells),	and	because	over-expression	occurs	in	only	13%	of	ovarian	cancers	(178).	These	decisions	were	also	informed	by	other	emerging	data	in	our	 laboratory	suggesting	 that	 targeting	 too	many	cell	 surface	proteins	 for	cell	 isolation	 may	 not	 be	 beneficial.	 This	 is	 further	 discussed	 later	 in	 the	chapter.	
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Figure	 3.3	 Immunomagnetic	 isolation	 of	 cultured	 of	 cancer	 cells	
targeting	candidate	cell	surface	markers.	Recovery	rates	of	ovarian	cancer	cell	lines	spiked	into	PBS	and	subject	to	immunomagnetic	cell	isolation.	(A)	ES-2,	 PEO1	 and	 SKOV-3	 cell	 recovery	 when	 subject	 to	 EpCAM,	 EGFR,	 N-cadherin	individually	or	indicated	combination	targeted	isolation.	(B)	PEO1	and	 SKOV-3	 cell	 recovery	 when	 subject	 to	 EpCAM,	 Her-2	 individually	 or	combination	targeted	isolation.	
 
3.3.4 EpCAM, N-cadherin and combination targeted CTC isolation 
from advanced ovarian cancer patients 
CTC	isolation	was	performed	using	the	Isoflux	Liquid	Biopsy	System	(Fluxion,	San	Francisco,	USA).	To	validate	whether	N-cadherin	in	addition	to	EpCAM	
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targeting	improves	CTC	isolation,	CTC	isolation	was	performed	on	20	patient	blood	 collections	 from	 18	 advanced	 ovarian	 cancer	 patients.	 CTC	 isolates	were	analysed	and	enumerated	according	to	standard	CTC	identification,	i.e.	nuclei	 containing,	 cytokeratin-positive	 and	 CD45-negative	(Nuc+/CK+/CD45-)	events.	CTCs	were	captured	 in	90%	(18/20)	of	patient	samples	 when	 EpCAM	 and	 N-cadherin	 were	 targeted	 together,	 in	 90%	(18/20)	 directing	 isolation	 at	 N-cadherin	 alone	 and	 slightly	 fewer	 (80%,	16/20)	by	directing	isolation	at	EpCAM	alone	(see	Figure	3.4	A,	Table	3.3).	CTC	 counts	 showed	 high	 intra-patient	 variability	 for	 all	 three	 isolation	methods	(0-376	for	EpCAM-,	0-853	for	N-cadherin-	and	0-1300	for	combined	targeted	isolation).	N-cadherin	directed	CTC	isolation	outperformed	EpCAM	based	 isolation	 by	 2.1-fold,	 based	 on	 median	 fold-change	 of	 CTC	 capture,	while	combined-targeting	of	N-cadherin	and	EpCAM	increased	CTC	capture	3.0-fold	 (see	 Table	 3.3).	 In	 10	 healthy	 blood	 donor	 control	 samples	 a	background	 of	 cells	 was	 observed	 that	 met	 the	 staining	 criteria	 for	 CTCs	particularly	 when	 N-cadherin	 alone	 or	 in	 combination	 with	 EpCAM	 was	targeted	 for	 isolation.	 Importantly,	 these	 “false	positive	CTCs”	were	highly	variable	in	number,	and	most	healthy	individuals	had	only	moderate	counts.	Forty	percent	(4/10)	of	healthy	individuals	had	however	>10	cells	detectable	in	9	mL	blood	meeting	the	CTC	definition	of	Nuc+/CK+/CD45-	(Figure	3.4	B).	
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Table	 3.3	 Comparative	 CTC	 isolation	 approaches	 with	 indicated	
antibodies	and	common	CTC	identification	(Nuc+/CK+/CD45-)	
Patient	 EpCAM	 N-
cadherin	
Fold-
change	
Combination	 Fold-
change	Pt	1	 20	 38	 1.9	 24	 1.2	Pt	2	 0	 17	 -	 2	 -	Pt	3	 0	 0	 -	 0	 -	Pt	4	 19	 25	 1.3	 58	 3.1	Pt	5*	 8	 288	 36.0	 82	 10.3	Pt	6	 48	 82	 1.7	 125	 2.6	Pt	7	 376	 853	 2.3	 1300	 3.5	Pt	72*	 236	 307	 1.3	 697	 3.0	Pt	8	 8	 24	 3.0	 42	 5.3	Pt	9*	 16	 162	 10.1	 68	 4.3	Pt	10	 4	 7	 1.8	 9	 2.3	Pt	11	 0	 0	 -	 0	 -	Pt	12	 51	 530	 10.4	 465	 9.1	Pt	13	 7	 47	 6.7	 29	 4.1	Pt	132	 20	 38	 1.9	 74	 3.7	Pt	14	 6	 46	 7.7	 8	 1.3	Pt	15	 0	 2	 -	 1	 -	Pt	16	 5	 21	 4.2	 8	 1.6	Pt	17	 4	 6	 1.5	 9	 2.3	Pt	18	 4	 3	 0.8	 1	 0.3	
	 	
Median	
fold-
change:	
2.1	 Median	fold-change:	 3.0	CTC	counts	per	9mL	blood.	Data	from	18	patients/20	blood	collections	with	CTCs	stained	by	the	common	identification	stain	(Nuc+/CK+/CD45-)	(n=10)	or	relevant	data	 from	 common	 stain	plus	Vim	 (n=4)	 or	VE-cadherin	 (n=6)	 are	 combined.	 Pt:	patient;	2:	re-collection	post	>3month	
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Figure	3.4	Cell	isolation	from	advanced	ovarian	cancer	patients.		
(A)	Data	from	20	blood	collections	(18	patients)	are	presented	to	compare	EpCAM,	 N-cadherin	 (N-cad)	 or	 the	 combination	 (Combi)	 targeted	 CTC	isolation	efficiencies	when	applying	standard	CTC	identification	(Nuc+,	CK+,	CD45-).	(B)	False	positive	“CTCs”	in	10	healthy	donor	blood	samples,	when	
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using	 standard	 CTC	 identification	 (Nuc+,	 CK+,	 CD45-).	 (C)	 CECs	 in	 heathy	individuals	and	patients:	The	same	cell	isolation	method	using	a	VE-cadherin	(VE-cad)	CEC	staining	protocol	identified	co-isolated	CECs	in	patients	(n=6)	and	healthy	controls	(n=9).		
Red	symbols:	patient-derived	CTCs	(A)	or	CECs	(C);	Black	symbols:	healthy	control-derived	false	positive	“CTCs”	(B)	or	CECs	(C).	All	counts	are	presented	as	cells	per	9mL	blood.	
 
3.3.5 Distinguishing CECs from CTCs 
Normal	 endothelial	 cells	 can	 shed	 into	 the	 bloodstream	 under	 certain	conditions	 and	 are	 then	 referred	 to	 as	 circulating	 endothelial	 cells	 (CECs).	CECs	are	present	in	healthy	individuals	(0-29/mL	blood),	are	found	at	higher	numbers	in	cancer	patients	and	most	importantly,	express	cytokeratin	and	N-cadherin	(1).	Thus,	it	is	likely	that	CECs	are	co-enriched	with	our	assay	and	may	 appear	 as	 “false	 positive	 CTCs”	 when	 isolation	 is	 directed	 at	 EMT	markers.		
To	 identify	 CECs,	 a	 quadruple-staining	 identification	 strategy,	 which	 was	specifically	 developed	 for	 this	 project,	 and	 included	 probing	 for	 the	endothelial	 marker	 VE-cadherin	 (VE-cad),	 revealed	 that	 isolated	 CECs,	defined	 as	 nuclei	 positive,	 cytokeratin	 positive,	 VE-cad	 positive	 and	 CD45	negative,	(Nuc+/CK+/VE-cad+/CD45-)	were	enriched	from	blood	collections	from	 an	 ovarian	 cancer	 patient	 cohort	 as	 well	 as	 healthy	 controls	 with	 a	
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comparable	distribution	to	the	cells	we	identified	as	“false	positive	CTCs”	(see	Figure	3.4	B,	C).	
The	 prevalence	 of	 CECs	 in	 ovarian	 cancer	 patients	 and	 healthy	 controls	confirmed	that	CEC	co-isolation	by	EpCAM	targeting	is	rare,	while	N-cadherin	targeting	is	associated	with	increased	identification	of	co-isolated	CECs.	CEC	counts	are	highly	variable	between	individuals	and	low	(<5)	in	approximately	60%	of	assayed	healthy	controls	and	patient	samples.	Strikingly	though,	 in	patient	 14,	 CECs	 (44/46)	 outnumbered	 CTCs	 (2/46)	 (see	 Figure	 3.5	 A),	highlighting	the	value	of	CEC	co-staining	during	CTC	identification. 
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Figure	3.5	CEC	and	EMT-CTC	capture	by	immunomagnetic	isolation.	(A)	
Top:	Representative	quadruple	staining	of	a	CTC	(VE-cad-,	CK+,	CD45-,	Nuc+)	and	 CEC	 staining	 (VE-cad+,	 CK+,	 CD45-,	 Nuc+).	 Bottom:	 Ovarian	 cancer	patient	 cells	 were	 isolated	 by	 EpCAM,	 N-cadherin	 (N-cad)	 or	 combined	targeting	as	indicated.	The	proportion	of	total	CTCs	and	CECs	captured	with	each	isolation	strategy	is	displayed.	All	counts	are	presented	as	cells	per	9mL	blood.	(B)	Top:	Representative	quadruple	staining	of	an	epithelial	(EPI)	and	an	EMT	phenotype	CTC.	Bottom:	Comparison	of	EMT-CTC	and	CECs	isolated	from	advanced	ovarian	cancer	patients	by	EpCAM	or	combined	EpCAM	plus	N-cadherin	 (Combi)	 targeting.	All	 counts	 are	 presented	 as	 cells	 per	 9	mL	blood.	
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3.3.6 EMT-CTC detection and discrimination from CECs 
To	 confirm	 the	 detection	 of	 EMT-CTCs,	 another	 quadruple-stain	 was	developed	for	Nuc+/CK+/CD45-	CTCs	by	including	the	EMT	marker	vimentin	(Vim)	into	the	identification	protocol	after	immunomagnetic	CTC	enrichment.	Due	to	microscope	limitations	(four	colour	detection	only),	it	was	impossible	to	include	Vim	and	VE-cad	detection	in	the	same	assay.	Moreover,	our	ethics	approval	at	the	time	prevented	taking	more	than	30mL	of	blood	per	patient	at	a	single	blood	draw.	Therefore,	to	determine	whether	the	presence	of	CECs	affected	EMT-CTC	detection,	we	decided	to	focus	on	CTCs	isolated	by	either	EpCAM	alone	or	in	combination	with	N-cadherin	targeting.	Quadruple-stain	for	VE-cad	or	for	Vim	in	CTCs	was	performed	on	parallel	blood	samples	from	six	patients,	five	of	whom	proved	positive	for	CTCs.	EMT-CTCs	were	observed	at	higher	counts	than	CECs	in	the	majority	of	patient	samples	regardless	of	isolation	method.	Only	patient	22	displayed	higher	CEC	counts	than	EMT-CTC	counts	associated	with	CTC	isolation	by	combination	targeting.	Importantly,	regardless	 of	 varying	 CEC	 co-purification,	 counts	 of	 cells	 considered	 true	EMT-CTC	 were	 always	 higher	 in	 combination-based	 CTC	 isolates	 in	comparison	to	EpCAM	alone	based	isolation	(Figure	3.5	B).		
This	project	set	out	to	demonstrate	increased	CTC	isolation	efficiency	with	a	newly	developed	method	and	blood	collections	were	not	restricted	to	specific	time	 points	 throughout	 treatment.	 Thus,	 not	 unexpectedly,	 no	 significant	correlation	 between	 CTC	 presence	 and	 disease	 parameters	 was	 observed	(Table	3.4).	
Chapter 3 Isolation of EMT-CTCs in ovarian cancer patients 
	75		
Table	3.4	CTC	positivity	and	correlation	with	patient	clinical	characteristics	
 
Clinical	Parameter	 Number	(%)	
Targeting	Method	
EpCAM	 P-
value	
N-cadherin	 P-
value	
Combination	 P-
value	CTC	+	 CTC	-	 CTC	+	 CTC	-	 CTC	+	 CTC	-	
CA-125	 		 		 		 		 		 		 		 		 		 		rising	 9	(56%)	 5	 3	 0.6145	 7	 2	 0.5962	 6	 3	 0.5846	stable	or	falling	 7	(44%)	 3	 4	 	 4	 3	 	 6	 1	 	
Stage	 	          I-III	 10	(59%)	 5	 5	 >0.99	 8	 2	 >0.99	 9	 1	 0.25	IV	 7	(41%)	 4	 3	 	 5	 2	 	 4	 3	 	
Ascites	 	          Yes	 3	(19%)	 1	 2	 0.55	 2	 1	 0.4893	 1	 2	 0.1357	No	 13	(81%)	 8	 5	 	 11	 2	 	 11	 2	 	
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On	Therapy	at	
Time	of	Blood	
Collection	
	          
Yes	 7	(44%)	 3	 4	 0.6145	 5	 2	 >0.99	 6	 1	 0.5846	No	 9	(56%)	 6	 3	 	 7	 2	 	 6	 3	 	
Disease	Status	 	          Progressing	 12	(70%)	 8	 4	 0.5928	 10	 2	 >0.99	 8	 4	 0.2605	Stable/Responding	 5	(30%)	 2	 3	 	 4	 1	 	 5	 0	 	
Age	 	          <63	 6	(35%)	 4	 2	 >0.99	 6	 0	 0.5147	 5	 1	 >0.99	≥63	 11	(65%)	 6	 5	 	 8	 3	 	 8	 3	 	
PFS	(days)	 	          <161	 7	(44%)	 6	 3	 >0.99	 7	 2	 >0.99	 8	 1	 0.55	≥161	 9	(56%)	 4	 3	 	 6	 1	 	 5	 2	 	
#	Previous	Lines	of	
Therapy	
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≥2	 8	(47%)	 4	 4	 0.6372	 6	 2	 0.5765	 4	 4	 0.0294	0-1	 9	(53%)	 6	 3	 	 8	 1	 	 9	 0	 	
Disease	bulk	 	          ≥5cm	 7	(58%)	 5	 2	 0.2424	 6	 1	 0.5227	 6	 1	 0.5227	<5cm	 5	(42%)	 1	 4	 		 3	 2	 		 3	 2	 		CTC	positivity	determined	as	a	CTC	count	>5,	>85	and	>29	for	EpCAM,	N-cadherin	and	combination	targeting	respectively	as	per	highest	number	of	DAPI+/CK+/CD45-	events	detected	in	healthy	donor	blood;	disease	bulk	determined	at	time	of	CTC	analysis;	PFS	and	age	dichotomised	as	per	median;	PFS	=	progression	free	survival;	P-value	determined	using	Fisher’s	exact	test
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3.4 Discussion In	 this	 study,	 we	 aimed	 to	 improve	 immunomagnetic	 CTC	 isolation	 from	ovarian	cancer	patients	with	a	particular	focus	on	capturing	both	CTCs	with	epithelial	 and	mesenchymal	 phenotype	 as	well	 as	 those	with	 intermittent	EMT	phenotype.		
 
3.4.1 Alternative identification markers 
Accompanying	an	E-cadherin	to	N-cadherin	switch,	other	epithelial	markers	are	also	down	regulated	(75,	179,	180).	While	additional	N-cadherin	targeting	may	 capture	 EMT	 phenotype	 CTCs,	 an	 issue	 for	 this	 study	 was	 that	cytokeratin,	 the	 most	 common	 positive	 identifier	 for	 CTCs	 (181),	 is	 an	epithelial	cytoskeletal	protein	that	may	also	be	downregulated	during	EMT	(180).	Downregulation	of	cytokeratin	expression	may	prevent	identification	of	EMT-CTCs	within	enriched	samples.	In	ovarian	cancer,	serum	CA-125	level	is	 the	 only	 tumour	 biomarker	 used	 in	 the	 clinic	 for	 diagnosis,	monitoring	recurrence,	and	to	an	extent,	assessing	tumour	burden	(164,	182).	While	CA-125	serum	levels	may	not	be	an	ideal	biomarker	(183,	184),	overexpression	of	 CA-125	has	 been	observed	 in	 a	 variety	 of	 ovarian	 cancer	 tissues	 and	 is	currently	the	best	marker	available	(162,	165).	Therefore,	 the	reliability	of	CA-125	 as	 a	 possible	 identification	 marker	 for	 ovarian	 cancer	 CTCs	 was	evaluated	 in	 this	 project.	 However,	 while	 the	 tested	 ovarian	 cancer	 cells	expressed	 CA-125,	 in	 our	 hands	 PBMCs	 also	 stained	 positive	 for	 CA-125.	Accordingly,	CA-125	detection	appears	unsuitable	as	a	method	to	distinguish	CTCs	from	residual	white	blood	cells.	This	is	further	substantiated	by	a	study	
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reporting	 that	 up	 to	 35%	 of	 peripheral	 blood	 and	 peritoneal	 fluid	lymphocytes	had	detectable	cell	surface	CA-125	(185).	
Without	a	better	ovarian	cancer	marker	available,	this	study	continued	to	use	of	 cytokeratin	 for	 CTC	 identification	 regardless	 of	 their	 EMT	 phenotype.	While	cytokeratin	probing	for	EMT-CTC	identification	is	not	ideal,	since	cells	can	be	present	at	any	stage	from	epithelial	to	intermittent	to	mesenchymal	transition	(see	Chapter	1,	Figure	1.1)	cytokeratin	probing	has	been	shown	to	detect	CTCs	of	at	least	the	intermittent	EMT	phenotype.	Even	cells	that	may	not	 express	 enough	EpCAM	 to	be	 immunomagnetically	 isolated	by	EpCAM	targeting	 can	be	 identified	 as	 long	 as	 sufficient	 cytokeratin	 is	 present.	 For	instance,	several	studies	have	reported	cytokeratin	positive	CTCs	expressing	EMT	markers,	 such	 as	 vimentin,	 N-cadherin	 and	 twist	 in	 breast,	 prostate,	colorectal,	pancreatic,	hepatocellular,	gastric,	 liver	and	NSCLC	patients	(17,	179,	 186-191).	 Additionally,	 despite	 ongoing	 research	 into	 alternative	markers,	cytokeratin	remains	the	most	common	CTC	identification	marker	to	date	 (27,	 162,	 165,	 192-195).	Most	 importantly,	we	 found	 that	 ES-2	 cells,	defined	as	an	ovarian	cancer	cell	line	displaying	a	mesenchymal	phenotype,	showed	 detectable,	 albeit	 low	 level	 cytokeratin,	 suggesting	 that	 ovarian	cancer	 EMT-CTCs	may	 express	 sufficient	 cytokeratin	 to	 be	 detected.	 Thus,	while	more	effective	identification	markers	may	emerge	in	the	future,	EMT-CTCs	 in	 this	 study	 were	 detected	 by	 cytokeratin	 probing.	 However,	 one	disadvantage	 is	 that	 some	 mesenchymal	 phenotype	 CTCs	 may	 have	 been	missed	(discussed	below).	
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3.4.2 Disregarded candidate proteins for immunomagnetic isolation 
Four	out	of	 six	cell	 surface	protein	candidates	studied	 in	 this	project	were	found	to	be	less	suitable	for	EMT-CTC	isolation	for	various	reasons:	
Epithelial	E-cadherin:	E-cadherin	is	an	epithelial	cell	surface	protein	and	has	been	used	as	an	epithelial	marker	to	identify	CTCs	in	a	broad	range	of	cancers	including	 NSCLC,	 prostate,	 colorectal	 and	 hepatocellular	 cancers	 (17,	 169,	196,	197).	During	EMT,	a	switch	from	E-cadherin	to	N-cadherin	expression	is	characteristic	(reviewed	by	(75)).	Flow	cytometry	and	immunocytostaining	data	 presented	 here	 confirm	 that	 EpCAM	 expression	 is	 closely	 associated	with	 E-cadherin	 expression	 although	 more	 common	 in	 a	 large	 cohort	 of	ovarian	cancer	cell	lines,	confirming	that	the	established	EpCAM-alone	based	isolation	of	CTCs	is	adequate	to	isolate	epithelial	cells.		
Epithelial	 MUC-1:	 MUC-1	 has	 previously	 been	 proposed	 as	 an	immunomagnetic	 target	 for	 ovarian	 cancer	 CTC	 isolation	 and	 reported	 as	being	 highly	 expressed	 in	 ovarian	 cancer	 tissue	 (198,	 199)	 .	 In	 this	 study	however,	MUC-1	cell-surface	expression	was	undetectable	in	7	of	9	ovarian	cancer	cell	lines	and	present	in	less	than	15%	of	both	CAOV3	and	COLO316	cells.	The	low	overall	MUC-1	detection	noted	here,	compared	with	previous	studies,	may	be	attributed	to	the	antibody	clone	used	here	(VU4H5),	which	binds	to	the	hypoglycosylated	tandem	repeated	protein	backbone	(200).	This	protein	 backbone	 is	 differentially	 exposed	 depending	 on	 the	 level	 of	glycosylation,	which	can	disrupt	antibody	binding,	resulting	in	poor	antigen	detection.	Notably,	cytoplasmic	staining	in	a	very	minor	proportion	of	CAOV3	and	COLO316	cells	was	very	distinct	and	easy	to	distinguish	(data	not	shown),	
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suggesting	the	antibody	used	in	this	study	did	detect	MUC1	and	that	the	lack	of	surface	expression	of	MUC1	found	by	FACS	in	most	of	the	tested	cell	lines	is	 a	 real	 result.	 We	 hypothesized	 that	 MUC-1	 could	 be	 expressed	 in	 vivo	(tissue)	but	not	necessarily	during	cell	culture,	but	other	studies	noted	the	presence	of	cell-surface	and	cytoplasmic	MUC-1	expression	in	ovarian	cancer	cell	 lines	 (139,	 201)	 so	 we	 are	 unclear	 as	 to	 the	 reasons	 behind	 the	discrepancies	between	this	study	and	other	reports.	Regardless	of	the	reason	for	 the	 discrepancy,	 we	 found	 that	 MUC-1	 was	 not	 suitable	 for	 use	 as	 an	immunomagnetic	isolation	target	protein.	
EMT	 associated	 EGFR:	 EGFR	 is	 often	 overexpressed	 in	 cancers,	 including	NSCLC,	primary	GBM	and	head	and	neck	cancers	(202-204).	However,	EGFR	expression	 in	 ovarian	 cancer	 as	 an	 independent	 prognostic	 marker	 is	controversial	with	no	clear	correlation	with	response	to	therapy	or	survival	(reviewed	 (205)).	 A	 recent	 study	 of	 CTC	 isolation	 using	 the	 CellSearch	platform	 and	 immunomagnetically	 targeting	 EpCAM,	 EGFR,	 or	 FGFR	 in	metastatic	colon,	prostate,	breast	and	endometrial	cancers	found	that	EGFR	targeting	 isolated	more	CTCs	than	EpCAM	targeting	 in	only	18%	(4/22)	of	patients	(169).	More	importantly,	 in	endometrial	cancers,	EpCAM	targeting	and	EGFR	targeting	detected	CTCs	in	71%	(5/7)	and	29%	(2/7)	respectively	and	 EGFR	 targeting	 did	 not	 detect	 CTCs	 in	 EpCAM	 targeted	 CTC	 negative	patients.	While	it	is	difficult	to	determine	if	EGFR	targeting	in	this	study	did	indeed	capture	some	CTCs	that	would	have	otherwise	been	missed	by	EpCAM	targeting,	the	data	suggest	that	EGFR	would	only	provide	marginal	benefit	in	addition	to	EpCAM.	In	our	hands,	EGFR	expression	was	detected	in	80-100%	
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of	 the	overall	 cell	population	 in	8/9	of	 the	 tested	ovarian	cancer	cell	 lines,	suggesting	 that	 EGFR	 targeting	 would	 perform	 well	 for	 cell	 isolation.	However,	 this	 hypothesis	 did	 not	 hold	 as	 strongly	 as	 expected	 for	 the	recovery	of	cultured	cells	in	this	project.	In	fact,	combined	targeting	of	EpCAM	and	EGFR	achieved	very	similar	cell	isolation	to	combined	targeting	of	EpCAM	and	N-cadherin	across	ES-2,	PEO1	and	SKOV-3	ovarian	cancer	cell	lines.	Given	that	 N-cadherin	 is	 a	 very	 well-established	 marker	 for	 EMT,	 EGFR	 was	consequently	dropped	in	favour	of	using	N-cadherin	targeting	for	this	study.		
EMT	 associated	 Her-2:	 Her-2	 overexpression	 has	 been	 reported	 to	 be	associated	with	the	EMT	phenotype	in	Her-2	inhibitor	resistant	breast	cancer	cells,	as	indicated	by	an	increase	in	growth	rate,	invasiveness,	increased	N-cadherin	 and	 decreased	 E-cadherin	 expression	 (206).	 Her-2	 is	 also	 a	 cell	surface	 protein	 targeted	 for	 CTC	 isolation	 in	 several	 studies	 and	 in	commercial	CTC	isolation	approaches	in	breast	and	gastric	cancers	(175,	207).	In	 this	 project,	 Her-2	 expression	 was	 heterogeneous	 across	 the	 cohort	 of	ovarian	 cancer	 cell	 lines.	 One	 cell	 line	 (SKOV-3)	 stood	 out	 not	 only	 by	expressing	 Her-2	 on	 nearly	 100%	 of	 cells,	 but	 also	 as	measured	 by	 FACS	analysis	due	to	a	very	high	mean	fluorescence	indicating	very	high	antigen	expression	 on	 all	 cells.	 This	 is	 in	 agreement	with	 SKOV-3	 being	 known	 to	overexpress	 Her-2	 (208).	 This	 finding	 together	 with	 the	 presented	 cell	capture	experiments	also	suggests	that	Her-2	targeting	may	only	be	effective	in	capturing	CTCs	from	Her-2	overexpressing	ovarian	cancers.	A	large,	multi-centre	 prospective	 trial	 indicated	 Her-2	 overexpression	 by	immunohistochemistry	staining	occurs	in	only	13%	of	ovarian	cancers	(178).	
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Thus	 Her-2	 targeting	 might	 provide	 additional	 benefit	 in	 enriching	 CTC	capture	from	only	a	small	subset	of	ovarian	cancer	patients.	On	this	basis,	Her-2	was	not	used	as	an	alternative	marker	for	this	project.		
	
3.4.3 Effective immunomagnetic cell surface marker for CTC isolation 
As	we	expected,	cell	surface	marker	expression	of	E-cadherin	mirrored	that	of	EpCAM	in	our	cohort	of	ovarian	cancer	cell	lines,	and	since	EpCAM-based	CTC	 isolation	 is	 a	 well-established	 and	 efficient	 method	 for	 capturing	epithelial	CTCs,	EpCAM	was	retained	as	the	only	CTC	isolation	marker	in	this	study.	 Because	 a	 switch	 from	 E-cadherin	 to	 N-cadherin	 is	 a	 central	characteristic	 of	 EMT	 (75,	 209,	 210),	 we	 hypothesised	 that	 combined	targeting	 of	 EpCAM	 and	 N-cadherin	 would	 enrich	 CTCs	 across	 the	 EMT	spectrum.	Consequently,	a	comparison	of	targeting	EpCAM,	N-cadherin	or	the	combination	of	both	for	immunomagnetic	ovarian	cancer	CTC	isolation	was	undertaken	in	this	study.		
We	 showed	 that	N-cadherin	 targeting	 can	 isolate	 cells	 that	do	not	 express	EpCAM	but	express	N-cadherin	(ES-2),	and	also	that	the	combination	of	N-cadherin-	and	EpCAM	targeting	may	increase	cell	capture	of	cells	expressing	both	 proteins.	 It	 is	 noteworthy	 that	 the	 capture	 efficiency	 of	 our	 isolation	strategies	using	defined	numbers	of	cultured	cells	was	below	expectations,	as	only	 10-60%	 of	 cultured	 cells	 were	 captured,	 which	 did	 not	 match	 the	proportion	 of	 cells	 shown	 to	 express	 the	 proteins	 by	 FACS.	 A	 background	capture	of	up	to	10%	was	observed	in	cases	where	lack	of	protein	expression	
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did	not	predict	capture.	Possible	reasons	for	this	observation	include	the	fact	that	 cell	 capture	 efficiencies	 are	 affected	 by	 the	 levels	 of	 target	 antigen	expression	 on	 cells,	 cross-reactivity	 of	 isolation	 antibodies	with	 other	 cell	surface	markers	in	a	non-specific	manner,	or	other	limitations	of	the	method.	
Varying	recovery	rates	of	cultured	cells	used	to	model	CTCs	have	also	been	reported	in	many	other	studies.	Using	the	CellSearch	CTC	isolation	platform,	one	study	showed	that	the	recovery	of	MCF-7,	SKBR3,	MDA-MB	231	breast	cancer	cells	was	66.6%,	49%	and	40.6%	respectively	(211).	Using	size-based	tumour	cell	isolation	with	the	Parsortix	platform,	the	mean	recovery	rate	of	prostate	cancer	cell	lines	PC3	and	DU145	were	54.4%	and	56.6%	respectively,	while	recovery	of	breast	cancer	cell	 line	MCF-7	was	56.7%	(212).	In	CD45-depleted	 samples	 combined	with	 immunofluorescence	 staining	 for	EpCAM	positive	cells,	proposed	 to	be	CTCs,	 the	mean	recovery	rate	of	 lung	HT116	cancer	 cells	 was	 61%	 (213).	 Moreover,	 in	 our	 laboratory,	 cell	 recovery	efficiencies	varied	from	70-80%	for	MDA-MB-231	and	PC3	cells	to	only	40-60%	 for	 HT29	 and	 LoVo	 cells	 (unpublished	 data)	 when	 using	 standard	EpCAM	targeted	immunomagnetic	isolation.	
Even	 within	 the	 same	 technology	 (eg.	 antibody-based	 immunomagnetic	capture),	 variations	 in	 capture	 efficiency	 are	 dependent	 on	 various	parameters	 including	 accuracy	 and	 strength	 of	 antibody	 binding,	 level	 of	antigen	expression	on	the	cell	surface	(which	would	determine	the	number	of	beads	that	may	potentially	bind	to	a	single	cell),	degree	of	heterogeneity	of	antigen	expression	from	cell	to	cell,	cell	size,	as	well	as	physical	cell	plasticity.	Thus	 cell	 line	 derived	 isolation	 efficiency	 data	may	 provide	 a	 guide	when	
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testing	cell	capture	techniques	in	principle,	but	it	is	clear	that	translation	of	these	data	 to	actual	patient	CTC	capture	efficiencies	 should	be	 interpreted	with	caution,	due	to	differences	between	cultured	cells	and	 in	vivo	CTCs	as	well	as	inter-	and	intra-patient	CTC	heterogeneity.	The	use	of	parallel	blood	samples	 is	 a	 more	 appropriate	 method	 to	 compare	 different	 CTC	 capture	methods.	 Therefore,	 the	 emphasis	 in	 this	 study	was	 put	 on	 comparing	 N-cadherin	 targeting	 to	 the	 EpCAM	 targeting	 for	 CTC	 isolation	 from	 patient	samples.		
 
3.4.4 EpCAM and N-cadherin-based CTC isolation from advanced 
ovarian cancer patients  
The	 data	 here	 show	 that	 targeting	 the	 EMT	 marker	 N-cadherin	 with	 a	commercially	 available	 anti-N-cadherin	 antibody	 [clone	GC-4]	 isolates	 2.1-fold	more	CTCs	from	advanced	ovarian	cancer	patients	than	EpCAM-alone-based	isolation	and	3.0-fold	more	when	used	together	with	EpCAM	targeting.	This	 increase	 in	 capture	 efficiency	 using	 anti-N-cadherin	 antibodies	 is	consistent	 with	 cell	 line	 data	 for	 mesenchymal-like	 cells	 ES-2,	 while	expectedly	 not	 in	 epithelial-like	 cells	 (SKOV-3,	 PEO1).	 CTC	 isolation	efficiencies	 from	80-90%	of	 our	 patients	 are	 comparable	 to	 other	 ovarian	cancer	 studies	 that	 detected	 CTCs	 from	 14%	 to	 85%	 of	 ovarian	 cancer	patients	depending	on	disease	stage	and	CTC	detection	methods	(214,	215).	Notably,	 CTC	 counts	 when	 targeting	 EpCAM	 alone	 were	 similar	 to	 those	reported	in	a	recent	ovarian	cancer	study	using	the	Isoflux	platform	(range	0-1208;	 median	 55)	 (216).	 In	 comparison	 to	 EpCAM	 alone	 targeted	 CTC	
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isolation,	 this	 study	 showed	 that	 CTC	 counts	were	 always	higher	when	N-cadherin	was	targeted	alone	or	in	combination	with	EpCAM.	
In	our	hands,	N-cadherin	alone	based	isolation	of	CTCs	always	isolated	more	CTCs	than	EpCAM	alone	based	isolation.	Also,	the	combined	targeting	always	improved	 CTC	 isolation	 compared	 to	 EpCAM	 alone	 targeting,	 but	 the	combination	 strategy	 was	 only	 superior	 to	 N-cadherin	 alone	 based	 CTC	isolation	 in	 about	half	 of	 the	 samples.	We	 speculate	 that	 immunomagnetic	beads	with	different	antibodies	in	the	same	admixture	can	cause	interference	with	 cell	 capture	 if	 only	 one	 of	 the	 targeted	 antigens	 is	 predominantly	expressed.	 Thus,	 an	 EMT-CTC	 population	 predominantly	 expressing	 N-cadherin	might	be	expected	to	be	more	efficiently	isolated	with	N-cadherin	only	targeting	than	by	adding	potentially	interfering	beads	coupled	to,	in	this	context	 less	 relevant	 anti-EpCAM	 antibodies.	 This	 scenario	 is	 evident	 in	EpCAM-null	ES-2	cells	recovery	where	combining	anti-EpCAM	with	anti-N-cadherin	immunomagnetic	beads	lead	to	reduced	cell	recovery	(Figure	3.3).	We	therefore	propose	that	antibody	cocktails	used	in	CTC	isolation	should	be	considered	with	caution.	Nevertheless,	we	propose	 that	 combining	EpCAM	with	N-cadherin	based	ovarian	cancer	CTC	isolation	will	ultimately	be	a	more	successful	 strategy	 than	 EpCAM	 alone	 targeting,	 particularly	 if	 also	investigating	 early	 stage	 patients,	 who	 would	 be	 expected	 to	 have	 more	epithelial	phenotype	CTCs.	
Other	strategies	to	improve	isolation	of	CTCs	that	have	undergone	EMT	have	been	reported	previously,	for	example	size	exclusion-based	CTC	enrichment.	While	this	is	an	elegant	approach,	it	may	miss	CTCs	of	sizes	equal	to	or	smaller	
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than	 blood	 cells.	 Immunomagnetic	 targeting	 of	 extracellular	 vimentin	 has	shown	some	success	in	capture	of	mesenchymal	phenotype	CTCs	(122,	217).	The	antibody	used	in	that	study	was	not	commercially	available	until	recently,	thus	our	study	did	not	compare	it	with	our	CTC	isolation	method.		
	
3.4.5 N-cadherin targeting co-isolates CECs and enriches EMT-CTCs 
The	data	 from	 this	 study	 confirm	 that,	 similar	 to	 size	 filtration-based	CTC	enrichment	 methods,	 CTC	 isolation	 strategies	 accounting	 for	 more	 than	EpCAM	expressing	CTCs	alone	 leads	to	higher	total	CTC	counts	(115,	120).	The	data	also	confirm	that	EpCAM-only	based	CTC	isolation	yields	purer	CTC	populations	as	contamination	with	false	positives	are	rare	in	comparison	to	N-cadherin-based	 CTC	 isolation.	 Our	 data	 also	 highlight	 that	 CECs	 are	 an	important	 cause	 of	 “false	 positive”	 CTC	 identification	 and	 are	 not	distinguished	 by	 the	 common	 CTC	 identification	 (Nuc+/CK+/CD45-).	Moreover,	CECs	not	only	express	N-cadherin	but	a	number	of	other	markers	that	have	been	previously	proposed	for	CTC	isolation,	such	as	EGFR,	vimentin	and	fibronectin.	With	a	cell	size	ranging	up	to	around	10	µm,	it	is	not	proven	that	size	exclusion	methods	of	CTC	isolation	will	exclude	CECs	efficiently.	Our	data	agree	with	studies	 that	 specifically	 targeted	CECs	 for	 isolation,	where	CEC	counts	were	highly	variable	in	healthy	individuals	(0-29/mL	blood)	and	tended	to	be	increased	in	some	disease	states,	including	cancer	(reviewed	in	(1)).	 Therefore,	 it	 is	 important	 to	 account	 for	 CECs	 when	 using	 any	 non-EpCAM-based	CTC	isolation	method.	This	project	developed	quadruple-stain	CTC	identification	(Nuc+/CK+/CD45-/VE-cad-)	to	reduce	the	identification	of	
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“false	 positive”	 CTCs	 by	 distinguishing	 them	 from	 co-isolated	 CECs.	Importantly,	regardless	whether	CECs	might	make	up	a	varying	proportion	of	cells	in	a	CTC	isolate,	parallel	samples	confirmed	that	immunomagnetic	CTC	isolation	based	on	EpCAM	plus	N-cadherin	does	isolate	more	EMT-phenotype	CTCs	 than	 EpCAM	 targeting,	 and	 moreover,	 any	 CECs	 can	 be	 readily	distinguished.		
This	 study	 aimed	 to	 improve	 immunomagnetic	 CTC	 isolation	 by	 also	capturing	EMT-CTCs,	 	 and	was	successful	 in	establishing	a	novel	EMT-CTC	isolation	strategy	in	predominantly	advanced	disease	ovarian	cancer	patients	(52).	 Irrespective	 of	 the	 underlying	 biology,	 our	 data	 suggest	 that	combination	 targeted	 CTC	 isolation	 improves	 overall	 CTC	 isolation	 in	 the	advanced	ovarian	cancer	setting.	The	study	also	captured	a	larger	number	of	CTCs	in	a	higher	proportion	of	advanced	ovarian	cancer	patients	by	combined	targeting	 of	 EpCAM	 and	 N-cadherin	 and	 confirmed	 increased	 EMT-CTC	numbers.	Therefore	 this	data	also	 supports	 the	notion	 that	ovarian	cancer	CTCs	 are	 quite	 heterogeneous	 in	 regard	 to	 EMT	 status	 which	 in	 turn	strengthens	 the	 hypothesis	 that	 emerging	 EMT-phenotype	 CTCs	 might	 be	associated	with	poorer	response	to	therapy	(218).	
While	 this	 study	 demonstrated	 an	 improved	 isolation	method	 for	 ovarian	cancer	CTCs,	 no	 significant	 correlation	between	CTC	presence	 and	disease	parameters	was	observed.	However,	it	should	be	emphasized	that	the	main	aim	 of	 this	 pilot	 study	 was	 to	 establish	 and	 validate	 the	 increased	 CTC	isolation	efficiency	when	targeting	the	combination	of	EpCAM	and	N-cadherin.	Thus	blood	collection	time	points,	in	regards	to	diagnosis	and	therapy	–	such	
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as	number	of	therapies	the	patient	has	been	exposed	to,	whether	or	not	the	patient	 is	 currently	 undergoing	 therapy	 or	 the	 patients	 current	 tumour	burden	–	were	not	defined.	This	heterogenous	blood	collection	would	have	affected	 the	 ability	 to	 compare	 intra-patient	 CTC	 data	 with	 disease	parameters.	 This	 is	 further	 confounded	 by	 the	 small	 cohort	 recruited	 for	validation	of	the	CTC	isolation	method.	A	follow	up	study	investigating	CTCs	in	a	larger	cohort	with	clearly	defined	blood	collection	time	points	would	be	of	benefit	in	determining	the	clinical	utility	of	CTCs	in	the	advanced	ovarian	cancer	patient	setting.	
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3.5 Conclusion The	aim	of	this	project	was	to	establish	a	CTC	isolation	method	that	better	accounts	for	epithelial	and	mesenchymal	CTCs.	This	aim	was	achieved	and	a	combined	 EpCAM	 and	 N-cadherin	 immunomagnetic	 targeting	 strategy,	 to	improve	on	overall	CTC	isolation	was	established.	The	data	from	this	study	suggest	 that	 non-EpCAM-based	 CTC	 isolation	 methods	 should	 employ	 a	quadruple-staining	 method	 to	 avoid	 “false	 positives”.	 The	 significance	 of	detecting	more	and	a	wider	range	of	CTC	phenotypes	is	that	they	are	more	likely	to	better	represent	the	biology	of	a	patient’s	ovarian	cancer	at	any	point	in	time,	thus	improving	their	value	as	potential	tumour	biomarkers.	Finally,	this	 novel	 combined	 antibody	 targeting	 approach	 is	 likely	 also	 useful	 in	improving	CTC	capture	in	other	cancer	types	as	outlined	in	Chapter	4.		
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Chapter 4  Isolation of EMT-CTCs from other 
carcinomas – testing the utility of electron microscopy 
imaging for CTC characterisation 
The	 data	 in	 this	 chapter	 are	 currently	 being	 written	 up	 as	 a	 research	manuscript.	
4.1 Introduction	The	establishment	of	an	efficient	method	to	isolate	EMT-CTCs	from	ovarian	cancer	 patients	 described	 in	 the	 previous	 chapter	 has	 wider	 applications,	since	EMT	 is	 implicated	 in	disease	progression	and	resistance	 to	 radiation	and	chemotherapy	in	many	other	carcinomas	(see	Chapter	1,	Section	1.2.2;	(72,	 196,	 219-223)),	 especially	 in	 non-small-cell	 lung	 cancer	 (NSCLC)	 and	metastatic	prostate	cancer	patients	(18,	53,	217,	222,	224,	225).	However,	the	proportion	 of	 CTCs	 lacking	 EpCAM	 and	 thus	 likely	 to	 have	 a	 more	mesenchymal	 phenotype,	 varies	 between	 studies	 and	 malignancies.	Remarkably,	some	reports	analysed	highly	metastatic	patients	that	would	be	expected	 to	 have	 CTCs,	 but	 none	 were	 found	when	 relying	 on	 traditional	epithelial	 marker-based	 isolation/identification,	 implying	 the	 presence	 of	mesenchymal	phenotype	CTCs	that	were	missed	using	the	isolation	strategy	(115,	169,	226-229).		
Our	hypothesis	is	that	these	types	of	CTCs	are	missed	by	canonical	EpCAM	–	based	methods	for	isolation;	in	other	words,	the	captured	CTC	spectrum	may	not	 fully	 represent	 the	patient’s	 cancer.	 Importantly,	 the	CTCs	missed	may	represent	the	most	aggressive	or	undifferentiated	population	of	CTCs,	having	
Chapter 4 Isolation and EM imaging of EMT-CTCs from other carcinomas 
	92		
lost	epithelial	characteristics	and	possibly	having	gained	metastatic	potential	(42,	45).		
As	mentioned	in	Chapter	1	(see	Section	1.4),	ultrastructural	analysis	of	CTCs	has	 recently	 been	 pioneered	 and	 although	 the	 rarity	 of	 CTCs	makes	 these	approaches	 difficult,	 identifying	 ultrastructures	 in	 CTCs	 that	 have	 been	associated	with	EMT	or	cancer	cell	phenotype	may	help	understanding	CTC	biology.	To	date,	studies	investigating	ultrastructural	changes	–	a	critical	tool	used	 to	 identify	 subtle	 morphological	 changes	 that	 contribute	 to	 the	modification	of	cellular	phenotype	and	behaviour	-	in	patient	CTCs	have	been	largely	unexplored	(230-233).	While	efforts	have	been	made	to	 investigate	patient	CTCs	at	the	electron	microscopic	level,	studies	to	date	have	focused	on	 in	 vitro-modelled	 CTCs	 (cultured	 cells)	 and/or	 scanning	 electron	microscopy	 which	 is	 limited	 to	 external	 cellular	 features	 (63-65).	 To	investigate	the	ultrastructure	of	CTCs,	super-resolution	confocal	microscopy	(SRCM)	and	correlative	light	electron	microscopy	(CLEM)	could	potentially	be	used.	
This	chapter	describes	validation	testing	of	the	newly	developed	method	for	EMT-CTC	isolation	in	blood	samples	from	patients	with	other	carcinomas,	in	particular	NSCLC	and	metastatic	prostate	cancer.	Additionally,	the	aim	was	to	investigate	 whether	 we	 could	 use	 EM	 strategies	 to	 detect	 ultrastructural	phenotypic	 differences	 of	 CTCs	 including	 EMT	 related	 features.	 EM	approaches	for	CTC	analysis	are	technically	very	challenging	in	our	samples,	due	to	the	rarity	of	CTCs	and	the	complex	preparations	required	for	electron	microscopic	 visualisation.	 Nevertheless,	 ultrastructural	 EMT	 related	
Chapter 4 Isolation and EM imaging of EMT-CTCs from other carcinomas 
	93		
characteristics	such	as	changes	in	cell	junctions,	intermediate	filaments	and	the	extracellular	matrix	have	been	detected	by	EM	previously	(234-236)	and	such	changes	could	be	present	in	EMT-CTCs.	
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4.2 Methods The	methods	described	and	used	in	this	chapter	are	separated	into	Section	1,	CTC	 methods	 slightly	 amended	 from	 previously	 established	 for	 ovarian	cancer	(Chapter	3)	and	Section	2	method	optimisation	to	allow	EM	imaging.	
	
Section 1. EMT-CTCs in NSCLC and prostate cancer 
4.2.1 Patients 
Patients	were	recruited	from	Liverpool	Cancer	Therapy	Centre.	Human	ethics	approval,	 HREC/13/LPOOL/158,	 was	 obtained	 and	 managed	 by	 the	CONCERT	Biobank.	Blood	samples	from	20	patients	were	analysed.	Patient	blood	was	processed	as	described	previously	(see	Chapter	3,	Methods,	CTC	isolation	from	patient	blood).	Clinical	information	was	sourced	from	patient	medical	records.	Patient	information	at	time	of	blood	sampling	was	collected	including	age	and	primary	cancer	site,	chemotherapy	regimen,	previous	lines	of	 therapy	prior	 to	CTC	 isolation,	 serum	biomarker	 levels	 and	 radiological	assessments	 (see	 Table	 4.1).	 All	 patients	 had	 advanced	 disease,	 as	determined	by	the	collaborating	oncologists	(distal	metastases,	resistance	to	therapy,	disease	burden,	treatment	history).	
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Table	4.1	Patient	clinical	characteristics	summary	
Clinical	Characteristic	 n	 %	
Age	Mean	(range)	 69	(51-87)	
Gender	 	 	Male	 13	 65%	Female	 7	 35%	
Cancer	Type	 	 	Lung	 14	 70%	Prostate	 6	 30%	
Disease	Status	#	 	 	Stable	 7	 35%	Progression	 11	 55%	N/A	 2	 10%	
Prior	Therapies	+	 	 	
<2	 7	 35%	≥2	 12	 60%	N/A	 1	 5%	#	at	time	of	diagnosis.	Disease	status	defined	by	the	overseeing	physician	as	patient	response	 to	 chemotherapy	 immediately	 prior	 to	 CTC	 sampling	 by	 assessing	radiological	 imaging	data	and	 clinical	notes.	+	prior	CTC	 sampling;	N/A:	data	not	available	from	electronic	medical	records	
	  
Chapter 4 Isolation and EM imaging of EMT-CTCs from other carcinomas 
	96		
4.2.2 Immunocytostaining of CTCs 
Samples	 were	 subject	 to	 immunocytostaining	 as	 previously	 described	 in	Chapter	 3	 (see	Methods	 Section,	 Immunocytostaining	 of	 CTCs)	with	 some	minor	 changes	 as	 follows.	 Following	 the	 10%	 FBS	 in	 PBS	 blocking	 step,	samples	 were	 probed	 with	 a	 combination	 of	 FITC-conjugated	 anti-CD45	(Biolegend,	California,	USA)	and	FITC-conjugated	anti-VE-cadherin	(Miltenyi	Biotec,	NSW,	Australia)	antibodies.	Both	exclusion	markers	(lymphocyte	and	endothelial	marker	respectively)	were	visualised	with	the	same	fluorescent	channel.	 AlexaFluor555-conjugated	 pan-cytokeratin	 (Cell	 Signaling	Technology,	 Massachusetts,	 USA)	 followed	 by	 Alexafluor647-conjugated	vimentin	 (Abcam,	 Melbourne,	 Australia)	 was	 used	 to	 probe	 patient	 CTC	samples	 (see	Table	4.2	 for	 antibody	and	dilution	details)	 and	Hoechst	dye	added	 to	 the	 mounting	 media	 to	 visualize	 nuclei.	 Finally,	 samples	 were	observed	using	the	ALS	CellCelector	and	images	were	scanned,	analysed	and	captured	as	described	below.	
 
	 	
Chapter 4 Isolation and EM imaging of EMT-CTCs from other carcinomas 
	97		
Table	4.2	Antibody	and	immunofluorescence	dilution	details	
α-human	antibody	 Dilution	 Company	(host);	[clone];	{conjugate}	 IF	 		VE-cadherin	(recombinant	human)	[REA199]	{FITC}	 1:10	 Miltenyi	Biotec	CD45	(mouse)	[HI30]	{FITC}	 1:50	 Biolegend	Pan-Cytokeratin	(mouse)	[C-11]	{AlexaFluor555}	 1:50	 Cell	Signaling	Technology	Vimentin	(mouse)	[V9]	{AlexaFluor647}	 0.57ng/μl	 Abcam	E-cadherin	(goat)	[polyclonal]	 1:200	 Abcam	N-cadherin	(rabbit)	[polyclonal]	 1:100	 Novus	Orange	quantum	dot	nanoparticles	(goat)	 1:100	 Sigma	Red	quantum	dot	nanoparticles	(rabbit)	 1:200	 Interpath	Biotinylated	IgG	 1:200	 Sigma	Streptavidin-blocking	reagent	 1-2	drops	 Thermofisher	Biotin-blocking	reagent	 1-2	drops	 Thermofisher	Rabbit	anti-goat	AlexaFluor488	secondary	antibody	 1:2000	 LifeTechnologies	Goat	anti-rabbit	AlexaFluor647	 1:1000	 Jackson	ImmunoResearch	
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4.2.3 ALS CellCelector imaging of patient CTC samples 
The	CellCelector	(ALS,	Jena,	Germany)	is	a	semi-automated	micromanipulator	consisting	of	 an	 inverted	 fluorescent	microscope	 (CKX41,	Olympus,	Tokyo,	Japan)	 with	 a	 CCD	 camera	 system	 (XM10,	 Olympus,	 Tokyo,	 Japan)	 and	 a	robotic	arm	with	a	vertical	glass	capillary.	For	CTC	micromanipulation	we	use	a	 30	 µm	 diameter	 capillary.	 After	 enrichment	 and	 immunostaining,	 CTC	samples	were	resuspended	in	300	µl	and	transferred	onto	specific	glass	slides	with	hydrophobic	boarders	(ALS)	using	aerosol	barrier	tips	(Interpath,	VIC,	Australia).	A	custom	slide	holder	(ALS)	with	magnetic	strips	bordering	the	glass	slide	aperture	was	used	to	help	maintaining	magnetic	bead	bound	cells	into	place	during	automatic	scanning.	Samples	were	automatically	scanned	using	the	following	channels:	DAPI	(detects	Hoechst	nuclear	staining),	FITC	(detects	 blood	 and	 endothelial	 cell	 markers	 CD45;	 VE-cadherin),	 TRITC	(detects	 CTC	 cytokeratin	 markers)	 and	 Cy5	 (detects	 the	 EMT	 marker	vimentin)	 at	 20	 X	 objective.	 Exposure	 times	 and	 threshold	 settings	 were	manually	 determined	 for	 each	 patient	 sample	 analysis	 using	 AVISO	CellCelector	software	3.0	(ALS,	Jena,	Germany)	within	the	listed	ranges	(see	Table	4.3).	Epithelial	phenotype	CTCs	(EPI-CTCs)	are	defined	as	positive	for	nuclear	 staining,	 positive	 for	 cytokeratin	 and	 CD45/VE-cadherin	(Hoechst+/CK+/CD45-/VE-cad-/Vim-)	 while	 EMT	 phenotype	 CTCs	 (EMT-CTCs)	are	additionally	positive	for	vimentin	(Hoechst+/CK+/CD45-/VE-cad-/Vim+).	 CTC	 numbers	 (epithelial	 and	 EMT-CTCs)	were	 semi-automatically	determined	from	CellCelector	scans.	
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Table	4.3	ALS	CellCelector	automated	scanning	exposure	and	analysis		
settings	
		
4.2.4 Cell lines 
NSCLC	cancer	cells	HCC827,	H3255	and	H1975	were	maintained	as	described	previously	(see	Section	2.2.2).	All	NSCLC	cell	lines	were	small	tandem	repeat	(STR)	authenticated	(AGRF,	Melbourne,	Australia)	and	Mycoplasma	negative.	
 
4.2.5 Immunofluorescence staining of NSCLC cell lines 
Cells	were	prepared	and	imaged	as	described	previously	(see	Section	2.2.4).	Briefly,	 NSCLC	 cancer	 cells	 were	 cultured	 in	 12-well	 plates	 on	 sterile	coverslips	for	72	hours,	blocked	with	10%	FBS	and	then	probed	with	relevant	primary	antibodies	(see	Table	4.2	for	antibody	dilutions).	Cells	were	washed	and	 probed	 with	 appropriate	 secondary	 antibodies	 (see	 Table	 4.2	 for	antibody	dilutions).	Following	a	PBS	wash	thrice,	coverslips	were	mounted,	and	observed	using	an	IX71	Olympus	fluorescent	microscope	(Olympus). 	
	
		
Scanning	 Event	Analysis	
Channel	 Exposure	Time	(ms-1)	 Threshold	(arbitrary	units)	DAPI	 10	-	20		 8	000	<	20	000	FITC	 50	-	100	 6	000	<	20	000	TRITC	 50	-	75	 5	000	<	20	000	CY5	 75	-	125	 6	000	<	20	000	
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Section 2. Method Optimisation Aimed at Electron Microscopy 
Imaging of CTCs 
Method	development	described	here	aimed	to	test	the	suitability	of	various	EM	 approaches	 to	 analyse	 CTCs.	 Importantly,	 the	 following	methods	were	explored	for	the	purposes	of	integrating	EM	methods	into	our	established	CTC	processing	workflow.		
a) Field-emission	 scanning	 electron	 microscopy	 (FESEM)	 imaging	combined	with	super-resolution	confocal	microscopy	correlative	light	electron	microscopy	(CLEM)	imaging	
b) Quantum	 dot	 nanoparticle	 immunolabelling	 optimisation	 validated	with	super-resolution	confocal	and	transmission	electron	microscopy	(TEM)	 imaging	 aiming	 at	 correlative	 fluorescence	 and	 electron	microscopy	
c) TEM	imaging	to	visualise	cellular	ultrastructures	
Various	initial	experiments	and	method	optimisations	used	cultured	cancer	cells	 (epithelial	 MCF-7	 breast	 cancer	 cells	 or	 mesenchymal	 ES-2	 ovarian	cancer	cells).	Only	promising	methods	were	validated	 in	some	of	 the	same	NSCLC	and	prostate	cancer	patient	CTC	samples	that	had	undergone	initial	testing	as	described	in	Section	1	of	this	chapter.	
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4.2.6 FESEM imaging of immunomagnetic bead-bound cultured cells 
First,	we	wished	to	establish	whether	magnetic	beads,	as	present	in	our	CTC	isolates	 from	 the	 IsoFlux	platform,	were	 compatible	with	FESEM.	Cultured	MCF-7	and	ES-2	cells	were	seeded	at	2	x	105	cells	into	T25	cm2	flasks	(Sigma),	harvested	 with	 PBS/EDTA	 and	 incubated	 with	 immunomagnetic	 beads	prepared	 as	 previously	 described	 (see	 Chapter	 3,	 Section	 3.2,	Immunomagnetic	 bead	 conjugation	 to	 isolation	 antibodies).	 Samples	were	then	 washed	 thoroughly	 with	 distilled	 H20,	 mounted	 onto	 carbon-coated	glass	 slides	 (Menzel-Glazer)	 and	 left	 to	 dehydrate.	 The	 slides	 were	 then	coated	with	 a	 thin	 layer	 of	 carbon	 using	 an	 agar	 automatic	 carbon	 coater	(Emgrid	Australia).	The	slides	were	marked	with	fiducial	markers	to	aid	with	re-finding	 visual	microscopic	 fields	 using	 the	 secondary	 electron	 detector.	Samples	 were	 then	 visualised	 using	 the	 GeminiSEM	 300	 field	 emission	scanning	electron	microscope	(Carl	Zeiss)	using	the	back	scattered	electron	detector	at	2.00	kV.	
	
4.2.7 Immunofluorescence microscopy validation of polyclonal 
antibodies E-cadherin/N-cadherin 
With	 a	 view	 to	 use	 correlative	 fluorescent	 light	 electron	 microscopy,	alternative	 antibodies	 targeting	 EMT-related	 markers	 E-cadherin	 and	 N-cadherin	 were	 optimised.	 Initially,	 the	 quality	 of	 the	 antibodies	 were	validated	with	conventional	immunofluorescence	microscopy	methods	using	secondary	antibodies	routinely	used	in	our	lab.	
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MCF-7	and	ES-2	cells	were	cultured	as	previously	described	(see	Chapter	3,	Section	3.2,	Tissue	Culture).	Briefly,	cells	were	seeded	at	2	x	105	cells	into	T25	cm2	flasks	(Sigma)	for	72	hours,	detached	with	EDTA/PBS	and	spun	at	300	x	g	 for	 3	 minutes.	 Cells	 were	 resuspended	 in	 1mL	 PBS	 and	 aliquoted	 into	samples	of	approximately	1.5	x	105	cells.	Cells	were	blocked	with	blocking	buffer	(10%	FBS	in	PBS)	for	20	minutes	followed	by	incubation	with	primary	antibodies	 goat	 polyclonal	 E-cadherin	 and	 rabbit	 polyclonal	N-cadherin	 at	1:100	dilution	in	blocking	buffer	for	180	minutes	and	60	minutes	respectively.	Samples	were	washed	with	PBS,	followed	by	incubation	with	rabbit	anti-goat	AlexaFluor488	 (LifeTechnologies)	 or	 goat	 anti-rabbit	 AlexaFluor647	(Jackson	ImmunoResearch)	diluted	1:2000	and	1:1000	respectively	in	10%	FBS	in	PBS	for	30	minutes.	After	a	final	wash,	supernatant	was	removed	and	samples	 mounted	 onto	 glass	 slides	 (Menzel-Glaser)	 with	 1	 x	 Hoechst	(Fluxion)	in	mounting	media	(Fluxion).	Cells	were	visualised	with	an	inverted	fluorescent	microscope	(Olympus	IX71)	and	images	captured	with	the	20	X	objective	with	CellSens	Dimension	imaging	software.	
 
4.2.8 Quantum dot immunostaining of cultured cells and CTC samples  
Having	 shown	 the	 suitability	 of	 the	E-cadherin	 and	N-cadherin	 antibodies,	their	 detection	 using	 quantum	 dots	 was	 assessed.	 Quantum	 dots	 are	essentially	 fluorescent	 cadmium	 selenide	 nanoparticles	 that	 are	 visualised	using	 fluorescence	 microscopy	 and	 are	 also	 detectable	 by	 EM.	 Since	 the	intention	was	to	add	the	quantum	dot	staining	to	the	already	analysed	CTC	samples	using	 the	EMT-CTC	 isolation	and	 identification	protocol,	 quantum	
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dot	immunostaining	was	validated	using	mimicked	CTC	samples	(MCF-7	and	ES-2	cells	 isolated	with	anti-EpCAM	and	anti	-N-cadherin	immunomagnetic	beads;	 as	 described	 in	 Chapter	 3,	 Section	 3.2,	 ‘Tissue	 Culture’;	‘Immunomagnetic	isolation	of	cultured	ovarian	cancer	cells’).		
CTC	 samples	 were	 then	 blocked	 with	 1-2	 drops	 of	 streptavidin-blocking	reagent	 (ThermoFisher)	 for	 30	minutes.	 After	washing	with	 PBS,	 samples	were	 blocked	 with	 1-2	 drops	 of	 endogenous	 biotin-blocking	 reagent	(ThermoFisher)	for	30	minutes	followed	by	another	PBS	wash.	Samples	were	then	probed	with	goat	polyclonal	E-cadherin	(R&D	Systems)	diluted	1:100	in	blocking	buffer	 for	180	minutes.	Samples	were	washed	with	PBS	and	 then	probed	with	anti-goat	IgG	conjugated	to	orange	quantum	dot	nanoparticles	(Sigma)	diluted	1:100	in	blocking	buffer	for	60	minutes.	After	briefly	washing	with	 PBS,	 the	 sample	 was	 then	 probed	with	 rabbit	 polyclonal	 N-cadherin	(Novus)	 diluted	 1:100	 in	 blocking	 buffer	 and	washed	with	 PBS	 again.	 The	sample	was	then	probed	with	biotinylated	goat	anti-rabbit	IgG	diluted	1:200	(Sigma)	in	blocking	buffer	for	60	minutes,	washed	briefly	in	PBS,	followed	by	probing	with	red	quantum	dot	585	nm	conjugated	anti-biotin	diluted	1:200	(Interpath)	 in	 blocking	 buffer	 for	 60	 minutes.	 Samples	 were	 washed	thoroughly	with	MilliQ	water	 thrice	 to	 remove	 residual	PBS	salts.	 Samples	were	 resuspended	 in	 MilliQ	 water	 and	 Hoechst	 nuclear	 dye	 to	 identify	nucleated	 cells,	 mounted	 onto	 a	 glass	 slide	 (Menzel-Glaser)	 with	 fiducial	markers	 for	 manual	 correlative	 light	 and	 electron	 microscopy	 (CLEM)	imaging.	Samples	were	viewed	and	confocal	images	captured	with	the	LSM-800	(Zeiss,	 Jena,	Germany)	at	20	X	/	40	X	objectives	using	Airyscan	mode.	
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Samples	 were	 subsequently	 imaged	 using	 Morgagni	 268D	 transmission	electron	microscope	(FEI	Company)	as	described	above.	
	
4.2.9 Super-resolution confocal laser scanning microscopy (SRLSM) 
Cultured	cell	preparations	were	viewed	using	a	Zeiss	LSM	800	confocal	laser	scanning	 microscope	 (Carl	 Zeiss)	 and	 images	 analysed	 using	 the	 LSM	Software	Zen	2.3	(Blue	Edition).	Prepared	samples	were	initially	located	and	visualised	using	the	10	X	and	20	X	objectives,	the	DAPI	channel	was	screened	followed	 by	 image	 acquisition.	 Following	 adjusting	 exposure	 and	 gain	settings	 within	 range	 indicator	 limits	 at	 the	 20	 X	 objective,	 images	 were	captured	using	oil	immersion	at	63	X	objective.	Finally,	Airyscan	mode	was	used	to	acquire	super-resolution	confocal	images.		
	
4.2.10 Transmission electron microscopy (TEM) 
Electron	microscopy	 is	 a	 powerful	 tool	 used	 to	 visualise	 cells,	 subcellular	organelles	 and	 their	 surrounding	matrix	 at	 sub-nanometre	 resolution.	The	ultrastructural	 features	of	cells	have	been	documented	over	many	decades	(237-239)	and	from	this	knowledge	it	is	possible	to	infer	biological	behaviour	and	cell	 function.	 In	this	study,	TEM	was	used	to	visualise	cultured	cells	to	mimic	CTCs	and,	importantly	for	the	first	time	to	visualise	patient	CTCs	at	an	ultrastructural	level.	The	presence	of	CTCs	was	confirmed	by	an	experienced	electron	microscopist	(A/Prof	Murray	Killingsworth)	by	defining	cancer	cells	versus	residual	blood	cells	as	per	 the	 following	criteria:	nucleus:cytoplasm	
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ratio,	nucleus	irregularities,	typically	larger	in	size	and	cytoplasm	abundant	with	 membrane-bound	 secretory	 organelles.	 Epithelial	 and	 EMT	characteristics	 in	 cultured	 cells	 and	 patient	 CTCs	 were	 also	 observed	including	 increased	 extracellular	 matrix,	 dilated	 rough	 endoplasmic	reticulum,	 fragmentation	 of	 collagen	 fibres,	 and	 cell	 membrane	migratory	protrusions	such	as	filopodia.	
Briefly,	 CTC	 samples	 were	 recovered	 following	 fluorescence	 microscopy	imaging.	 Samples	were	 fixed,	 dehydrated,	 embedded	 in	 resin	 and	 sections	prepared	using	an	ultramicrotome	as	described	below	(adapted	from	(240)).	Samples	were	visualised	using	a	Morgagni	268D	TEM	(FEI	Company,	USA),	and	images	acquired	using	an	integrated	MegaView	III	digital	monochrome	camera	(Olympus	SIS,	Germany)	as	described	below.	
	
4.2.11 TEM sample preparation 
Glutaraldehyde	fixative	at	0.1M	pH	7.4	was	added	to	recovered	CTC	samples	in	 PBS	 at	 a	 1:1	 ratio	 resulting	 in	 a	 final	 concentration	 of	 2.5%.	 Following	fixation,	samples	were	immersed	in	sodium	cacodylate	buffer	(0.1M	pH	7.4)	for	 20	 minutes	 and	 repeated	 for	 another	 20	 minutes	 to	 remove	 residual	fixative	from	samples.	Buffer	was	removed	then	samples	were	immersed	in	2%	 OsO4	 at	 room	 temperature	 for	 4	 hours.	 OsO4	 was	 then	 removed	 and	samples	 immersed	 in	2%	sodium	acetate	 for	10	minutes.	After	 removal	of	sodium	 acetate,	 2%	 uranyl	 acetate	 was	 added	 to	 samples	 at	 room	temperature	 for	 1	 hour.	 Samples	 were	 then	 dehydrated	 using	 increasing	
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ethanol	concentrations	in	10	minutes	intervals	using	50%,	70%,	95%	ethanol	then	a	20	minute	dehydration	with	100%	ethanol	twice.	A	final	100%	acetone	dehydration	for	30	minutes	twice	was	performed.	Spurr	low-viscosity	epoxy	resin	 (Sigma)	was	prepared	 in	 a	polyethylene	 cup	by	 adding	10.0	 g	 epoxy	monomer	 vinyl	 cyclohexene	 dioxide	 (ERL	 4221),	 6.0	 g	 of	 epoxy	 resin	diglycidyl	 ether	 of	 polypropylene	 glycol	 (DER	 732)	 and	 26.0	 g	 of	 nonenyl	succinic	anhydride	(NSA).	Resin	mixture	was	thoroughly	stirred	for	2	minutes	using	wooden	sticks.	Once	the	solution	was	 fully	mixed,	 fifteen	drops	of	2-dimethylaminoethanol	epoxy	accelerator	was	added	and	the	mixture	stirred	again	 for	 2	 minutes.	 Samples	 were	 resin	 embedded	 by	 replacing	 100%	acetone	with	a	1:1	ratio	of	resin	to	acetone	for	1	hour,	followed	by	6:1	resin	to	 acetone	 for	 3	 hours.	 Finally,	 100%	 resin	was	 added	 and	 left	 overnight.	Tissue	was	 transferred	 into	 fresh	resin	 in	8	mm	micromoulds	(Proscitech)	and	cured	overnight	at	70°C.	
Semithin	 sections	 (0.5	µm	 thick)	were	 cut	using	a	 semithin	diamond	knife	(Diatome,	 Switzerland)	 which	 was	 placed	 in	 an	 RMC	 Powertome	ultramicrotome	 (Boeckeler	 Instruments,	 USA)	 for	 sectioning	 0.5	 µm.	 The	knife	water	 trough	was	 filled	until	 the	knife	 edge	was	 covered	and	a	 level	reflection	of	the	water	surface	was	seen.	Sections	were	cut	onto	the	water	and	floated	on	the	surface.	Sections	were	then	collected	onto	a	glass	slide	which	was	then	dried	using	a	hotplate	at	110°C	for	10-20	seconds.	Sections	were	then	 etched	 with	 sodium	 ethoxide	 solution	 for	 20	 seconds	 followed	 by	washing	with	100%	ethanol	and	distilled	water.	Sections	were	then	stained	with	2%	methylene	blue	in	1%	borax	for	30	seconds	on	the	hotplate,	rinsing	
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with	tap	water	for	5	seconds	and	drying	on	the	hotplate	for	5	seconds.	They	were	then	stained	with	1.5%	basic	fuchsin	at	room	temperature	then	washed	in	tap	water	for	20	seconds	and	dried	on	the	hotplate.		
Bright-field	 light	microscopy	was	 used	 to	 identify	 a	 region	 of	 interest	 and	confirmed	presence	of	tumour	cells.	Ultrathin	sections	were	then	cut	using	an	ultrathin	Ultra	45	diamond	knife	(Diatome,	Switzerland).	Correct	knife	angle	of	6	degrees	and	cutting	speed	of	1	mm	/	second	were	set	up	as	recommended	by	the	manufacturer	and	90	nm	slices	generated.	Sections	were	stretched	and	flattened	by	waving	a	1	cm2	chloroform-soaked	filter	paper	within	1-2	mm,	making	sure	to	not	make	contact	with	the	water.	Ultrathin	sections	were	then	mounted	 on	 300-mesh	 thin-bar	 nickel	 TEM	 grid	 that	 had	 been	 dipped	 in	section	adhesive	solution,	and	sections	located	on	the	dull	side	of	the	grid.	The	section	adhesive	was	prepared	by	placing	20	cm	of	clear	tape	in	a	5	mL	vial	with	2.0	mL	of	acetone,	thoroughly	mixed,	and	left	to	stand	for	10	minutes.	The	tape	was	removed	and	adhesive	solution	left	in	the	vial.		
	
4.2.12 Optimized TEM preparation for rare cell imaging 
Due	to	the	rare	nature	of	CTCs	and	more	broadly	cells	present	in	the	samples,	TEM	 preparation	 methodology	 was	 optimized	 to	 concentrate	 the	 sample.	Samples	were	processed	as	above	(see	‘TEM	Sample	preparation’),	with	the	following	minor	changes:	sample	processing	was	performed	in	the	original	microfuge	 tube	 into	 which	 cells	 were	 collected,	 minimizing	 loss	 between	transfers	and	reducing	suspension	volume;	the	tubes	were	centrifuged	for	60	
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seconds	 following	each	 step,	 concentrating	 cells	 at	 the	bottom	of	 the	 tube.	Finally,	care	was	taken	during	initial	sectioning	of	the	cell-concentrated	tip	of	the	resin-embedded	sample	block.	0.5	µm	sections	were	prepared,	and	10	µm	field	of	vision	sections	screened	using	light	microscopy	to	identify	any	cellular	events	to	subsequently	image	using	TEM.	
	
4.2.13 TEM imaging 
The	sample	was	transferred	to	TEM	on	a	support	grid	for	visualisation	using	an	accelerating	voltage	of	80	kV.	Initially,	low	magnification	of	approximately	1400	x	was	used	to	navigate	around	the	grid	to	identify	CTCs	and/or	cultured	cells.	 Cells	 were	 then	 visualised	 at	 high	 magnification	 of	 approximately	50,000	x	or	above	to	identify	subcellular	organelles	for	confirming	the	CTC	phenotype.	TEM	images	were	captured	using	the	Morgagni	268D	TEM	(FEI	Company,	 The	 Netherlands)	 using	 a	 Megaview	 III	 digital	 monochrome	camera	equipped	with	a	1392	x	1040-pixel	sensor	with	Gamma	setting	of	1.00.	Images	were	 subsequently	 processed	 using	 TEM	 camera	 control	 software	(Soft	Imaging	System,	Germany).	
	
4.2.14 Analysing patient CTC samples with EM methods 
Six	NSCLC	patient	CTC	samples,	previously	analysed	and	described	in	Section	1,	were	subject	 to	quantum	dot	 immunostaining	and	visualised	using	TEM	imaging.	 Three	 NSCLC	 and	 two	 prostate	 cancer	 patient	 CTC	 samples	previously	 analysed	 and	 described	 in	 Section	 1,	were	 recovered	 following	
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fluorescent	microscopy	imaging	and	prepared	for	TEM	imaging	according	to	the	optimized	method	for	rare	cell	imaging	as	described	above.	
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4.3 Results 
Section 1. EMT-CTCs in NSCLC and prostate cancer 
4.3.1 CTC isolation in NSCLC and metastatic prostate cancer patients 
As	 previously	 described	 for	 ovarian	 cancer	 patient	 CTCs	 in	 Chapter	 3,	we	compared	efficiency	of	CTC	isolation	by	immunomagnetic	targeting	of	EpCAM,	N-cadherin	or	both.	The	aim	was	to	evaluate	whether	CTC	isolation	could	be	improved	by	enhancing	 the	detection	rate	of	CTCs	with	EMT	phenotype	 in	cancers	other	than	ovarian	cancer.	CTC	isolation	was	performed	from	blood	collected	from	14	advanced	NSCLC	and	6	metastatic	prostate	cancer	patients	in	total.	One	lung	cancer	patient	CTC	sample	was	excluded	from	the	analysis	due	 to	 technical	 issues	 during	 the	 fluorescent	 image	 capture,	 but	 the	remaining	19	samples	were	included	in	the	analyses	below.	All	patients	had	advanced	disease,	as	determined	by	clinical	parameters	(distal	metastases,	resistance	to	therapy,	disease	burden,	treatment	history;	see	Table	4.1).	Using	the	adapted	approach	for	ovarian	cancer	described	previously	(see	Section	3.3.3)	CTC-enriched	samples	were	probed	for	CK,	CD45,	VE-cad	and	vimentin	in	addition	to	nuclear	staining	(Hoechst)	with	the	difference	that	CD45	and	VE-cadherin	were	detected	together	 in	 the	same	fluorescent	channel.	CTCs	were	defined	as	nucleated	(Hoechst	positive),	CK	positive	and	CD45/VE-cad	negative	cells. 
Overall,	CTC	detection	across	all	cancer	types	was	highest	when	targeting	the	combination	 of	 EpCAM	 and	 N-cadherin	 for	 CTC	 isolation	 (11/19;	 58%)	compared	 with	 EpCAM	 or	 N-cadherin	 alone	 (8/19;	 42%	 and	 9/19;	 47%	respectively).	CTC	detection	was	significantly	higher	in	NSCLC	patients	when	
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targeting	 the	 combination	compared	with	EpCAM	alone	 (p=0.04,	Wilcoxon	matched-pairs	signed	rank	test).	While	CTC	detection	tended	to	be	higher	in	both	N-cadherin	or	combination	 isolated	approaches	compared	to	EpCAM-alone	 based	 isolation,	 CTC	 capture	 by	 targeting	 these	 various	 cell	 surface	markers	did	not	reach	statistical	significant	differences	regardless	whether	NSCLC	and	prostate	cancer	were	analysed	alone	or	combined	(see	Table	4.4).	Interestingly,	CTC	detection	was	statistically	significantly	higher	in	patients	younger	than	the	median	age	(<69),	when	the	combination	of	EpCAM	and	N-cadherin	was	 used	 (see	 Table	 4.4).	 Paradoxically,	 statistically	 significantly	higher	CTC	counts	were	observed	in	patients	with	stable	disease	rather	than	progressive	 disease	 in	 both	 N-cadherin	 alone	 and	 combination	 antibody	targeting	methods.	However,	due	to	the	small	cohort	recruited	here,	caution	is	advised	in	drawing	any	firm	conclusions	despite	statistical	significance.	
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Table	4.4	Correlation	of	clinical	characteristics	with	CTC	presence		
CTC	positivity	determined	as	a	CTC	count	≥1.	P-value	determined	using	one-sided	Fisher’s	exact	test.	
 
In	total,	CTCs	were	detected	in	13/19	(68%)	of	NSCLC	and	prostate	cancer	patient	samples,	with	11/13	(85%)	and	2/6	(33%)	detected	in	NSCLC,	and	
Clinical	
Parameter	 	
Targeting	Method	
EpCAM	
P-
value	
N-cadherin	
P-
value	
Combination	
P-
value	CTC	+	 CTC	-	 CTC	+	 CTC	-	 CTC	+	 CTC	-	
Age	 	 		 		 	 		 		 	 		 		 	<69	 	 5	 3	 0.1438	 4	 4	 0.2966	 7	 1	 0.0371	≥69	 	 3	 8	 	 3	 8	 	 4	 7	 	
Gender	 	 	 	 	 	 	 	 	 	 	Male	 	 4	 8	 0.2966	 7	 5	 0.2199	 5	 7	 0.0799	Female	 	 4	 3	 	 2	 5	 	 6	 1	 	
Cancer	
Type	 	 	 	 	 	 	 	 	 	 	Lung	 	 6	 7	 0.4938	 5	 8	 0.6215	 8	 5	 0.5062	Prostate	 	 2	 4	 	 2	 4	 	 3	 3	 	
Disease	
Status	 	 	 	 	 	 	 	 	 	 	Stable	 	 4	 4	 0.3522	 5	 3	 0.0317	 7	 1	 0.023	Progression	 	 7	 3	 	 1	 9	 	 3	 7	 	
#	Previous	
Lines	of	
Therapy	
	 	 	 	 	 	 	 	 	 	
<2	 	 2	 0	 0.164	 1	 1	 0.544	 1	 1	 0.678	≥2	 		 6	 11	 		 5	 12	 		 10	 7	 		
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prostate	cancer	patient	samples,	respectively	(see	Figure	4.1).	The	number	of	patients	where	CTCs	were	detected	was	higher	in	NSCLC	than	prostate	cancer	patient	samples;	CTCs	were	detected	in	6/13	(46%;	range	0-18),	7/13	(54%;	range	0-8)	and	9/13	(69%;	range	0-111)	when	using	EpCAM,	N-cadherin	or	the	 combination	 antibody	 targeting	 respectively.	 In	 metastatic	 prostate	cancer	 samples,	CTCs	were	detected	 in	2/6	 (33%;	 range	0-10),	2/6	 (33%;	range	0-8)	and	2/6	(33%;	range	0-10)	when	using	EpCAM,	N-cadherin	or	the	combination	 antibody	 targeting,	 respectively,	 however	 overall	 patient	numbers	were	very	low.	The	average	CTC	count	was	higher	when	N-cadherin	and	combination	antibody	 targeting	 for	CTC	 isolation	compared	 to	EpCAM	alone,	 while	 the	 median	 fold	 increase	 in	 number	 of	 CTCs	 isolated	 was	identical	 between	 N-cadherin	 and	 combination	 antibody	 compared	 with	EpCAM	targeting	alone.	
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Figure	 4.1	 Immunomagnetic	 isolation	 and	 immunofluorescence	
identification	 of	 CTCs	 from	 NSCLC	 and	 prostate	 cancer	 patients.	Comparison	of	CTC	isolation	efficiencies	when	targeting	EpCAM,	N-cadherin	or	 the	 combination	 targeting	 approach	 when	 applying	 standard	 CTC	identification	(Nuc+,	CK+,	CD45-/VE-cad-);	n=14	and	n=6	for	NSCLC	and	PCa	respectively.	Mean	 and	 standard	 deviation	 are	 shown	 in	 graph	 (*=p<0.05;	Wilcoxon	matched-pairs	signed	rank	test).		
	  
Chapter 4 Isolation and EM imaging of EMT-CTCs from other carcinomas 
	115		
4.3.2 Differential EMT-CTC detection in NSCLC and prostate cancer 
patients 
As	described	in	Chapter	3,	section	3.3	EMT-CTC	detection	is	defined	by	CTCs	that	 are	 also	 positive	 for	 the	 EMT	 marker	 vimentin.	 In	 our	 study,	 while	detectability	was	variable,	there	is	a	clear	trend	that	NSCLC	CTCs,	in	the	vast	majority	of	cases,	have	an	epithelial	phenotype	regardless	of	isolation	method,	whereas	 CTCs	 in	 prostate	 cancer	 patients,	 where	 detected,	 generally	displayed	EMT	phenotype.	In	CTC	positive	patient	samples,	EMT-CTCs	were	detected	in	4/11	(36%),	and	2/2	(100%)	of	NSCLC,	and	metastatic	prostate	cancer	patient	samples,	respectively	(see	table	4.5).	In	NSCLC	patients,	EMT-CTCs	 were	 detected	 in	 2/11	 (18%),	 2/11	 (18%)	 and	 4/11	 (36%)	 of	 CTC	positive	 patients	 when	 EpCAM,	 N-cadherin,	 or	 the	 combination	 antibody	targeting	 approach	 was	 used,	 respectively.	 Conversely,	 in	 prostate	 cancer	patients,	 EMT-CTCs	 were	 detected	 in	 2/2	 (100%),	 2/2	 (100%)	 and	 2/2	(100%)	 of	 CTC	 positive	 patient	 samples	when	 EpCAM,	 N-cadherin,	 or	 the	combination	antibody	targeting	approach	was	used	(see	Table	4.5).
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Table	4.5	Epithelial	and	EMT-CTC	Counts	in	NSCLC	and	metastatic	prostate	cancer	patients	
Sample	#	 Cancer	Type	
CTCs	
EpCAM	 N-cadherin	 Combination	
TOTAL	 EPI	 EMT	 TOTAL	 EPI	 EMT	 TOTAL	 EPI	 EMT	1	 Lung	 3	 3	 0	 5	 5	 0	 4	 4	 0	2	 Lung	 2	 2	 0	 0	 0	 0	 2	 2	 0	3	 Lung	 0	 0	 0	 0	 0	 0	 0	 0	 0	4	 Lung	 0	 0	 0	 3	 3	 0	 0	 0	 0	5	 Lung	 0	 0	 0	 0	 0	 0	 2	 0	 2	6	 Lung	 0	 0	 0	 0	 0	 0	 0	 0	 0	7	 Lung	 0	 0	 0	 8	 1	 7	 6	 6	 0	8	 Lung	 0	 0	 0	 0	 0	 0	 2	 2	 0	9	 Lung	 1	 1	 0	 0	 0	 0	 2	 2	 0	10	 Lung	 5	 5	 0	 6	 6	 0	 10	 8	 2	11	 Lung	 0	 0	 0	 0	 0	 0	 3	 2	 1	12	 Lung	 6	 4	 2	 8	 2	 6	 111	 108	 3	
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13	 Lung	 2	 0	 2	 	0	 0	 0		 0	 0	 0	14	 Prostate	 2	 0	 2	 3	 0	 3	 1	 0	 1	15	 Prostate	 0	 0	 0	 0	 0	 0	 0	 0	 0	16	 Prostate	 0	 0	 0	 0	 0	 0	 0	 0	 0	17	 Prostate	 0	 0	 0	 0	 0	 0	 0	 0	 0	18	 Prostate	 0	 0	 0	 0	 0	 0	 0	 0	 0	19	 Prostate	 10	 1	 9	 	8	 0	 8		 10	 0	 10	Average	 		 1.63	 	0.84	 	0.79	 1.94	 	0.89	 	1.26	 8.05	 	7.05	 	1.0	Median	Fold	Inc.	 -	 		 		 1.33	 		 		 1.33	 		 		Median	fold	inc.	refers	to	increase	in	CTC	count	in	respective	methods	when	compared	with	EpCAM	targeting	alone	TOTAL	count.	Indicated	CTC	count	refers	to	number	of	identified	CTCs	/	9mL.	EPI-CTC	is	defined	as	DAPI+/CK+/CD45-/VE-cad-/VIM-;	EMT-CTC	is	defined	as	DAPI+/CK+/CD45-/VE-cad-/VIM+.	
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In	 contrast	 with	 ovarian	 cancer	 patients,	 where	 better	 CTC	 isolation	 was	shown	 with	 the	 use	 of	 N-cadherin	 or	 combination	 antibody	 targeting	(Chapter	3,	see	Figure	4.2),	the	number	of	EMT-CTC	detected	in	NSCLC	and	prostate	 cancer	 patient	 samples	 only	 showed	 marginal	 increase.	 This	suggests	that	the	inclusion	of	N-cadherin	or	vimentin	as	an	EMT	marker	is	not	likely	 to	 boost	 the	 detection	 of	 EMT-CTC	 isolation	 in	 NSCLC	 and	 prostate	cancer	patients.		
Nevertheless,	when	all	NSCLC	and	prostate	cancer	patient	CTC	samples	are	considered	together,	the	N-cadherin	targeting	method	resulted	in	the	highest	EMT-CTC	detection	proportion	at	52%,	followed	by	EpCAM,	and	combination	targeting	at	40%	and	30%,	respectively.		
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Figure	 4.2	 Immunofluorescence	 detection	 of	 EMT-CTCs	 in	 NSCLC	 and	
metastatic	prostate	cancer	patient	samples	in	EpCAM,	N-cadherin	and	
combination	 targeted	 CTC	 isolation.	 Number	 of	 EMT	 positive	 CTCs,	indicated	by	vimentin	positivity,	in	NSCLC	and	prostate	cancer	and	ovarian	cancer	patient	samples.	Errors	bars	represent	standard	deviation.		
	
4.3.3 Heterogeneous expression of N-cadherin and vimentin 
expression in NSCLC cell lines 
To	 clarify	 whether	 co-expression	 of	 the	 EMT	 markers	 N-cadherin	 and	vimentin	in	NSCLC	cells	is	uncommon,	the	expression	of	EpCAM,	N-cadherin,	
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cytokeratin,	and	vimentin	was	determined	in	three	NSCLC	cell	lines,	available	in	 the	 laboratory,	 using	 immunofluorescence	microscopy.	NSCLC	 cell	 lines	HCC827,	 H3255	 and	 H1975	 demonstrated	 heterogeneous	 expression	 for	EpCAM,	 N-cadherin,	 cytokeratin	 and	 vimentin	 (see	 Table	 4.6).	 In	 HCC827	cancer	cells,	EpCAM	and	cytokeratin	were	found	to	be	highly	expressed,	with	minimal	N-cadherin	and	vimentin	expression	observed.	H3255	cancer	cells,	while	 highly	 expressing	 cytokeratin,	 were	 found	 to	 moderately	 express	EpCAM,	 but	 again	 had	 no	 detectable	 N-cadherin	 or	 vimentin.	 Only	 H1975	cancer	 cells	 were	 found	 to	 express	 high	 levels	 of	 vimentin,	 moderately	express	 cytokeratin,	 while	 poorly	 expressing	 EpCAM	 and	 N-cadherin.	Interpretation	of	data	from	three	cultured	cell	lines	requires	caution,	but	the	results	provide	 support	 for	 the	notion	 that	NSCLC	are	more	 likely	 to	have	epithelial	 features;	 further,	 if	 the	cells	undergo	mesenchymal	transition,	N-cadherin	 expression	 and	 vimentin	 expression	 is	 not	 necessarily	 tightly	correlated.		
 
Table	4.6	Expression	of	epithelial	and	EMT	markers	in	NSCLC	cell	lines	
Cell	Line	 EpCAM	 N-cadherin	 Cytokeratin	 Vimentin	
HCC827	 +++	 -	 ++	 -	
H3255	 -	 -	 +++	 -	
H1975	 +	 -	 ++	 +++	Staining	intensity	was	determined	from	5	fields	of	vision:	+++	very	strong	expression	in	all	cells,	++	strong	in	>85%	of	cells,	+detectable	in	some	cells,	-	negative	
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Section 2. Method Optimisation to Allow Electron Microscopic 
Imaging 
A	major	proportion	of	 the	work	presented	 in	this	chapter	 involved	trialing	different	preparations	for	analysis	of	CTCs	using	electron	microscopy	(EM).	The	aim	was	to	use	CTC	preparations	already	generated	to	provide	additional,	detailed	analysis	of	CTCs.	For	the	majority	of	experiments,	cultured	cells	were	first	used	to	model	patient	CTCs,	and	the	most	promising	electron	microscopy	methodologies	were	then	applied	to	patient	samples	to	validate	the	possible	integration	of	Electron	microscopy	into	the	CTC	sample	workflow.	
 
4.3.4 Visualising immunomagnetic bead-bound cells using FESEM	
To	assess	 the	 feasibility	of	FESEM	 imaging	 in	visualising	ultrastructures	 in	CTCs,	 epithelial-like	 MCF-7	 cells	 were	 bound	 to	 EpCAM	 bound	immunomagnetic	 beads,	 fixed,	 dehydrated	 and	 visualised	 using	 the	GeminiSEM	300	FESEM.	MCF-7	cells	appear	as	round-shaped	epithelial-like	cells	 and	 clumps.	While	 good	 resolution	of	MCF-7	 cells	was	observed,	 and	binding	 to	 immunomagnetic	 beads	 was	 evident	 (see	 Figure	 4.3),	ultrastructural	 visualisation	 was	 suboptimal	 as	 immunomagnetic	 beads	interfered	with	the	electron	beam,	thereby	lowering	the	contrast	between	the	cell	 surface	 and	 background.	 Due	 to	 difficulties	 in	 finding	 ultrastructural	contrast	 using	 FESEM,	 we	 turned	 to	 TEM	 imaging	 to	 better	 visualise	ultrastructures	while	providing	a	cross-sectional	perspective.	
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Figure	4.3	 Scanning	electron	microscopy	 (SEM)	 imaging	of	 epithelial-
like	MCF-7	cells.	Representative	SEM	imaging	of	epithelial-like	MCF-7	breast	cancer	cells	bound	to	immunomagnetic	beads	at	x	11.43k	magnification.	Scale	bar	=	10	µm.	Red	arrow	indicates	immunomagnetic	beads;	red	box	indicates	MCF-7	cell.	
 
4.3.5 Quantum dot localisation using confocal imaging 
Quantum	dots	(QD)	are	cadmium	selenide	nanoparticle	semi-conductors	(2-10nm)	that	emit	fluorescent	signals	upon	light	excitation,	and	also	yield	an	electron	density	detectable	by	electron	microscopy.	These	features	allow	for	
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visualisation	 of	 the	 same	 biological	 events	 using	 both	 fluorescence	 and	electron	microscopy	imaging	(240,	241).	
Initially,	 the	 binding	 quality	 of	 E-cadherin	 and	 N-cadherin	 polyclonal	antibodies	 to	 their	 respective	 antigens	was	 tested	 in	 epithelial	MCF-7	 and	mesenchymal	ES-2	cell	lines	known	to	express	the	E-cadherin	and	N-cadherin	target	markers	(242,	243)	(see	also	Chapter	3,	Section	3.3,	Figure	3.2.1);	this	revealed	 specific	 cell	 surface	 staining	 (see	 Figure	 4.4A)	 with	 strong	 E-cadherin	 (E-cad)	 and	N-cadherin	 (N-cad)	 staining	 on	 confocal	microscopy.	MCF-7	cell	staining	revealed	rafts	of	E-cadherin	staining	spanning	across	the	cell	 membrane	 (Figure	 4.4B)	 compared	 with	 a	 continuous	 cell	 surface	staining	 by	 immunofluorescence	 imaging	 (Figure	 4.4A).	 The	 ES-2	 cell	demonstrated	N-cadherin	 staining	 that	 formed	 fine	 spindle-like	extensions	(see	Figure	4.4B).	Finally,	 to	model	patient	CTC	samples,	MCF-7	cells	were	bound	 to	 EpCAM	 immunomagnetic	 beads	 and	 imaged	 using	 confocal	microscopy	 (see	 Figure	 4.4C).	 Quantum	 dot	 staining	 was	 clearly	 visible	despite	 the	 presence	 of	 the	 beads,	 and	 no	 cross-reactivity	 with	 magnetic	beads	or	background	was	observed.		
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Figure	4.4	E-cadherin	and	N-cadherin	quantum	dot	visualisation	using	
confocal	 imaging	on	cultured	cells.	(A)	 Immunofluorescence	microscopy	imaging	validation	of	E-cadherin	and	N-cadherin	staining	in	MCF-7	and	ES-2	cancer	cell	lines.	(B)	Confocal	imaging	at	63	X	objective	representation	of	E-cadherin	(left)	and	N-cadherin	(right)	bound	quantum	dot	localisation	within	cell	membrane	of	MCF-7	and	ES-2	cell	lines	respectively.	(C)	Confocal	imaging	at	40	X	objective	representation	of	quantum	dot	stained	cultured	MCF-7	cells	bound	to	immunomagnetic	beads.	Blue	stain	represents	DAPI	stained	nuclei,	orange	and	red	represents	quantum	dot	immunostaining	at	585	nm	and	655		nm	respectively.	White	arrow	indicates	cell	surface	staining	pattern;	yellow	arrow	 indicates	 quantum	 dot	 localisation;	 red	 arrow	 indicates	immunomagnetic	beads.	
 
4.3.6 Quantum dot localisation using TEM imaging 
TEM	 imaging	of	 cultured	MCF-7	cells	 confirmed	quantum	dot	visualisation	and	 confirmed	 localisation	 of	 E-cadherin	 to	membranous	 rafts,	 consistent	with	 the	 confocal	 imaging	 method	 described	 above	 (see	 Figure	 4.5).	Interestingly,	higher	resolution	images	revealed	that	E-cadherin	rafts,	while	dispersed	 throughout	 the	 cell	 membrane,	 were	 often	 present	 in	 small	extensions	from	the	cell	membrane	(Figure	4.5).	However,	despite	spending	considerable	amounts	of	time,	none	of	the	previously	confirmed	CTCs	were	detected	using	TEM	imaging	in	6	NSCLC	patient	CTC	samples.		
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 Figure	4.5	Quantum	dot	visualisation	using	TEM	imaging	on	cultured	
cells.	 TEM	 imaging	 (<50,000	 X	 magnification)	 illustrating	 localised	 E-cadherin	 quantum	 dots	 distributed	 on	 membrane-raft-like	 structures	
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throughout	 cell	membrane	of	MCF-7	breast	 cancer	 cell	 lines.	 Small	 arrows	indicate	the	quantum	dot	nanoparticle	localisation.	
	
4.3.7 Ultrastructure imaging of residual blood cells and CTCs in patient 
samples using TEM imaging 
While	 in	 vitro	 validation	 of	 quantum	 dot	 nanoparticle	 staining	 seemed	promising	for	the	correlative	light	electron	microscopy	use	in	patient	sample	imaging,	no	CTCs	were	detected	in	patient	samples	and	therefore	this	method	was	 deemed	 impractical	 for	 further	 patient	 CTC	 sample	 analysis.	 Instead,	TEM	 imaging	 of	 CTC	 samples	without	 prior	 quantum	 dot	 immunostaining	was	 investigated	 in	 selected	 patient	 samples	 with	 established	 high	 CTC	counts.		
TEM	imaging	was	used	to	identify	cancer-associated	ultrastructures	as	well	as	 any	 characteristics	 typical	 of	 primary	 tumour	 site	 from	4	NSCLC	 and	 1	prostate	 cancer	patient	CTC	samples	previously	analysed	and	described	 in	Section	1	of	this	Chapter.	One,	1and	2	NSCLC	samples	had	CTCs	isolated	by	EpCAM,	 N-cadherin	 and	 combination	 targeting	 methods	 respectively,	 and	CTCs	 in	 1	 prostate	 cancer	 sample	were	 isolated	 by	 combination	 targeting	methods.	Sample	integrity,	indicated	by	quality	of	ultrastructures,	was	noted	to	be	well	preserved	and	suggested	good	fixation.	CTCs	were	defined	as	cells	that	had	cancer-related	structures	identified	by	TEM	imaging	that	included	large,	irregular	nuclei,	microvilli,	and	nuclear	clefts	(see	Figure	4.6B-E).	The	cells	 identified	as	CTCs	were	notably	 larger	than	 identified	 leukocytes	(see	
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Figure	 4.6A).	 Interestingly,	 CTCs	 appeared	 to	 have	 specific	 structures	 that	anchored	 them	 to	 surrounding	 immunomagnetic	 beads,	 suggested	 by	 the	filamentous	structures	distorting	the	membrane.	All	CTCs	were	observed	to	have	 large,	 irregular	 nuclei.	 Three	 of	 4	 CTCs	 isolated	 from	 a	 lung	 cancer	patient	were	found	to	have	nuclear	clefts,	characteristic	of	cancer	origin	(244).	One	significant	structure	identified	in	one	of	 four	CTCs	confirming	a	cell	of	NSCLC	 origin	 was	 a	 cilial	 basal	 body,	 which	 is	 typically	 located	 in	 lung	epithelium	and	serves	as	an	anchor	for	flagella	or	cilia	(see	Figure	4.6D)	(245,	246).	 The	 basal	 body	 size	 and	 location	 in	 the	 periphery	 of	 the	 cell	 was	consistent	with	previously	reported	TEM	imaging	of	cilial	basal	bodies	(247,	248).	TEM	imaging	of	NSCLC	epithelium	acquired	by	the	same	operator	and	instrument	showed	comparable	ultrastructures	of	putative	CTCs	and	are	not	shown	in	further	detail.	One	cell	identified	as	a	CTC	(see	Figure	4.6E)	shown	to	 have	 microvilli	 was	 thought	 to	 be	 possibly	 dividing,	 indicated	 by	 two	separating	 nuclei	 within	 one	 cell.	 However,	 the	 image	 may	 alternatively	represent	a	double	nuclear	cleft	(249).	Two	out	of	the	four	 identified	CTCs	also	had	noticeable	microvilli.	
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Figure	 4.6	 Ultrastructural	 characteristics	 of	WBCs	 and	NSCLC	 patient	
CTCs	 illustrated	 by	 TEM.	 TEM	 illustrating	 (50,000	 X	 magnification)	ultrastructural	characteristics.	CTCs	and	WBCs	shown	here	are	from	a	NSCLC	patient	sample	subjected	to	EpCAM-targeted	immunomagnetic	isolation.	(A)	Representative	 white	 blood	 cells;	 (B-E)	 Four	 CTCs	 were	 isolated	 and	identified	using	TEM	from	NSCLC	patients	bound	to	immunomagnetic	beads.	Labelling	 includes	 leukocytes	 (LC),	 cilial	 basal	 bodies/plates	 (BB),	immunomagnetic	 bead	 (IB),	 nuclear	 cleft	 (NC)	 and	 microvilli	 cell	 surface	protrusions	(MV).		
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4.4 Discussion 
Section 1, EMT-CTCs in NSCLC and prostate cancer 
In	 this	 study,	 our	 aim	 was	 to	 improve	 the	 isolation	 of	 CTCs	 with	 EMT	characteristics	 from	NSCLC	 and	 prostate	 cancer	 patients	 by,	 as	 previously	described	for	ovarian	cancer	patient	samples	(see	Chapter	3),	by	combining	immunomagnetic	 capture	 targeting	 the	 EMT	 marker	 N-cadherin	 with	 the	conventional	CTC	isolation	marker	EpCAM.	Overall,	there	was	little	evidence	that	 N-cadherin	 alone	 or	 in	 combination	 with	 EpCAM	 could	 improve	 the	isolation	of	CTCs	in	advanced	NSCLC	or	prostate	cancer	patients,	or	detect	a	more	 phenotypically	 diverse	 spectrum	of	 CTCs	 as	 previously	 observed	 for	ovarian	cancer.		
Nevertheless,	several	findings	are	worth	further	discussion.	CTCs	were	found	in	a	higher	proportion	of	patients	and	counts	were	higher	in	NSCLC	patient	blood	 samples	 than	 in	 prostate	 cancer	 patient	 samples,	 which	 agree	with	some	other	reports	of	CTC	counts	in	NSCLC	and	prostate	cancer.	This	finding	could	be	 explained	by	 easier	 cellular	 egress	 into	 circulation	 from	 the	 lung	compared	 to	 the	 prostate,	 due	 to	 its	 intimate	 and	 vast	 contact	with	 blood	vessels.	However,	our	 findings	would	appear	to	contradict	other	studies	 in	the	 literature.	 While	 isolation	 and	 detection	 methods	 as	 well	 as	 patient	cohorts	 vary	 across	 studies,	 recent	 reviews	 and	 metanalyses	 suggest	 the	average	CTC	detection	rate	for	advanced	NSCLC	tends	to	be	lower	than	other	solid	malignancies,	ranging	from	20-40%,	while	much	higher	in	the	advanced	prostate	cancer	setting	~80%	(170,	250-254).	Our	independent	recent	study	
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detected	 CTCs	 (range 1-343) in 93% of EGFR	 mutated	 NSCLC	 patients 
(manuscript under review).	
In	our	small	patient	cohort	analysed	here,	higher	NSCLC	CTC	counts	may	be	explained	 by	 higher	 tumour	 burden,	 higher	 metastatic	 potential	 and	aggressiveness	as	indicated	by	the	relatively	short	survival	observed	in	our	NSCLC	compared	prostate	cancer	patients	(median	survival	of	NSCLC	versus	prostate	is	<12	months	versus	approximately	40	months)	(255-261).	
The	 NSCLC	 CTCs	 detected	 in	 our	 study	 were	 predominantly	 of	 epithelial	phenotype	with	few	EMT-CTCs	detected	in	this	small	patient	cohort	analysed.	While	 the	 EMT-CTC	 count	 reported	 here	 is	 lower	 than	 other	 studies,	 the	detection	rate	of	CTCs	and	EMT-CTCs	tends	to	be	higher.	For	example,	one	recent	 study	 isolating	 CTCs	 from	 125	 treatment-naïve,	 advanced	 NSCLC	patients	 at	 baseline	 reported	 detection	 of	 0-35	 EMT-CTCs,	 indicated	 by	vimentin	 positivity,	when	 using	 EpCAM-targeted	 isolation	 and	 cytokeratin	identification	(262).	While	that	study	reported	a	more	dynamic	range	than	what	we	observed,	the	CTC	and	EMT-phenotype	CTC	detection	rate	we	report	here	is	~50%	higher	(85%	and	36%	vs	54%	and	24%	respectively).	As	CTC	counts	taken	at	baseline	prior	to	therapy	should	yield	higher	CTCs	counts	as	a	reflection	of	tumour	burden	compared	to	our	blood	samples,	which	were	drawn	at	any	time	during	the	disease	course,	our	relatively	higher	CTC	counts	suggest	 that	our	 assay	may	be	more	 sensitive	 and	have	higher	 capacity	 to	detect	 lower	 tumour	 burden.	 However,	 this	 conclusion	 would	 need	 to	 be	substantiated	 in	 a	 larger	patient	 cohort	with	 standardised	 timing	of	 blood	collection,	particularly	before	the	start	of	therapy.	
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Another	 study	 investigating	 CTCs	 with	 EMT	 characteristics	 from	 NSCLC	patients	employed	the	CanPatrol	platform	-	a	size-based	isolation	method	–	and	used	an	RNA	in-situ	hybridisation	method	targeting	epithelial	and	EMT	marker	transcripts	(EpCAM,	CK	8/18/19	and	vimentin,	twist	respectively).	In	this	study,	CTCs	were	detected	in	23/29	(79%)	of	NSCLC	patients,	suggesting	either	the	inclusion	of	an	additional	EMT	marker	-	in	this	case	twist	–	allows	for	a	more	robust	detection	method.		
Our	 preliminary	 cell	 line	 data,	 and	 data	 from	 NSCLC	 tissue	immunohistochemistry	and	gene	expression	arrays	suggest	that	NSCLC	cells	tend	to	be	predominantly	of	epithelial	phenotype,	but	also	in	cells	that	have	undergone	EMT,	vimentin	and	N-cadherin	may	not	necessarily	be	tightly	co-expressed	(263-265).	This	observation	might	explain	the	detection	of	mainly	epithelial	CTCs	with	few	EMT-CTCs	using	our	strategy,	since	defining	an	EMT-CTC	relies	on	N-cadherin	and	vimentin	co-expression.	Probing	CTC	samples	for	alternative	EMT	markers	such	as	TWIST,	SNAIL	and	SLUG	may	potentially	increase	EMT-CTC	detection	post	N-cadherin	based	CTC	isolation	from	NSCLC	patients.	These	markers	have	been	detected	in	EMT	NSCLC	tissue	previously	(266-268).	
Prostate	 cancer	 is	 often	 indolent	 and	 may	 lay	 dormant	 for	 many	 years,	indicating	biological	behaviour	consistent	with	slower	disease	progression.	Due	 to	 the	 longer	 survival	 times	 and	 the	 availability	 of	 more	 therapeutic	options,	prostate	cancer	patients	are	typically	exposed	over	longer	periods	to	several	lines	of	therapy	compared	with	lung	cancer	patients.	Therefore,	due	to	 tumour	 plasticity	 and	 the	 long	 treatment	 journey,	 cells	 may	 evade	
Chapter 4 Isolation and EM imaging of EMT-CTCs from other carcinomas 
135		
treatment	by	undergoing	EMT.	These	facts	may	reflect	the	high	proportion	of	EMT-CTC	detection	from	the	analysed	prostate	cancer	patients,	although	the	overall	small	number	of	analysed	patients	and	of	CTC	positive	patients	in	this	study	prevent	drawing	any	firm	conclusions.		
In	 the	 advanced	prostate	 cancer	 setting,	 the	majority	of	patients	will	 have	been	previously	 treated	with	 a	wide	 range	of	 therapies	 targeting	different	cellular	mechanisms	(269).	Considering	the	prevalence	of	EMT	markers,	such	as	vimentin,	fibronectin	and	N-cadherin	expressed	in	prostate	cancer	tissue	in	the	advanced	cancer	setting,	as	well	as	in	vitro	data	suggesting	a	central	role	 of	 EMT	 in	 the	 development	 of	 therapy	 resistance	 in	 prostate	 cancer	patients	 receiving	 chemotherapy,	 the	 lack	 of	 increase	 in	 total	 CTC	 counts	when	 N-cadherin	 based	 CTC	 isolation	 was	 combined	 with	 EpCAM	 based	isolation	 (223,	 270,	 271)	was	 surprising.	However,	 the	 high	 proportion	 of	EMT-CTC	detection	in	our	prostate	patient	samples	is	consistent	with	studies	demonstrating	 presence	 of	 EMT	 markers	 vimentin	 and	 N-cadherin	 in	 a	significant	proportion	of	advanced	prostate	cancer	patient	CTCs	(17).	
Section 2. Method Optimisation to Allow Electron Microscopic 
Imaging 
Microscopy	 was	 added	 to	 our	 established	 CTC	 work	 flow	 to	 complement	findings	of	EMT	characteristics	in	CTCs	through	antibody	targeting.	Here	we	demonstrate	that	FESEM	imaging,	while	capable	of	generating	high	resolution	images,	 had	 limited	 utility	 in	 the	 CTC	 workflow	 due	 to	 electron	 beam	interference	 caused	 by	 immunomagnetic	 beads	 still	 bound	 to	 the	 CTCs.	Moreover,	 we	 identified	 clear	 quantum	 dot	 nanoparticle	 staining	 using	
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confocal	microscopy	 and	 TEM	 imaging,	 although	 this	was	 not	 translatable	into	correlated	imaging	of	CTCs	in	our	hands.	Finally,	we	demonstrated,	for	the	 first	 time,	 TEM	 imaging	 of	NSCLC	CTCs	 identifying	 key	ultrastructures	indicating	 cancer	 cell	 origin,	 providing	 more	 evidence	 that	 these	 cells	 in	patient	blood	samples	were	truly	CTCs.	
Electron	microscopy	has	 been	used	 for	 decades	 to	 identify	ultrastructures	within	tissues,	cells	and	subcellular	compartments	(240,	272,	273).	The	use	of	electron	microscopy	 in	the	CTC	field	has	been	 limited	due	 in	part	 to	the	scarcity	of	CTCs	present	in	samples	and	also	the	difficulty	integrating	complex	electron	 microscopy	 sample	 preparations	 into	 CTC	 workflows.	 Scanning	electron	microscopy	(SEM)	allows	for	high	resolution	imaging	comparable	to	
-	especially	with	the	recent	introduction	of	field-emission	scanning	electron	microscopy	(FESEM)	-	higher	resolution	than	traditional	transmission	TEM	imaging	and	with	more	compatible	sample	preparation	requirements	(274,	275).	TEM	however	enables	visualisation	of	internal	ultrastructures	whereas	SEM	imaging	reveals	only	external	structures.	
Here,	 FESEM	 was	 initially	 used	 to	 visualise	 cell	 surface	 membrane	ultrastructures	using	MCF-7	bound	to	immunomagnetic	beads	as	a	model	for	patient	 derived	 CTCs.	 FESEM	 potentially	 holds	 many	 advantages:	 sample	preparation	 is	 much	 shorter	 than	 typical	 for	 TEM	 samples,	 a	 higher	magnification	 can	 be	 achieved,	 software	 can	 easily	 overlay	 confocal	 and	electron	 microscopy	 images,	 and	 ease	 of	 access	 to	 an	 FESEM	 which	 also	becomes	important	when	considering	transferring	of	samples	from	confocal	to	FESEM	 imaging.	Upon	visualisation	at	~11	000	x	magnification,	MCF-7s	
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bound	 to	 immunomagnetic	 beads	 were	 clearly	 visible.	 However	 due	 to	limitations	 inherent	 to	 electron	 microscopy	 caused	 by	 interference	 from	paramagnetic	particles	in	the	samples,	it	was	not	surprising	that	the	magnetic	beads	still	present	in	our	samples	interfered	with	the	contrast	of	cell	surface	structures.	 Regrettably,	 this	 methodology	 was	 thus	 disregarded	 for	 CTC	visualisation,	 and	 instead	 TEM	 strategies	 were	 investigated	 for	 sample	visualisation.	
To	use	TEM	imaging,	several	critical	elements	were	identified	that	may	limit	the	application	of	electron	microscopy	for	the	investigation	of	CTCs,	including	fixative	type,	maintenance	of	ultrastructure	integrity,	the	required	technical	expertise	 for	 EM	 methods,	 and	 the	 time-consuming	 sample	 processing.	Certain	 technical	 limitations	when	 using	 TEM	 also	 need	 to	 be	 considered.	First,	EM	is	a	method	conventionally	used	to	observe/identify	ultrastructures	in	cell-dense	samples.	Secondly,	shrinkage	of	organelles	and	cell	membrane	caused	 by	 sub-optimal	 fixation	 is	 a	 common	 issue	 observed	 in	 electron	microscopy	preparations	 and	 can	 compromise	 the	ultrastructure	 integrity,	attributed	 to	 various	 factors	 including	 fixative	 concentration,	 fixative	duration	and	storage	duration	(276).	Finally,	EM	sample	preparation	favours	the	use	of	polyclonal	antibodies	that	recognise	and	bind	to	multiple	epitopes,	however	different	antibody	batches	may	limit	reproducibility	of	the	results.	
CTC	samples	themselves	introduce	further	limitations	due	to	the	rare	nature	of	CTCs,	the	long	processing	time	from	blood	draw	to	fixation,	and	potential	technical	issues	such	as	the	immunomagnetic	bead	composition	potentially	
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damaging	 delicate	 preparation	 tools	 (electron	 beam	 interference	 due	 to	immunomagnetic	beads;	diamond	knife	may	be	damaged	by	the	iron	core).		
Quantum	dot	(QD)	nanoparticles	are	a	newly	emerging	tool	for	use	in	electron	microscopy	 due	 in	 part	 to	 the	 advent	 of	 correlative	 light	 and	 electron	microscopy	 (CLEM),	 or	 the	 ability	 to	 overlay	 fluorescent	 light	microscopy	images	with	electron	microscopy	images	(240,	241).	Here,	we	showed	clear	membranous	QD	staining	of	E-cadherin	in	cultured	MCF-7	cells,	both	in	the	confocal	 and	 TEM	 setting.	 Following	 establishment	 of	 the	 experimental	methods	and	workflow,	6	NSCLC	cancer	patient	samples	were	investigated.	However,	 no	 CTCs	 were	 detected,	 possibly	 due	 to	 CTCs	 lost	 during	 the	additional	processing,	poor	affinity	or	binding	to	the	polyclonal	antibodies,	or	simply	missed	during	the	electron	microscopy	imaging	process.	
CTCs	were	only	detected	in	samples	not	subjected	to	additional	quantum	dot	staining,	 suggesting	 that	 the	 additional	 processing	 compromises	 CTC	detection.	 Due	 to	 the	 already	 rare	 nature	 of	 CTCs,	 and	 extensive	 operator	handling	 time	 required	 for	 QD	 immunostaining	 and	 TEM	 scanning,	 this	method	was	deemed	 impractical	 to	analyse	CTCs.	We	 therefore	decided	 to	employ	TEM	imaging	without	prior	QD	immunostaining	in	selected	patient	samples	with	previously	established	high	CTC	counts.	
While	recent	studies	have	reported	pseudopodia,	microvilli	and	membrane	blebbing	in	SEM	images	of	patient	CTCs	(63-65),	this	is	to	our	knowledge	a	world	 first	 use	of	TEM	 imaging	 to	 show	 internal	CTC	ultrastructures.	This	chapter	presented	images	of	four	individual	cells,	considered	to	be	CTCs,	from	a	single	NSCLC	patient,	showing	ultrastructures	characteristic	of	cancer	cells.	
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One	identified	CTC	contained	a	basal	body,	typical	for	cells	of	lung	epithelium	origin.	Interestingly,	one	CTC	identified	by	TEM	methods	shows	what	appears	to	be	dividing	cell,	indicated	by	a	nuclei	potentially	undergoing	division	(see	Figure	 4.6E).	 This	 suggest	 that	 CTCs	may	 have	 the	 capacity	 to	 proliferate	within	 the	bloodstream,	 consistent	with	 reports	of	CTCs	with	proliferative	capacity,	 indicated	by	positive	Ki67	staining	(187,	277,	278).	Further,	TEM	imaging	also	appears	 to	reveal	 filamenteous	structures	connecting	CTCs	to	magnetic	beads,	unique	to	CTCs	and	not	observed	for	any	cells	considered	to	be	lymphocytes.	It	should	be	noted	that	leukocytes	identified	by	TEM	were	notably	smaller	than	CTCs	and	nuclei	noted	as	irregular.	However,	this	may	also	be	due	to	sample	processing	causing	distortions	in	the	nuclear	material	by	physical	stress.		
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4.5 Conclusion In	our	hands,	the	optimized	method	for	rare	cell	identification	allowed	for	the	detailed	 structural	 visualisation	 of	 four	 NSCLC	 patient	 CTCs	 with	 defined	ultrastructural	features	as	identified	by	a	senior	electron	microscopist	expert.	It	has	to	be	highlighted	however,	that	using	current	CTC	isolation	protocols,	preparing	CTC	samples	for	EM	and	then	finding	CTCs	using	EM	technology	remains	 a	 tedious	 and	 time-consuming	 work	 flow,	 the	 latter	 part	 usually	performed	by	an	expert	electron	microscopist	with	other	 time	constraints.	Alternative	methods	of	yielding	higher	CTC	numbers	such	as	higher	volume	blood	 sampling	 or	 even	 leukaphoresis	 could	 make	 CTC	 ultrastructure	analysis	a	more	suitable	tool	that	could	reveal	details	about	CTCs	in	various	cancers	(279-281).	Despite	these	challenges,	the	power	of	TEM	in	identifying	ultrastructures	in	these	rare	cells	can	allow	us	to	infer	biological	mechanisms	of	 metastases	 or	 treatment	 resistance	 that	 highlight	 the	 potential	 of	 TEM	integration	into	liquid	biopsies	as	a	research	tool	for	elucidating	the	biology	of	CTCs.	
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Chapter 5  Isolation of EpCAM-negative CTCs from 
melanoma patients 
The	following	chapter	is	essentially	the	amended	version	of	the	manuscript	published	in	the	journal	PLoSone	(51)	(see	Appendix	5)	
Prefix The	 techniques	of	evaluating	 ideal	cell	 surface	 targets	 for	CTC	 isolation,	as	developed	 and	 validated	 in	 the	 previous	 chapters,	 has	 further	 potential	applications.	While,	as	discussed	in	Chapter	1,	EpCAM	targeted	CTC	isolation	can	be	a	useful	approach	to	isolate	cells,	for	immunomagnetic	capture	of	non-epithelial-derived	CTCs	without	EpCAM	expression,	better	markers	need	to	be	defined.	CTC	isolation	from	melanoma	patients	is	particularly	challenging	due	 to	 a	 number	 of	 reasons,	 including	 phenotypic	 heterogeneity.	 More	importantly,	 while	 lower	 grade	 primary	 melanoma	 cells	 can	 express	 cell	surface	E-cadherin,	an	epithelial	marker	and	critical	mediator	of	melanocyte-keratinocyte	interactions,	melanoma	cells	do	not	express	EpCAM	(282,	283)	(Figure	5.0),	as	melanocytes	embryologically	develop	from	the	neural	crest	(284-286).	 Further,	 although	 some	 expression	 of	 the	 common	 CTC	identification	marker	cytokeratin	has	previously	been	reported	in	melanoma	tumour	tissue,	it	is	often	low	and	variable	(287-289).		
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Figure	5.0.	Quantitative	flow	cytometry	analysis	of	EpCAM	expression	in	
MelRM	and	SW480	cell	lines.	EpCAM	expression	was	determined	using	flow	cytometry	in	a	representative	melanoma	and	a	colorectal	cell	line,	MelRM	and	SW480	respectively.	Proportion	of	cells	expressing	EpCAM	is	shown	(%)	with	standard	deviation.		
	
This	 chapter	 evaluates	 melanoma	 cell	 surface	 molecules	 for	 their	 use	 in	immunomagnetic	 methods	 for	 melanoma	 CTC	 isolation	 and	 identify	 a	suitable	antibody	cocktail	for	CTC	identification.	This	method	is	also	used	to	identify	 melanoma	 CTCs	 in	 patient	 samples	 in	 combination	 with	 a	 newly	developed	co-staining	for	PD-L1.	PD-L1	is	an	emerging,	potentially	important	biomarker	for	immunotherapy	response	in	melanoma.		
Importantly,	this	project	has	formed	the	basis	of	a	follow	up	Honours	project,	investigating	 changes	 in	 PD-L1	 expression	 in	 melanoma	 patient	 CTCs	longitudinally	in	response	to	immunotherapy	targeting	the	PD-1/PD-L1	axis.	In	addition	 to	determine	changes	of	CTC	PD-L1	expression,	patient	T-cells,	collected	at	the	same	time	points,	will	be	analysed	for	PD-1	expression	and	T	cell	 markers.	 The	 Honours	 student	 was	 taught	 and	 the	 T-cell	cryopreservation	and	staining	method	codeveloped	by	J.	Po.		  
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5.1 Introduction Improved	 technology	 for	 the	 capture	 of	 circulating	 tumour	 cells	 (CTCs)	 is	increasing	the	utility	of	CTCs	to	predict	prognosis	and	patient	survival.	CTCs	are	 a	 non-invasive	 biosource	 for	 molecular	 biomarker	 detection	 that	 can	inform	precision	 therapy	 and	 together	with	 analysis	 of	 circulating	 tumour	nucleic	 acids	 (ctRNA	 and	 ctDNA)	 are	 emerging	 with	 high	 potential	 for	widespread	clinical	utility	(reviewed	by	(59,	290,	291)).		
One	challenge	for	biomarker	testing	from	common	tissue	biopsies	is	tumour	heterogeneity.	It	is	now	widely	accepted	that	a	single	tissue	biopsy	is	poorly	representative	for	a	patient’s	cancer.	This	is	particularly	relevant	in	advanced	malignancies,	 where	 biopsies	 of	 the	 primary	 tumour	 provide	 limited	information	at	a	 time	of	 therapy	resistance	and	tumour	progression	(292).	CTCs	have	been	shown	to	accurately	reflect	tumour	heterogeneity	(55,	293).	Since	blood	draws	can	be	performed	repeatedly	during	disease	progression,	they	 are	 well	 suited	 to	 identifying	 emerging	 resistance	 mechanisms	 and	monitor	treatment	response.	Blood	biopsies	offer	the	opportunity	to	analyse	both	ctDNA	and	CTCs	 for	biomarkers.	ctDNA	analysis	 is	more	sensitive	 for	mutation	 analysis	 and	 easier	 to	 perform;	 CTC	 analysis	 provides	characterisation	of	cellular	heterogeneity	and	cell	specific	expression	of	RNA	or	proteins	(293-297).	
In	keeping	with	this	paradigm,	CTC	isolation	should	be	efficient	and	include	heterogeneous	populations	of	cancer	cells.	Currently	most	carcinoma	CTCs	are	 isolated	 using	 capture	 and	 identification	 methods	 targeted	 to	 the	
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epithelial	cells.	However,	these	CTC	detection	strategies	can	not	be	utilised	for	certain	malignancies	including	melanoma	(49,	144,	298,	299).		
A	challenge	in	melanoma	is	marked	heterogeneity	in	gene	expression	leading	to	altered	expression	of	proteins	targetable	for	CTC	isolation	or	identification.	Thus,	targeting	multiple	cell	surface	proteins	for	isolation	and	identification	may	be	better	suited	for	optimal	melanoma	CTC	detection	(151,	300).		
Systemic	 treatment	 of	 melanoma	 has	 recently	 undergone	 revolutionary	changes	with	the	discovery	of	predictive	tumour	biomarkers,	such	as	BRAF	or	c-Kit,	which	predict	the	efficacy	of	targeted	therapy	with	small	molecule	inhibitors	 such	 as	 vemurafinib,	 debrafinib	 or	 imatinib,	 respectively.	Remarkable	responses	are	restricted	to	tumours	with	the	relevant	mutations	and	limited,	as	resistance	inevitably	develops	within	6-18	month	of	therapy	(301,	 302).	 More	 recently,	 immune	 checkpoint	 inhibition	 (ICI)	 using	antibodies	directed	at	either	the	programmed	cell	death	protein	1	(PD-1),	its	ligand	 (PD-L1)	 or	 CTLA-4,	 alone	 or	 in	 combination,	 has	 dramatically	improved	 the	outcome	of	metastatic	melanoma.	Approximately	30-60%	of	patients	 respond	 to	 drugs	 like	 nivolumab	 alone	 or	 in	 combination	 with	ipilimumab	 (303,	 304).	 Combination	 immunotherapy	 enhances	 response	rates	 but	 results	 in	 greater	 systemic	 toxicity.	 The	 Checkmate	 067	 trial	combining	 nivolumab	with	 ipilimumab	 resulted	 in	 59%	 grade	 3-4	 toxicity	compared	with	21%	nivolumab	and	28%	with	ipilimumab	alone	(303).	Hence,	it	is	highly	important	to	develop	mechanisms	to	identify	likely	responders	to	these	efficacious	but	toxic	therapies.		
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Tumour	 cells	 have	been	 shown	 to	 express	 cell	 surface	markers	 that	 cause	immune-suppressive	effects	such	as	the	ICI-modulating	PD-L1,	acquiring	the	capacity	 to	 avoid	 immune	 surveillance	 mechanisms.	 Therapies	 have	 now	emerged	that	disrupt	this	interaction	between	PD-L1	and	corresponding	T-cell	receptor	PD-1,	and	to	an	extent	have	become	a	common	therapy	modality	for	melanoma,	 lung	 cancer	 and	 renal	 cell	 carcinoma	 among	 other	 cancers	(305-307).	
However,	PD-L1	positivity	of	tumours	does	not	strictly	predict	response	to	ICIs.	 For	 instance,	 patients	 with	 PD-L1	 negative	 tumours	 have	 shown	treatment	 response	 (308-310).	 	 One	 study	 showed	 that	 PD-L1	 positive	tumours	in	a	cohort	of	300	melanoma	patients	correlated	with	response	to	ICIs	 and	 overall	 survival	 but	 PD-L1	 positivity	 was	 not	 a	 great	 predictive	marker	(311).	Furthermore,	a	recent	study	showed	that	PD-L1	positivity	in	114	advanced	melanoma	patient	tumours	was	not	a	predictor	of	response	to	ICIs	or	overall	survival	(312).		
In	addition,	testing	for	PD-L1	requires	tumour	samples,	which	should	ideally	be	 taken	 shortly	 before	 therapy	 commencement	 and	 be	 longitudinally	available	 to	 monitor	 changes	 and	 response.	 While	 this	 is	 challenging	 for	tumour	tissue	biopsies	it	is	realistic	for	CTCs.	
The	aim	of	 the	current	study	 is	 to	demonstrate	 that	 screening	PD-L1	 from	liquid	biopsies	(CTCs)	is	feasible	with	the	use	of	an	efficient	protocol	to	isolate	melanoma	CTCs.	We	also	present	in	vitro	data	suggesting	that	melanoma	cell	PD-L1	levels	are	increased	when	these	cells	are	in	blood.	 
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5.2	 Methods	
5.2.1 Patients 
Fourteen	patients	with	stage	 IV	metastatic	melanoma	were	recruited	 from	Liverpool	 and	Wollongong	Hospitals,	 Australia	 (Table	 5.1).	 The	 study	was	undertaken	with	written	patient	consent	and	approval	of	the	South	Western	Sydney	 Biosafety	 Committee	 (HREC/13/LPOOL/158).	 3	 x	 9mL	 EDTA	vacutube	 (Greiner	 Bio-One,	 Frickenhausen,	 Germany)	 blood	 samples	were	taken	per	blood	draw.	
Table	5.1	Patient	Cohort	
Clinical	Characteristic	 n	 %		Patient	Median	Age*	63	(47-88)	 14	 100	
Gender	 	 	Male	 9	 64%	Female	 5	 36%	
Stage	IV	subclass*	 	 	M1a/M1b	 6	 43%	M1c	 7	 50%	Unknown	 1	 7%	
Prior	Therapies	 	 	0-1	 13	 93%	≥2	 1	 7%	
Treatment	#	 	 	ICI	 10	 71%	Targeted	therapy	(BRAF/MEK)	 4	 29%	Other/Unknown	 1	 7%	ICI=	immune	checkpoint	inhibitors,	*	at	diagnosis,	#	at	time	of	CTC	sample	
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5.2.2 Cell lines 
SkMel28,	 501mel,	 A375,	 WMM1175,	 MelRM,	 NM176,	 MelMS	 and	 M230	melanoma	 cells	 were	 maintained	 in	 DMEM	 /	 10%	 FCS,	 WME-099	lymphocytes	 were	 maintained	 in	 RPMI	 /	 10%	 FCS	 at	 37°C	 with	 5%	 CO2	enriched	 atmosphere	 (S1	 Table).	 All	 cell	 lines	 were	 small	 tandem	 repeat	(STR)	authenticated	(AGRF,	Melbourne,	Australia).	
 
5.2.3 Cell surface marker immunocytostaining on cultured cells 
Melanoma	 cells	were	 seeded	at	3	 x	104	 cells	per	well	 in	12-well	 plates	on	sterile	cover	slips.	24	hours	post	seeding	attached	cells	were	fixed	and	probed	with	primary	antibody	(S2	Table)	and	AlexaFluor488	conjugated	goat-anti-mouse	secondary	antibody	(Life	Technologies,	Mulgrave,	Australia,	1:3000)	and	mounted	with	Prolong	Antifade	containing	DAPI	(Invitrogen,	Carlsbad,	USA).		
 
5.2.4 Flow cytometry 
Approximately	5	x	104	cells	were	pelleted,	washed	with	PBS,	blocked	with	10%	 FCS/PBS	 and	 incubated	 with	 the	 relevant	 primary	 antibodies	 or	matched	IgG	controls	(S2	Table)	in	10%	FCS	/	PBS.	After	PBS	washes	the	cells	were	 probed	 with	 AlexaFluor488	 goat-anti-mouse	 secondary	 antibody	(1:3000,	Life	Technologies),	washed	once	before	suspension	in	300	µl	PBS.	Cells	were	detected	using	a	FACS-Canto	II	(Becton	Dickinson).		
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5.2.5 Melanoma cell identification antibodies 
Initial	testing	was	performed	by	immunocytostaining	as	outlined	above	using	the	rabbit	derived	antibodies	against	human	Melan	A	(clone	EP1422Y,	LSBio,	Seattle,	USA,	1:300),	S100-b	 (clone	EP1576Y,	Abcam,	Melbourne,	Australia,	1:300)	and	GP100	(clone	Ep4863(2),	Abcam,	1:600)	with	secondary	FITC	anti	rabbit	 antibody.	 Inclusion	 of	 healthy	 donor	 peripheral	 blood	mononuclear	cells	 (PBMCs)	 discounted	 antibody	 interactions	 with	 blood	 cells.	Fluorescently	 conjugated	 anti-human	 GP100	 [AlexaFluor488]	 (clone	DT101/BC199/HMB4,	Novus	Biologicals,	Littleton,	USA;	1:100),	anti-human	Melan-A	 [AlexaFluor488]	 (clone	 SPM555,	 Novus	 Biologicals,	 1:100),	 anti-human	S100-b	 [FITC]	(clone	4C4.9+S100B/1012,	Novus	Biologicals,	1:500)	were	 obtained	 for	 ease	 of	 CTC	 identification	 staining,	 throughout	 the	manuscript	referred	to	as	Mel-ID	staining.	
 
5.2.6 Spiking of cultured melanoma cells 
Cultured	 cells	 were	 detached	 using	 0.2mM	 EDTA	 in	 PBS,	 counted	 using	 a	hemocytometer	and	a	suspension	of	5	x	103	cells	per	mL	was	prepared.	Cell	concentration	was	 confirmed	 by	 counting	 cells	 in	 4	 independent	 5	 µL	 cell	suspension	was	spotted	on	an	 input	control	slide	as	well	as	 independently	spiked	into	3	parallel	9mL	blood	(or	pre-enriched	PBMC)	samples	per	healthy	donor	 and	 cell	 line,	 followed	 by	 another	 input	 control	 slide.	 Input	 control	slides	 were	 air-dried	 and	 cells	 counted	 after	 Hoechst	 staining.	 Only	experiments	 with	 less	 than	 5%	 deviation	 between	 first	 and	 second	 input	
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control	 cell	numbers	were	 included	 in	 the	analysis	with	 the	 input	number	defined	as	the	average	of	both	input	control	counts.	
 
5.2.7 Melanoma cell isolation 
Selected	antibodies	were	conjugated	to	immunomagnetic	beads	(IsoFlux	rare	cell	enrichment	kit,	Fluxion,	San	Francisco,	USA)	according	to	the	supplier’s	instructions	(S2	Table).	Magnetic	beads	conjugated	to	individual	(30	µl	per	sample)	or	a	combination	of	antibodies	(30	µl	each	per	sample)	were	used	to	capture	cultured	melanoma	cells	spiked	in	defined	numbers	into	106	healthy	donor	PBMCs.	After	immunostaining	for	CTC	(Mel-ID),	CD45	(Alexa	Fluor	647	conjugated	 anti-CD45	 clone	 HI30,	 Novus	 Biologicals;	 1:200)	 and	 Hoechst	(Fluxion),	 imaging	 was	 performed	 using	 the	 IX71	 fluorescent	 microscope	(Olympus,	Tokyo,	Japan).	
 
5.2.8 Immunodetection of melanoma CTCs 
Melanoma	CTCs	from	3	x	9mL	metastatic	melanoma	patient	blood	samples	were	captured	in	the	same	way	and	first	probed	for	CD45	and	rabbit	anti-PD-L1	PD-L1	antibody	(clone:	E1L3N,	Cell	Signaling	Technology,	Massachusetts,	USA;		1:50),	then	with	Alexa	Flour	555	conjugated	goat-anti-rabbit	secondary	antibody	(Life	Technologies;	1:2000),	followed	by	permeablisation	with	0.2%	Triton	X-100	and	Mel-ID	probing.	Hoechst	dye	was	included	in	the	mounting	media.	
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5.2.9 PD-L1 modulation on melanoma cells in blood 
MelRM,	NM176	and	SkMel28	cells	were	spiked	into	3	x	9mL	blood	samples	from	the	same	blood	draw	for	3	(for	MelRM)	or	6	(for	NM176	and	SkMel28)	healthy	 donors	 and	 on	 input	 control	 slides	 as	 described	 above.	 Cells	 from	blood	 samples	were	 recovered	by	using	 combined	 targeting	of	MCAM	and	MCSP	for	immunomagnetic	“CTC”	isolation	after	0,	24	and	48	hour	storage	at	room	 temperature.	 Samples	 were	 stained	 as	 per	 immunodetection	 of	melanoma	 CTCs	 including	 PD-L1	 detection.	 Cells	 were	 enumerated	 by	fluorescent	microscopy.	
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5.3 Results 
5.3.1 Cell surface proteins for melanoma CTC isolation  
We	tested	expression	of	a	range	of	cell	surface	antigens	on	a	cohort	of	eight	heterogeneous	 melanoma	 cell	 lines	 to	 identify	 possible	 targets	 for	immunomagnetic	cell	isolation	of	melanoma	CTCs	(S1	Table).		
All	but	two	c-Kit	mutant	cell	lines	expressed	MCAM	strongly	on	70-100%	of	cells,	 irrespective	 of	 the	 anti-MCAM	 antibody	 used.	 MCSP	 expression	 was	even	 more	 pronounced	 for	 most	 cell	 lines	 with	 nearly	 100%	 of	 cells	expressing	 the	marker	 strongly.	However,	 BRAFV600E	mutant	 501mel	 cells,	and	both	c-Kit	mutant	 lines,	were	MCSP	negative	 (Figure	5.1).	None	of	 the	other	cell	surface	antigens	remained	convincing	candidates	for	cell	isolation	due	to	inadequate	expression	on	the	majority	of	cells.	(S1	Fig).	
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Figure	5.1	MCAM	and	MCSP	are	 the	Dominant	Melanoma	Cell	 Surface	
Markers	
(A)	Representative	FACS	histograms	and	immunocytostaining	for	MCAM	and	MCSP	presented	for	MelRM	(left	panel)	and	501mel	(right	panel)	cells.	(B)	Compiled	 data	 for	 all	 indicated	 cell	 lines	 showing	 proportion	 of	 cells	expressing	MCAM	and	MCSP	as	detected	with	the	indicated	antibodies.	Mean	fluorescence	 (by	FACS	 analysis)	 is	 included	 as	 a	 red	bar	 and	 indicates	 the	antigen	expression	level	on	positive	cells.	
 
5.3.2 Melanoma markers for CTC identification 
The	 combination	 of	 three	 antibodies,	 anti-Melan	 A,	 -S100b	 and	 -GP100	detected	 all	 melanoma	 cell	 lines	 well	 (S3	 Table)	 and	 showed	 negligible	
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interaction	with	PBMCs.	Directly	fluorescently	conjugated	antibodies	against	these	 markers	 confirmed	 adequate	 detection	 in	 representative	 cell	 lines	(Table	5.2).		
	
Table	5.2	Melanoma	CTC	identification	marker	detection	in	cell	lines	
Cell	Line	 Melan-A	*		 S100b	#	 GP100	*	 All		SkMel28	 +	 +++	 ++	 +++	501Mel	 ++	 +/-	 +++	 +++	WMM1175	 +	 +/-	 ++	 ++	MelRM	 +/-	 ++	 ++	 ++	PBMCs	 -	 -	 -	 -	+++	very	strong	in	all	cells,	++	strong	in	≥85%	of	cells,	+	clearly	detectable	in	most	cells,	 +/	 -	 clearly	 detectable	 in	 ≥40%	 of	 cells,	 -	 undetectable,	 *	 AF488,	 #	 FITC	conjugated	antibodies.	
	
5.3.3 Isolation of melanoma cells  
Initially	it	was	confirmed	that	both	MCAM	antibody	clones	(P1H12	and	F4-35H7)	 behaved	 similarly	 in	 isolating	 MelRM	 from	 healthy	 donor	 PBMCs	(Figure	5.2A).	Comparison	of	melanoma	cell	capture	using	anti-MCAM	(clone	P1H12),	 anti-MCSP	 (clone	 9.2.27)	 revealed	 cells	 expressing	 both	 proteins	(SKMel28)	were	isolated	with	either	antibody.	Combining	the	two	antibodies	for	isolation	improved	cell	recovery.	Expectedly,	501mel	cells,	which	do	not	express	MCSP,	were	only	isolated	by	MCAM	targeting	(Fig	5.2B).		
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5.3.4 Melanoma CTC detection from advanced melanoma patients 
When	comparing	CTC	 isolation	 from	three	parallel	9mL	blood	samples	per	patient,	immunomagnetic	targeting	of	MCAM	isolated	melanoma	CTCs	from	62.5%	(10/16),	MCSP	from	81.3%	(13/16)	and	combined	MCAM	and	MCSP	targeting	from	87.5%	(14/16)	of	samples	with	median	CTC	counts	of	2.5,	9	and	16	respectively	(Table	5.3,	Figure	5.2C).		
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Figure	 5.2	 Immunomagnetic	 Melanoma	 Cell	 Isolation.	 The	 indicated	melanoma	 cells	 (n=100)	 were	 spiked	 into	 pre-enriched	 PBMCs	 and	 then	recovered	using	immunomagnetic	beads	(Rare	Cell	Kit,	Fluxion)	coupled	to	either	(A)	anti	human	MCAM	antibody	clone	H1P12	or	F4-35H7	or	(B)	to	anti	human	MCAM	antibody	clone	H1P12	(αMCAM)	or	anti	human	MCSP	antibody	clone	 9.2.27	 (αMCSP)	 or	with	 the	 combination	 of	 both.	The	 proportion	 of	isolated	melanoma	cells	 is	presented.	 (C)	 14	 advanced	melanoma	patients	(16	blood	draws,	3	x	9mL	each)	were	compared	for	CTC	counts	after	αMCAM	(H1P12)	based,	αMCSP	(9.2.27)	based	or	combination	based	CTC	 isolation.	CTC	counts	are	graphed	as	box	blot.	
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Table	5.3	Melanoma	CTC	counts	and	PD-L1	positive	CTCs		
	 	 	 	 	 	 Isolation	antibodies	 	
Patient	 Gender	 Age#	 Stage#	 Therapy	 Status	 αMCAM	(PD-L1+)	
αMCSP	(PD-
L1+)	
αMCAM	/	
αMCSP	(PD-
L1+)	
combined	
(27mL	blood	
draw)	1	 F	 53	 M1a	 Targeted	 N/A	 13	(*)	 0	(*)	 17	(*)	 30	(*)	2	 M	 47	 M1c	 Immuno	 N/A	 0	(*)	 0	(*)	 0	(*)	 0	(*)	3	 M	 56	 M1a	 Immuno	 PR	 40	(0)	 43	(2)	 146	(0)	 229	(2)	32	 M	 56	 M1a	 Immuno	 PR	 0	(0)	 23	(0)	 9	(0)	 32	(0)	4	 M	 60	 M1a	 Targeted	 CR	 10	(2)	 18	(1)	 25	(10)	 53	(13)	42	 M	 60	 M1a	 Immuno	 CR	 0	(0)	 61	(0)	 85	(0)	 146	(0)	5	 M	 55	 M1c	 Targeted	 N/A	 2	(0)	 8	(0)	 15	(0)	 25	(0)	6	 F	 62	 M1c	 Immuno	 PR	 0	(0)	 5	(0)	 4	(0)	 9	(0)	7	 F	 70	 M1c	 Immuno	 Prog	 7	(0)	 9	(0)	 48	(0)	 64	(0)	8	 M	 61	 M1b	 Immuno	 PR	 25	(0)	 67	(1)	 59	(0)	 151	(1)	
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9	 M	 88	 M1c	 Immuno	 S	 26	(0)	 8	(0)	 49	(0)	 83	(0)	10	 F	 64	 M1c	 Immuno	 CR	 10	(0)	 18	(0)	 9	(2)	 37	(2)	11	 M	 78	 M1a	 Targeted	 Prog	 2	(0)	 9	(0)	 43	(0)	 54	(0)	12	 F	 75	 M1c	 Immuno	 Prog	 0	(0)	 0	(0)	 0	(0)	 0	(0)	13	 M	 85	 M1a	 Immuno	 Prog	 3	(0)	 17	(0)	 8	(0)	 28	(0)	14	 M	 64	 N/A	 N/A	 N/A	 0	(0)	 2	(1)	 5	(3)	 7	(4)	#	At	diagnosis,	PR:	partial	response,	CR:	complete	response,	Prog:	progression,	S:	stable,	N/A:	data	not	available,	*:	no	PD-L1	staining	done,	Immuno:	PD-1/PD-L1	inhibitor,	ImmunoC:	PD-1	combined	with	CTLA-4	inhibitor,	superscript2:	repeat	sample	at	later	treatment	timepoint,	αMCAM:	anti	MCAM	antibody	[P1H12];		αMCSP:	anti-MCSP	antibody	[9.2.27]	
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5.3.5 Detection of PD-L1 on melanoma CTCs 
As	 shown	 in	 Figure	 5.3A,	 PD-L1	 immunodetection	 is	 compatible	 with	melanoma	CTC	 identification	probing.	Since	 tissue	based	cancer	cell	PD-L1	expression	 tends	 to	 be	 associated	 with	 tumour	 infiltrating	 lymphocytes	(TILs)	(308,	313),	we	postulated	that	cancer	cell	exposure	to	lymphocytes	in	the	blood,	as	is	the	case	for	CTCs,	may	trigger	adaptive	PD-L1	expression	in	melanoma	CTCs.		
MelRM	and	SkMel28	cells,	known	to	be	IFN-g	inducible	for	PD-L1	expression	(314),	as	well	as	NM176	melanoma	cells	without	previously	reported	data	regarding	 PD-L1	 inducibility,	 were	 spiked	 into	 healthy	 donor	 blood	 and	recovered	 using	 the	 melanoma	 CTC	 isolation	 protocol	 after	 room	temperature	storage	for	0,	24	or	48	hours.	While	for	MelRM	longer	delay	until	CTC	 isolation,	 as	 expected,	 reduced	 melanoma	 cell	 recovery,	 a	 higher	proportion	of	melanoma	cells	had	detectable	PD-L1	after	 storage.	After	24	hours,	average	cell	recovery	had	dropped	by	about	50%,	but	the	total	number	of	PD-L1	positive	cells	had	increased	and	made	up	about	a	third	of	recovered	MelRM	 cells.	 Although	 this	 increased	 to	 approximately	 50%	 by	 48	 hours,	overall	 MelRM	 recovery	 was	 unacceptably	 low	 by	 then.	 For	 SkMel28	 and	NM176	cells	no	PD-L1	was	expressed	at	baseline,	but	was	detected	on	>10%	of	cells	after	24	or	48	hours	in	blood.	Interestingly	for	both	these	cell	 lines	total	recovery	seemed	to	slightly,	but	not	significantly	increase	post	24	hours,	while	only	dropping	after	48	hours	(Figure	5.3B).	
Finally,	we	 probed	 for	 PD-L1	 on	melanoma	CTCs	 isolated	 from	melanoma	patients.	For	this	measure,	CTCs,	isolated	using	the	various	antibodies	from	
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the	three	parallel	bloods,	were	combined.	PD-L1	positive	CTCs	were	detected	in	 38.6%	 (5/13)	 of	 CTC	 positive	 blood	 samples.	 In	 total	 1.5%	 -	 60%	 of	detected	CTCs	were	PD-L1	positive	(range	of	0-13)	(Table	5.3).	
Most	of	the	patients	analysed	in	this	study	were	already	on	ICI	treatment	for	various	 cycles	 and	 the	 small,	 heterogeneous	 patient	 cohort,	 although	sufficient	for	CTC	isolation	method	validation,	showed	no	association	of	CTC	or	PD-L1+	CTC	 counts	with	 clinical	 parameters,	 including	 response,	 stable	disease	or	disease	progression	(data	not	shown).	
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Figure	5.3	PD-L1	on	Melanoma	CTCs.	 (A)	Representative	melanoma	CTC	identification	 staining	 with	 PD-L1	 detection	 of	 a	 patient	 derived	 CTC	surrounded	 by	 lymphocytes.	 (B)	 MelRM,	 NM176	 or	 SkMel28	 cells	 were	spiked	into	blood	samples	of	healthy	donors	and	isolated	immediately	or	after	room	temperature	blood	storage	for	the	indicated	time	before	recovery	using	our	melanoma	CTC	isolation	and	immunostaining	protocol	including	PD-L1	probing.	Data	 from	three	experiments	 (three	different	healthy	donors)	are	
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combined.	 Mel-ID:	 probed	 with	 cocktail	 of	 three	 fluorescently	 conjugated	melanoma	identification	antibodies.	
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5.4 Discussion 
5.4.1 Melanoma CTC isolation 
The	 most	 comprehensive	 previous	 investigation	 of	 melanoma	 antigens	suitable	for	 immunomagnetic	 isolation	of	melanoma	CTCs	was	reported	by	Freeman	et	al.	Their	study	chose	antigens	either	relatively	highly	expressed	on	melanoma	 cells	 (MCAM	 and	MCSP)	 or	 expressed	 on	 subpopulations	 of	melanoma	 cells	 proposed	 to	 be	 particularly	 aggressive	 and	 competent	 to	initiate	metastasis	(CD271	and	ACBC5).	Dynabeads	mediated	 isolation	was	validated	with	one	melanoma	cell	line	(A2058)	known	to	express	the	relevant	antigens,	spiked	into	blood.	Recovery	efficiency	was	35%	with	either	MCAM	or	 MCSP	 antibodies,	 with	 no	 significant	 increase	 in	 recovery	 rates	 by	combining	both	antibodies.	Nevertheless,	 the	authors	 suggest	 combination	might	still	be	advantageous	for	heterogeneous	patient	samples	(315).		
Our	study	revisits	the	same	antigens,	but	to	potentially	improve	on	melanoma	CTC	isolation,	tested	three	additional	antibodies	against	cell	surface	proteins	either	commonly	upregulated	during	melanoma	progression	(N-cadherin),	or	promising	 antigens	 with	 common	 membrane	 staining	 of	 melanoma	 cells	(KBA.62,	 LHM3).	 To	 predict	 suitability	 as	 isolation	 target	 we	 analysed	 a	cohort	 of	 eight	melanoma	 cell	 lines	with	 various	 genetic	 backgrounds	 and	phenotypes	to	account	for	heterogeneity.	
Our	data	confirms	heterogeneous	levels	of	MCAM	expression	in	6	melanoma	cell	 lines,	 which	 is	 in	 keeping	with	MCAM	 expression	 in	 tissue	 of	 68%	 of	primary	melanoma	 and	 89%	 of	 melanoma	 lymph	 node	metastases	 (316).	Very	high	detectable	levels	of	MCSP	were	observed	in	5	of	8	melanoma	cell	
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lines,	 while	 the	 remaining	 3	 lines	 (501mel,	 MelMS	 and	 M230)	 lacked	detectable	 MCSP.	 Targeting	 MCAM	 alone	 has	 previously	 shown	 to	satisfactorily	 recover	 SkMel-28	melanoma	 cells	 (74-88%	 recovery)	 spiked	into	blood	with	the	CellSearch	isolation	platform.	In	those	studies	the	anti-MCSP	antibody	clone	we	used	here	for	cell	isolation,	was	not	used	for	isolation	but	 for	 identification	 of	 MCAM	 isolated	 CTCs	 (317,	 318).	 Sakaizawa	 et	 al	targeted	MCSP	for	melanoma	CTC	isolation	and	efficiency	was	tested	on	three	melanoma	cell	lines	preselected	to	express	MCSP	(888mel,	928mel	or	MMG1).	1-24%	recovery	was	achieved	when	cells	were	spiked	into	blood	of	healthy	donors	(319).	Our	data	confirms	that	combined	targeting	of	both	MCAM	and	MCSP	for	melanoma	CTC	isolation	using	the	IsoFlux	CTC	isolation	platform	improves	 cell	 isolation	 from	cultured	 cells	 and	patient	blood	 samples.	Our	cultured	cell	isolation	data	also	suggests	that	from	patients	with	“501mel-like”	CTCs,	MCAM	targeting	would	isolate	CTCs.	However,	if	in	this	instance	relying	on	MCSP	probing	for	identification,	these	CTCs	would	be	missed.	Importantly,	in	our	hands	the	anti-MCAM	antibody	clone	(F4-35H7)	used	in	the	CellSearch	studies	 was	 similarly	 effective	 in	 binding	 melanoma	 cells	 (FACS,	immunostaining	and	spiked	cell	isolation)	as	the	more	readily	commercially	available	clone	P1H12.	Therefore	we	relied	on	the	latter	to	isolate	melanoma	CTCs	from	patient	blood.	
Our	small	patient	cohort	includes	two	patients	with	CTCs	that	behaved	like	501mel	 cells	 as	 they	were	 not	 (patient	 1)	 or	 relatively	 poorly	 (patient	 9)	isolated	by	MCSP	but	well	by	MCAM	targeting	(Table	3).	More	patient	samples	showed	 the	 opposite	with	 higher	 CTC	 counts	 found	with	MCSP	 compared	
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with	 MCAM	 based	 isolation.	 These	 findings	 support	 our	 melanoma	 CTC	isolation	strategy	and	combined	targeting	of	MCAM	and	MCSP.	This	is	in	line	with	our	study	detecting	CTCs	in	87.5%	of	stage	IV	patients,	while	a	recent	study	reported	detection	of	melanoma	CTCs	in	42%	of	stage	IV	patients	using	the	 CellSearch	 strategy	 (320).	 It	 should	 however	 be	 noted,	 that	 the	combination	of	both	antibodies	not	always	increased	CTC	counts.	Previously	published	work	 in	 ovarian	 cancer	 suggests	 that	 the	 presence	 of	magnetic	beads	conjugated	to	an	antibody	against	an	antigen	of	minor	abundance	may	interfere	with	optimum	isolation	of	CTCs	lacking	the	antigen	(52).	Hence,	use	of	multiple	isolation	antibodies	for	immunomagnetic	cell	capture,	especially	targeting	relatively	rare	markers,	needs	careful	consideration.	
Regarding	 the	 other	 potential	 targets	 we	 tested	 for	 immunomagnetic	melanoma	 CTC	 isolation:	 N-cadherin	 positivity	 correlated	 with	 MCSP	detection	for	all	cell	 lines.	This	is	not	surprising	since	MCSP	is	proposed	to	induce	epithelial	to	mesenchymal	(EMT)	like	changes	in	melanoma	cells	and	N-cadherin	 is	 an	 important	 EMT	 marker	 (321).	 However	 in	 all	 cases,	 a	significantly	lower	proportion	of	cells	(25-75%)	interacted	with	the	anti-N-cadherin	antibody.	Thus,	although	we	successfully	validated	this	antibody	for	isolation	of	 EMT-CTCs	 from	ovarian	 cancer	patients,	we	disregarded	 it	 for	melanoma	CTC	isolation	in	favour	of	the	anti-MCSP	antibody	(52).	All	tested	antibodies,	other	than	anti-MCAM	and	anti-MCSP,	failed	as	relevant	isolation	tools	 for	 melanoma	 cells	 due	 to	 poor	 interaction	 with	 melanoma	 cells.	Although	 some	 of	 the	 correlating	 target	 cell	 surface	markers	 may	 still	 be	expressed	 in	 some	 melanoma	 cells,	 since	 our	 data	 supports	 careful	
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rationalisation	of	isolation	antibodies,	we	consider	targeting	both	MCAM	and	MCSP	is	the	most	viable	immunomagnetic	melanoma	CTC	isolation	strategy.	This	is	supported	by	other	studies	identifying	MCAM	and	MCSP	as	dominating	melanoma	cell	surface	proteins	(294).	
Interestingly,	 disregarding	 marginal	 MCAM	 and	 LRM3	 expression,	 both	tested	 c-Kit	mutant	 cell	 lines	 (MelMS	and	M230)	were	negative	 for	 all	 the	tested	cell	surface	markers.	This	finding	suggests	that	isolation	of	CTCs	from	c-Kit	mutant	melanoma	patients	may	need	further	refinement.	This	should	be	kept	 in	 mind	 when	managing	 patients	 with	 acral	 or	 mucosal	 melanomas,	which	 have	 significantly	 higher	 rates	 of	 c-Kit	mutation	 (322).	 Isolation	 of	melanoma	 CTCs	 using	 size	 based	 spiral	 microfluidics	 may	 provide	 an	alternative,	but	it	is	limited	to	cells	larger	than	average	blood	cells	(55).	
 
5.4.2 Detection of PD-L1 on CTCs 
There	is	some	debate	regarding	PD-L1	antibodies	as	certain	antibody	clones	are	less	reliable,	and	others	are	recommended	for	companion	diagnostics	and	PD-L1	detection	 (323).	We	chose	the	anti-human	PD-L1	rabbit	monoclonal	antibody	(clone	E1L3N),	because	PD-L1	positivity	in	tissue	detected	with	this	antibody	 correlates	well	with	 other	 anti-PD-L1	 antibodies	 (323-325).	 This	antibody	was	also	previously	successful	for	PD-L1	probing	in	bladder	cancer	CTCs	(326).		
Although	PD-L1	expression	in	melanomas	correlates	with	good	response	to	PD-1	 inhibitory	 therapy,	 it	 is	 not	 strictly	 required	 with	 a	 significant	
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proportion	of	patients	responding	to	ICI	despite	the	lack	of	detectable	PD-L1	in	 their	 tumour	 tissue	(308-310).	Since	PD-L1	expression	 in	 tumour	 tissue	appears	 to	 be	 induced	 by	 TILs,	 it	 has	 been	 proposed	 that	 this	 so	 called	adaptable	PD-L1	expression	in	tumour	cells	could	be	the	key	to	its	value	as	a	therapy	 response	 biomarker	 and	 adaptable	 PD-L1	might	 be	missed	 in	 TIL	deficient	tumours	(308, 323).	As	predicted,	our	data	suggest	that	melanoma	cells	in	blood	can	show	increased	PD-L1	expression.	Interestingly,	although	these	 findings	 are	 very	 preliminary,	 PD-L1	 inducibility	 appeared	 to	 be	dependent	on	the	blood	donor.	In	blood	from	donors	with	higher	induction	of	PD-L1	melanoma	cell	 recovery	 remained	 stable	over	a	 longer	 time,	maybe	indicating	 protection	 of	 melanoma	 CTCs	 through	 PD-L1	 presentation.	Induction	 of	 PD-L1	 on	 melanoma	 cells	 in	 the	 blood	 implies	 that	 PD-L1	screening	of	CTCs	may	detect	adaptable	PD-L1	even	when	the	tumour	tissue	exhibits	no	or	 low	counts	of	TILs.	Whether	 such	adaptable	PD-L1	on	CTCs	correlates	with	ICI	response,	needs	to	be	tested	in	suitable	patient	cohorts.		
Unfortunately,	for	our	proof	of	concept	study	to	validate	the	effectiveness	of	our	 MCAM	 and	 MCSP	 based	 melanoma	 CTC	 isolation	 method,	 we	 had	predominantly	access	 to	blood	samples	of	patients	already	on	 ICI	 therapy.	Nevertheless,	we	found	overall	38.6%	(5/13)	of	patients	whose	samples	were	probed	for	PD-L1	had	some	PD-L1	positive	CTCs	with	the	proportion	of	PD-L1	positive	CTCs	varying	between	1.5-60%.	Ideally	PD-L1	assaying	in	CTCs	should	be	done	prior	as	well	as	during	the	course	of	treatment	to	evaluate	their	value	as	a	predictive	biomarker.	One	would	expect	a	higher	proportion	of	 PD-L1	 positive	 CTCs	 before	 commencement	 of	 treatment	 as	 these	 cells	
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should	lose	protection	upon	PD-1/PD-L1	inhibition	and	be	rapidly	targeted	by	blood-based	immune	cells	upon	therapy.	 
Nevertheless,	 our	 PD-L1	 detection	 on	 CTCs	 is	 similar	 to	 studies	 in	 other	cancers.	A	breast	cancer	study	using	the	mouse	monoclonal	antibody	130021	to	detect	PD-L1	found	69%	(11/16)	hormone	sensitive	breast	cancer	patients	positive	for	CTCs	(defined	as	≥1	CTCs	per	7.5mL	blood,	CellSearch).	Of	those	72%	(8/11)	had	PD-L1	positive	CTCs	with	a	range	of	0.2-100%	being	PD-L1	positive	 (327).	 With	 the	 same	 antibody	 in	 a	 non-small	 cell	 lung	 cancer	(NSCLC)	 study,	 at	 baseline	 80%	 (20/25)	 of	 patients	 had	 1-20	 CTCs	(Cellsearch)	and	of	those	95%	(19/20)	had	some	CTCs	with	detectable	PD-L1	ranging	 from	25-100%	of	 the	CTCs	(328).	A	study	 into	PD-L1	detection	on	bladder	cancer	CTCs	used	the	same	antibody	clone	(E1L3N)	we	employed	in	our	 study.	 That	 study	 found	 CTCs	 in	 80%	 of	 patient	 samples	 and	 PD-L1	positive	CTCs	in	35%	of	CTC	positive	patient	samples.	Proportion	of	PD-L1	positive	CTCs	varied	between	0.9-67%	(326).		
Two	of	the	mentioned	studies,	appraised	the	correlation	of	presence	of	PD-L1	CTC	 detection	 on	 CTCs	 and	 ICI	 therapy	 response.	 In	 the	 NSCLC	 study	 by	Nicolazzo	et	al.	patient	attrition	meant	that	only	10	patients	were	analysed	at	6	 months	 into	 nivolumab	 treatment.	 There	 was	 a	 trend	 towards	 worse	response	with	retention	of	PD-L1	positive	CTCs	at	this	time	point.	PD-L1	CTC	detection	at	baseline	was	not	response	related.	This	was	consistent	with	the	finding	that	some	tissue	PD-L1	positive	NSCLC	patients	were	not	responding	to	ICI	(328).	Anantharaman	et	al’s	study	assessed	the	relationship	between	
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PD-L1	on	CTCs	and	ICI	response	in	only	four	bladder	cancer	patients	finding	progressive	disease	on	ICI	regardless	of	CTC	PD-L1	status	(326).	
To	 our	 knowledge,	 there	 are	 no	 melanoma	 studies	 investigating	 the	relationship	of	the	presence	of	PD-L1	on	CTCs	and	response	to	PD-1	inhibitor	therapy.	This	is	despite	the	widespread	and	expanding	use	of	PD-1	inhibitor	in	melanoma	therapy.	More	comprehensive	studies	are	required	to	delineate	whether	 PD-L1	 detection	 on	 CTCs	 could	 be	 a	 suitable	 biomarker	 of	 ICI	therapy	outcomes	in	melanoma.		
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5.5 Conclusion We	were	able	to	develop	an	efficient	isolation	and	identification	protocol	for	melanoma	CTCs	which	included	PD-L1	detection	on	CTCs.	Our	 in	vitro	data	suggest	 that	CTCs	with	adaptable	PD-L1	may	 increase	PD-L1	expression	 in	the	blood.	Whether	that	makes	CTCs	a	good	biosource	to	screen	for	PD-L1	and	how	levels	of	PD-L1	on	melanoma	CTCs,	measurable	with	this	relatively	fast	and	 easy	 detection	 assay,	 correlate	 to	 patient	 response	 needs	 to	 be	investigated	in	larger	scale	studies.	
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S1	Fig	Melanoma	Cell	Surface	Protein	Expression.	Compiled	data	 for	all	designated	cell	lines	showing	proportion	of	cells	expressing	the	indicated	cell	surface	proteins.	
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S1	Table.	Melanoma	Cell	Lines	
Cell	Line	 Mutation	Signature	/	Characteristics	
SkMel28	 BRAFV600E,	 CDK4R24C,	 EGFRP753S,	 PTENT167A,PTENR130Q,	p53L145R,	express	wild	type	p16INK4a,	epithelial	expression	signature	(329)	#	
501mel	 BRAFV600E,CTNNB1D32H,	CTNNB1D37F,	p16-null,	(330)	#	
NM176	 BRAFV600E,	 CDK4R24C,	 express	 wild	 type	 p16INK4a,	 high	melanin	expression	(331)	
A375	 BRAFV600E,	p16INK4aE61*,	p16INK4aE69*	#	
WMM1175	 NRASG13R,	p16-null,	p53-null	(332,	333)	
MelRM	 NRASQ61R	(314)	
MelMS	 c-KitW557-K558del,	high	melanin	expression	(334)	
M230	 c-KitL576P	(335,	336)	*	 Nonsense-substitution;	 #	
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ 
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S2	Table.	Candidate	Antibodies:	Melanoma	Cell	Isolation	
Antigen	[other	
names]	
Clone,	
distribut
er	
	
Concentratio
n	
	
Comments	
MCAM	 (melanoma	cell	 adhesion	molecule),	 [MelCAM,	MUC18,	 CD146/	 S-Endo,	A32]	
P1H12,	Millipore		 IF/FACS:	1:250	IM:	1µg	 Marker	 of	 melanoma	 progression	 (316);	used	 for	 melanoma	 CTC	 isolation	 with	Dynabeads	(315)		F4-35H7,	Biocytex		 IF/FACS:	1:20	IM:	1:4§	 Used	 for	 melanoma	 CTC	 isolation	 with	CellSearch	instrument	(317,	318,	320)	
MCSP	 (melanoma	chondroitin	 sulfate	proteoglycan),	 [high	molecular	 weight-melanoma	associated	 antigen	(HMW-MAA),	neuron-glial	 antigen	2	(NG2)]	
9.2.27#,	Millipore		 IF/FACS:	1:500	IM:	0.5µg	 MSCP	 reviewed	 by	 (337);	 used	 for	melanoma	 CTC	 isolation	 with	 Dynabeads	(315)		
CD271,	 [nerve	growth	 factor	receptor	 p75NGFR,	p75NTR,	LNGFR]	
C40-1457,	 BD	Biosciences		
IF/FACS:		1:500	IM:	0.5µg	 Proposed	 as	 marker	 for	 aggressive,	metastatic	 melanoma	 cells	 within	heterogeneous	populations	(338);	used	for	melanoma	 cell	 isolation	 with	 Dynabeads	(315)		
ABCB5	 	 (ATP-binding	 cassette	protein)	 5H3C6,	Abcam		 IF/FACS:		1:100	IM:	N/A	 Proposed	 as	 marker	 for	 aggressive,	metastatic	 melanoma	 cells	 within	heterogeneous	populations	(339);	different		
rabbit	anti-ABCB5	used	for	melanoma	CTC	isolation	with	Dynabeads	(315)		
N-cadherin	[CD325]	 GC-4,	Abcam		 IF/FACS:		1:20	IM:	1.25µg	 Increases	 with	 melanoma	 progression	(340);	 used	 for	 ovarian	 cancer	 CTC	isolation	(52)	
LHM3	 LHM3,	Santa	Cruz		
IF/FACS:		1:40	IM:	N/A	 Anti-melanoma	 antibody	 raised	 against	A375	 extract;	 candidate	 for	 imaging	 of	disseminated	melanoma	cells	(341)	
KBA.62	“”	 KBA.62,	Abcam,		 IF/FACS:	1:40	IM:	N/A	 Anti-melanoma	 antibody	 raised	 against	KAL	extract;	melanoma	specific	membrane	antigen	(342)	
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#:	mouse	 IgG2a,	 all	 other	 antibodies	 are	mouse	 IgG1;	 IF/FACS:	 antibody	dilution	used	 for	 immunofluorescence	 and	 FACS	 analysis;	 IM:	 antibody	 amount	 used	 to	conjugate	50	µl	of	magnetic	beads;	§	no	concentration	provided;	N/A	not	applicable	
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S3	Table.	Immunoreactivity	of	melanoma	cell	detection	antibodies	
Cell	line	 Melan-A	 S100-b	 GP100	 All	
combined	
SkMel28	 ++	 +++	 +++	 +++	
501mel	 +++	 +/-	 ++	 +++	
NM176	 +++	 ++(-)	 ++	 +++	
A375	 -	 +-	 ++	 ++	
WMM1175	 -	 +-	 ++	 ++	
MelRM	 +/-	 ++	 +/-	 ++	
MelMS	 +++	 ++	 +++	 +++	
M230	 +++	 ++	 +++	 +++	+++	very	strong	in	all	cells,	++	strong	in	>85%	of	cells,	+	clearly	detectable	in	most	cells,+/	-	clearly	detectable	in	>40%	of	cells,	-	negative	
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Chapter 6  Overall Discussion 
The	 development	 of	 metastatic	 disease	 accounts	 for	 >90%	 cancer	 patient	deaths	 (2-4).	 Initiation	 of	 the	metastatic	 cascade	 is	 a	 critical	 first	 step	 for	haematogenous	dissemination	of	cells	from	a	primary	site,	and	CTCs	collected	from	 the	 bloodstream	 are	 the	 primary	 evidence	 for	 the	mediation	 of	 this	process	 (40).	 Therefore,	 it	 is	 not	 surprising	 that	 CTC	 enumeration	 from	modern	 methodologies	 provides	 prognostic	 information	 in	 a	 variety	 of	cancers;	indeed,	an	important	cut-off	value	(>3	or	5	CTCs	/	7.5	mL)	indicates	poor	prognosis	 for	breast,	 colorectal	and	prostate	cancer	patients	 (20-22).	Whether	CTC	counts	are	able	to	predict	response	to	a	therapeutic	agent	is	still	unclear.	Importantly,	the	detection	of	CTCs	in	the	window	following	therapy	for	localised	cancers	does	indicate	a	higher	likelihood	of	recurrence	(33-36).	Ongoing	studies	are	investigating	whether	CTC	detectability,	increase	in	CTC	counts	or	interrogating	molecular	profile	of	CTCs	will	aid	in	stratifying	patient	populations	to	help	guide	patient	therapy.	
Conventional	 methods	 for	 CTC	 detection	 rely	 predominantly	 on	 the	expression	 of	 epithelial	markers,	 and	 that	 has	 produced	 success	 since	 the	majority	 of	 cancers	 arise	 from	 epithelial	 origins.	 However,	 this	 limits	 the	utility	of	CTC	assays,	broadly	speaking,	to	cancers	from	non-epithelial	origins	but	 also,	 due	 to	 tumour	 heterogeneity	 in	 epithelial	 cancers,	 as	 it	 has	 little	relevance	 when	 cells	 possess	 mesenchymal	 characteristics	 (115-119).	Moreover,	given	the	array	of	different	methodologies	of	enrichment	of	CTCs	from	blood	samples,	 it	 is	not	clear	whether	there	is	an	ideal	technique.	Put	
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together,	this	indicates	that	CTC	isolation	methodologies	may	be	suboptimal	and	ultimately	prevents	adequate	analysis.		
In	summary,	this	work	aimed	to	investigate	novel	methodologies	beyond	the	canonical	epithelial	CTC	enrichment	techniques,	by	utilising	antibody-based	combination	approaches	to	isolate	CTCs	from	a	range	of	cancers.	Our	over-arching	 ambition	 was	 to	 capture	 more	 CTCs	 and	 to	 improve	 the	 limited	capacity	for	standard	epithelial	marker	evaluation.	In	the	process,	we	found	evidence	that	some	of	these	“extra”	CTCs	had	truly	undergone	EMT	since	they	did	express	high	levels	of	vimentin	and	this	project	was	also	able	to	detect	other	features	such	as	PD-L1	expression	on	CTCs	–	for	the	first	time	detected	on	melanoma	 CTCs	 –	 and	 ultrastructural	 characteristics	 such	 as	 the	 cilial	basal	body	within	a	CTC	from	a	lung	cancer	patient,	also	demonstrated	for	the	first	 time.	 Ultimately,	 we	 hope	 this	 work	 will	 extend	 the	 utility	 of	 liquid	biopsies,	and	specifically,	CTC	analyses.			
	
6.1 Summation of experimental discoveries This	project	did	address	several	specific	aims	and	made	important	findings:	
Aim	 1:	 Establishing	 a	 method	 to	 enrich	 and	 characterise	 EMT-CTCs	 and	epithelial-phenotype	CTCs	from	ovarian	cancer	patients	
This	project	demonstrated	 the	 isolation	of	 a	wider	phenotypic	diversity	of	epithelial	 and	 EMT-phenotype	 CTCs	 by	 combining	 canonical	 EpCAM-targeting	with	 targeting	of	 the	EMT	marker	N-cadherin	 for	ovarian	 cancer	
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patients.	Moreover,	 this	project	 confirmed	EMT	characterisation	of	patient	CTCs	by	immunodetection	of	the	EMT	marker	vimentin.		
	
Aim	 2:	 Enrich	 EMT-CTC	 and	 epithelial	 phenotypes	 in	 other	 carcinomas,	combined	with	CTC	ultrastructure	analysis	
Interestingly	the	methods	developed	in	aim	1	for	ovarian	cancer	CTCs	were	not	well	 applicable	 for	 NSCLC	 and	metastatic	 prostate	 cancer	 patients.	 N-cadherin	based	CTC	isolation	alone	or	in	combination	with	EpCAM	targeting	provided	 little	 if	 any	 increase	 in	 CTC	 detection	 from	 NSCLC	 and	 prostate	cancer	 patients	 and	 vimentin	 detection	 did	 not	 correlate	 well	 with	 CTCs	captured	in	this	way.	These	findings	suggested	that	the	importance	of	EMT	may	 vary	 between	 cancers	 and	 that	 vimentin	 and	N-cadherin	may	 be	 less	commonly	co-expressed	in	NSCLC	than	in	ovarian	cancer.	Importantly,	in	this	aim	it	was	possible	to	further	analyse	some	of	the	CTC	samples	by	EM.	Initially	quantum	 dot	 nanoparticle	 using	 in	 vitro	 models	 of	 CTCs	 bound	 to	immunomagnetic	beads	were	validated,	while	finally	transmission	electron	microscopy	 methodology	 was	 the	 best	 to	 integrate	 EM	 analysis	 into	 CTC	sample	processing	and	enabled	ultrastructural	analysis	of	patient	CTCs.	
	
Aim	3:	Non-EpCAM-based	enrichment	of	melanoma	CTCs	and	determination	of	PD-L1	expression	
This	 project	 validated	 antibody-based	 immunomagnetic	 targeting	 of	melanoma	markers	MCAM	and	MCSP	for	the	isolation	CTCs	from	melanoma	
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patients	 and	 validated	 melanoma	 CTC	 identification	 by	 probing	 for	 three	melanoma	markers.	Moreover,	this	project	demonstrated	immunodetection	of	PD-L1,	an	important	biomarker	of	immune	checkpoint	therapy	response.	
	
6.2 Implications and clinical translation The	cornerstone	of	CTC	isolation	in	the	recent	decade	has	relied	heavily	upon	epithelial	markers	–	cell-surface	EpCAM	expression	for	isolation	followed	by	intracellular	cytokeratin	expression	for	identification.	While	this	has	proven	to	provide	robust	prognostic	information	in	a	range	of	cancers,	this	method	neglects	the	cancers	–	and	presumably	CTCs	–	that	are	variable	in	epithelial	marker	expression	or	in	some	cases	entirely	devoid	of	it.	
The	assay	developed	in	Chapter	3	aimed	to	address	this	gap	by	broadening	the	 landscape	 of	 CTC	 phenotypes	 isolated	 and	 analysed	 by	 targeting	 the	combination	 of	 EpCAM	 and	 the	 EMT	marker	 N-cadherin.	 Surprisingly,	 the	major	focus	of	studies	investigating	CTC	isolation	in	ovarian	cancer	to	date	have	 relied	mainly	 on	 epithelial	marker	 expression	 for	 identification	with	only	 a	 few	 exceptions.	 EMT-CTCs	 may	 very	 well	 represent	 the	 most	aggressive	CTCs	as	extravasation	is	one	of	the	early	critical	steps	in	metastatic	formation	and	so	incorporating	EMT	markers	for	CTC	isolation	as	shown	in	this	 project	 allows	 for	 the	molecular	 characterization	 of	 these	 EMT-CTCs.		Given	 the	 importance	 of	 EMT	 in	 metastasis	 this	 method	 could	 form	 a	foundation	to	use	CTCs	for	detailed	investigations	into	metastatic	pathways	and	to	identify	the	key	changes	in	cancer	cell	biology	that	promote	metastasis.	Such	analysis	may	provide	possible	targets	for	specific	drug	intervention	to	
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disrupt	 CTCs	 from	 invading	 into	 the	 bloodstream	 and	 ultimately	 help	preventing	metastasis.		
The	results	shown	in	Chapter	3	demonstrate	 improved	CTC	isolation,	even	though	 no	 obvious	 trend	 was	 seen	 when	 comparing	 CTC	 counts	 to	clinicopathological	parameters	for	this	small	study.	Improved	ovarian	cancer	CTC	 isolation	 is	 timely	 as	 a	 few	 recent	 studies	 have	 demonstrated	 the	potential	 for	CTC	 analysis	 in	 ovarian	 cancer	 setting	 to	be	 of	 clinical	 utility	beyond	prognostic	value	as	they	detected	relevant	biomarkers	in	CTCs	(142,	214,	343-346).		
As	outlined	in	Chapter	1,	ovarian	cancer	progression	and	resistance	is	linked	to	emerging	EMT	phenotypes.	Recent	studies	do	suggest	the	prognostic	value	and	 correlation	 between	 recurrence	 and	 EMT	 phenotype	 CTCs	 (217,	 347-351).	The	ability	to	improve	detection	of	EMT-CTCs	in	ovarian	cancer	patients	may	 also	 allow	 to	 understand	 better	 how	 EMT	 phenotype	 changes	 are	associated	with	resistance	to	therapy.		
Firstly,	 the	novel	 assays	may	allow	 researchers	 to	 validate	EMT-CTCs	as	 a	poor	 prognostic	 marker	 and	 an	 early	 identifier	 of	 developing	 therapeutic	resistance	although	this	would	need	to	be	proven	in	larger	studies.	Secondly,	EMT	CTCs	could	be	compared	to	epithelial	CTCs	to	further	characterise	EMT	associated	pathways	using	emerging	multi-parameter	 imaging	approaches.	Finally,	these	assays	may	help	to	stratify	patients	for	clinical	trials	in	ovarian	cancer.	 Better	 treatments	 in	 the	 ovarian	 cancer	 setting	 are	 still	 urgently	needed	 as	 the	 majority	 of	 patients	 will	 eventually	 become	 resistant	 to	platinum-based	chemotherapy.	Identifying	treatment	resistance	using	a	non-
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invasive	blood	test	early	during	therapy	provides	a	window	of	opportunity	to	cease	an	ineffective	treatment	regime,	to	avoid	unnecessary	side	effects	and	to	ideally	move	patients	onto	other	treatments	or	clinical	trials	once	available.		
This	 project	 also	 succeeded	 in	 showing	 that	 CTCs	 can	 be	 analysed	 using	electron	 microscopy.	 So	 far,	 less	 than	 a	 handful	 of	 studies	 have	 trialed	electron	microscopy	imaging	of	CTCs;	to	the	best	of	our	knowledge,	this	study	demonstrated	for	the	first	time,	transmission	electron	microscopy	images	of	CTCs.	Currently,	scarce	literature	only	indicates	utility	of	scanning	electron	microscopy	to	provide	information	limited	to	the	exterior	of	the	cell	and	the	accompanying	 cell	 membrane	 protrusions	 (63-65).	 These	 may	 indeed	highlight	important	structural	differences	which	cancer	cells	have	adapted	to	promote	 survival,	 motility	 and	 invasiveness.	 Transmission	 electron	microscopy	of	CTCs,	as	shown	in	Chapter	4,	on	the	other	hand	allows	for	the	identification	of	 intracellular	structures	aiding	 in	 locating	cell-type	specific	aspects	which	 indicate	 the	 site	 of	 origin.	 Complexity	 of	 using	 this	method	aside,	this	adds	another	dimension	and	a	notable	improvement	in	technical	approaches	to	analyzing	CTCs	not	done	before.	It	may	serve	as	a	significant	tool	in	CTC	analysis	at	least	at	the	research	level.	Our	workflow	and	reliance	of	relatively	large	immunomagnetic	beads	for	CTC	isolation	appears	to	limit	the	 utility	 of	 electron	 microscopy	 in	 the	 routine	 detection	 of	 CTCs,	nevertheless	the	ability	to	visualise	structures	at	the	subcellular	level	opens	up	opportunities	to	investigate	other	biological	structures	that	may	elucidate	adaptations	that	cancer	cells	acquire	to	survive	through	the	circulation	and	ultimately	 seed	 metastases.	 Our	 laboratory	 is	 currently	 introducing	
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additional	strategies	 for	CTC	 isolation	resulting	 in	 largely	reduced	residual	lymphocyte	 contamination	 while	 using	 much	 smaller	 immunomagnetic	particles.	 Conceivably,	 using	 this	 CTC	 isolation	 method	 with	 transmission	electron	microscopy	would	improve	this	method	for	future	applications.	
This	PhD	project	also	applied	methods	developed	 for	rare	CTC	 isolation	to	another	cancer,	melanoma,	that	does	not	express	EpCAM.	The	establishment	of	novel	methods	to	detect	circulating	melanoma	cells	sets	the	foundations	for	 studying	 specific	 markers	 relevant	 in	 the	 currently	 most	 promising	therapy	used	in	the	disease.	
The	 ability	 to	 detect	 PD-L1	 expression	 on	 CTCs,	 as	 shown	 in	 Chapter	 5,	provides	the	opportunity	to	test	if	expression	of	this	biomarker	on	CTCs	may	be	related	to	response	to	treatment	with	check	point	inhibitor	therapies,	as	better	response	biomarkers	are	still	needed	in	this	setting.	In	melanoma	this	is	a	critically	unmet	need	as	there	is	no	clinically	approved	biomarker	for	PD-1	 immunotherapy	 treatment,	 although	 this	 therapy	 is	 commonly	 used.	Evidence	 is	 now	 emerging	 that	 PD-L1	 expression	 on	 cancer	 patients	 CTCs	does	indeed	correlate	with	patient	outcomes,	however	the	field	is	currently	in	 its	 infancy	 and	 more	 comprehensive	 studies	 are	 needed	 (352,	 353).	Nevertheless,	our	observation	that	indeed	PD-L1	expression	may	be	induced	in	CTCs	due	 to	 exposure	 to	 the	blood	environment	 suggests	 that	CTCs	are	indeed	 a	 good	 biopsy	 to	 investigate	 PD-L1	 expression.	 Further	 it	 will	 be	interesting	 to	do	a	 “real-time”	 evaluation	of	 any	 changes	of	PD-L1on	CTCs	over	 time	 as	 it	 may	 accompany	 response	 and	 relapse	 with	 immune	checkpoint	 inhibitors.	 Importantly,	 the	 ability	 to	 customize	 CTC	 isolation	
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panels	as	shown	for	melanoma	in	Chapter	5	is	opening	up	opportunities	to	isolate	CTCs	 from	a	 variety	of	 cancers.	 Indeed,	 in	 collaboration	with	other	teams	we	are	investigating	CTC	isolation	and	isolation	of	rare	cancer	stroma	cells	 in	 a	 range	 of	 cancers	 including	 melanoma,	 brain	 cancer,	 pancreatic	cancer	and	sarcoma.	While	these	studies	are	ongoing,	the	data	look	promising	and	the	follow	up	studies	 investigating	the	clinical	utility	of	each	will	be	of	great	interest	in	the	CTC	research	field.	
	
6.3 Limitations and challenges of these methodologies The	 data	 presented	 here	 describe	 novel	 findings	 in	 antibody-based	 CTC	detection	 methodologies,	 electron	 microscopy	 method	 integration	 and	biomarker	 detection.	 While	 these	 provide	 novel	 contributions	 to	 CTC	literature,	there	were	some	limitations	and	challenges.	
In	Chapter	3	and	4,	we	investigated	EMT	phenotype	CTCs	in	advanced	ovarian,	NSCLC	and	metastatic	prostate	cancer	patients.	While	we	showed	an	increase	in	 CTC	 isolation	 efficiency	when	 including	 EMT	marker	 N-cadherin	 in	 the	isolation	method	in	ovarian	cancer	patients,	we	did	not	confirm	these	findings	in	 NSCLC	 and	 prostate	 cancer	 patients.	 This	 may	 be	 due	 to	 inherent	limitations	 of	 antibody-based	 approaches	 in	 general,	 reflect	 tumour	pathology	in	different	cancer	types,	or	the	poor	expression	of	N-cadherin	seen	in	these	cancer	types.	Another	significant	challenge	in	regard	to	liquid	biopsy	research	 is	 the	 timing	 of	 blood	 draws,	 particularly	 in	 relation	 to	 specific	events	 (baseline,	 recurrence,	 disease	 progression	 etc.)	 and	 comparison	 to	standard	clinical	outcomes	as	determined	by	imaging	methods.	Ideally,	all	the	
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different	methodologies	should	be	compared	head-to-head	to	determine	the	“best”	method,	but	 this	 is	 logistically	and	ethically	very	difficult,	since	only	small	 amounts	 of	 blood	 are	 available	 at	 any	 one	 point	 in	 time.	 However,	clinical	correlation	is	essential	in	determining	utility	of	biomarker	detection	using	CTCs	and	other	components	of	the	liquid	biopsy	(e.g.	circulating	tumour	DNA,	 exosomes),	 especially	 if	 CTC	 analyses	 are	 used	 in	 the	 future	 as	predictive	and	prognostic	markers.	
While	EM	is	potentially	a	powerful	tool	to	investigate	CTC	biology,	there	were	challenges	 in	 integrating	 immunomagnetic-targeted	CTC	 isolation	with	EM	sample	preparation.	More	specifically,	the	super-resolution	FESEM	platform	was	 unable	 to	 adequately	 resolve	 cell	 surface	 markers	 from	 CTCs	 due	 to	interference	artefacts	produced	by	the	electron	beam.		
	
6.4 Future perspectives  The	work	 shown	 here	 contributes	 to	 our	 understanding	 of	 CTC	 detection	methodologies	 and	 will	 guide	 future	 EMT-CTC	 detection	 studies.	 The	antibody-based	CTC	isolation	and	electron	microscopy	methods	established	here	have	set	the	foundations	for	important	follow	up	studies,	some	of	which	are	already	underway.	
There	 remains	 a	 significant	 gap	 in	 understanding	 CTC	 biology	 and	 the	mechanisms	that	drive	metastatic	formation,	with	many	questions	regarding	the	indispensability	of	EMT	in	the	metastatic	cascade	remaining.	The	results	from	this	work	suggest	that	EMT-CTC	detection	is	especially	important	in	the	
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more	heterogeneous	cancers	such	as	advanced	ovarian	cancer,	but	this	may	not	be	universal	in	regard	to	all	cancers.	Thus,	careful	consideration	needs	to	be	given	as	to	which	markers	are	best	employed	for	EMT	characterisation.		
To	further	study	EMT-related	ultrastructures	using	TEM,	high	blood	volume	and	other	CTC	 enrichment	procedures	 (such	 as	 leukaphoresis),	may	 allow	increased	concentrations	or	clusters	of	CTCs	to	be	investigated	en	masse.	The	application	of	EM	 imaging	 in	 the	CTC	 field	 is	very	much	 in	 its	 infancy,	and	future	work	in	this	area	may	reveal	critical	CTC	components	and	features	that	contribute	to	a	better	understanding	of	CTC	biology	and	metastasis.	
	
6.5 Final conclusions This	 thesis	 has	 demonstrated	 the	 various	 applications	 for	 antibody-based	CTC	 capture,	 extending	 beyond	 conventional	 methods.	 We	 reported	 the	inclusion	of	EMT-markers	for	detection	and	characterisation	of	EMT-CTCs	in	the	ovarian	cancer	 setting.	This	methodological	 advancement	may	prove	a	critical	step	in	understanding	the	role	EMT	plays	in	CTC	formation,	metastasis	and	potentially	therapeutic	resistance.	In	addition,	we	explored	integration	of	electron	 microscopy	 methods	 into	 CTC	 sample	 processing,	 allowing	 for	ultrastructure	analysis	of	CTCs	and	improving	the	tools	to	help	understand	CTC	biology.	Finally,	we	explored	antibody-based	CTC	isolation	methods	in	the	melanoma	setting	with	additional	biomarker	PD-L1	detection,	enabling	real-time	monitoring	of	therapy	response	to	PD-1	inhibitors.	
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Overall,	the	knowledge	gained	from	this	thesis	will	aid	the	CTC	research	field	from	three	different	perspectives:	(1)	The	clinical	perspective:	capitalize	on	CTC	detection	by	adding	 important	biomarker	detection	 that	may	 indicate	response	to	therapy;	(2)	The	technical	perspective:	demonstrating	feasibility	of	integrating	electron	microscopy	sample	preparation	into	CTC	analyses;	(3)	
The	biological	perspective:	establishing	EMT	detection	in	a	range	of	cancers.	
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Abstract
The  current  dogma  is  that  epithelial-to-mesenchymal  transition  (EMT)  promotes
circulating tumour cell (CTC) formation and is ultimately a driver of metastasis. There
is also accumulating evidence that EMT-phenotype changes are commonly associated
with therapy resistance. Thus, capturing EMT-phenotype CTCs is expected to yield
important clinical information in regard to prognosis and response to therapy as well
as allowing the study of metastatic processes. However, the isolation and identifica‐
tion of EMT-phenotype CTCs with commonly used isolation/detection methods are
suboptimal, and current efforts on improving the isolation of EMT-phenotype CTCs are
associated with pitfalls that need to be overcome. This chapter explores the signifi‐
cance of EMT in CTC formation and the role of EMT in cancer metastasis and resist‐
ance to therapy. We also comprehensively review the past and current limitations of
evaluating EMT phenotypes in CTC isolation and analysis and discuss how CTCs can
be seen in a more holistic fashion as important biomarkers for clinical management.
Keywords: CTC, EMT, vimentin, immunomagnetic cell isolation, metastatic disease
1. Introduction
Circulating tumour cells (CTCs) were first discovered by the Australian pathologist Thomas
Ashworth in  1869,  who described single  cells  and cell  clusters  in  a  patient’s  blood and
proposed a role for CTCs in the metastatic  process [1].  Recently,  due to improved CTC
detection techniques, these cells, together with circulating tumour nucleic acids (ctNA), are
emerging as  attractive,  accessible,  non-invasive  biopsies  to  guide the  best  therapy for  a
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
patient’s cancer. CTC counts are closely related to cancer progression and stage, and there is
mounting evidence from studies on prostate-, breast-, colorectal- and other cancers that CTCs
have prognostic value (reviewed by Caixeiro et al. [2]).
In essence, CTCs are very rare cells, and usually only between 0 and 30 CTCs can be isolated
from a 5–10-ml blood sample of a cancer patient; although for some patients, CTC counts can
be considerably higher. Isolation technologies allow enrichment and separation of CTCs from
the millions of surrounding blood cells by initial gradient centrifugation or red blood cell lysis
followed by further enrichment of CTCs due to their physical properties or by employing
antibody-based negative or positive enrichment techniques (reviewed by Yu et al. [3]).
Enrichment steps are followed by CTC identification primarily by immunocytostaining. The
most common CTC identification pattern relies on positive staining for nucleated cells (4',6-
diamidino-2-phenylindole (DAPI) or Hoechst staining) and cytokeratin (CK; positive CTC
marker) associated with a lack of CD45 staining (negative CTC marker, expressed on leuco‐
cytes). Advances in single cell analysis technology have contributed to maximise the informa‐
tion that can be gained from CTCs isolated from a single blood sample. Tumour biomarkers
such as gene amplification, mutation, rearrangement and expression can be successfully
analysed while CTC protein levels can be determined. There are high expectations that CTC-
based assays will find utility for clinical testing, guiding therapy and monitoring treatment in
the not-too-distant future (reviewed by Becker et al. [4]). However, cancer cells, including
CTCs, are extremely heterogeneous, and therefore, isolating a representative range of CTCs
remains difficult.
A particular challenge is the capture of CTCs that have undergone epithelial-to-mesenchymal
transition (EMT) [5, 6]. EMT and its reverse, the mesenchymal-to-epithelial transition (MET),
are reversible phenotypical changes that allow a cell to form either dense epithelial structures
with tight interaction to neighbouring epithelial cells or, by undergoing EMT, to loosen
interactions with other cells and become more mesenchymal and migratory. The ability to
undergo these changes is important for cells during development to allow the migration of
cells and the formation of different tissues. Cancer cells that are able to take advantage of these
processes and undergo EMT are proposed to be more motile and consequently are more likely
to become CTCs by entering the blood stream [7]. Not surprisingly, EMT-phenotype cancer
cells are linked to the presence of metastases. Additionally, cancer cells that have undergone
EMT tend to be distinctly more resistant to chemo and radiation therapy [8]. Consequently,
the detection and analysis of EMT-phenotype CTCs appear necessary to fully harness CTC
information about a given cancer and monitor disease evolution; yet, we are still poorly
equipped to detect these cells. Currently, most methods to isolate CTCs, and nearly all current
approaches to identify CTCs, rely on the presence of epithelial cell markers. CTC isolation
predominantly relies on immunomagnetic targeting of the epithelial cell adhesion molecule
(EpCAM), but this epithelial glycoprotein diminishes during EMT, thereby compromising the
effectiveness of this strategy [5, 6]. The identification of CTCs usually involves immunocytos‐
taining for epithelial proteins of the cytokeratin protein family, which are similarly downre‐
gulated during EMT [9]. Equally problematic is the method of probing for EpCAM, which is
frequently used to identify CTCs after size exclusion enrichment [10].
Tumor Metastasis242
In this chapter, we summarise the current understanding of EMT in CTC formation, detection
of EMT markers in CTCs isolated by common methods and their limitations, and new
approaches to better isolate and identify EMT-phenotype CTCs (EMT-CTCs). The clinical
relevance of detecting EMT-CTCs is also discussed.
2. EMT in CTC formation
The role of EMT in the metastatic process has been controversial mainly because cells in
metastatic tumours often display epithelial rather than mesenchymal characteristics, despite
the presence of cells with mesenchymal features in the primary cancer. The recognition that
EMT is a reversible process has led to a model adaptation, which postulates that EMT reversal,
termed MET, has to occur after extravasation to allow motile cancer cells to resettle and form
metastases [11] (Figure 1). Regardless of robust in vivo data that show increased metastasis
associated with an EMT phenotype in the primary tumour, experimentally tracking EMT or
MET in the metastatic process remains challenging [12].
Figure 1. EMT in CTC formation. Simplified illustration of cells in a primary tumour undergoing EMT changes, which
enable them to disseminate from the primary cancer, intravasate into the blood stream and travel as CTCs before ex‐
travasating the vascular system and, by undergoing MET, regain the ability to form a metastatic tumour.
Several elegant studies and in vivo evidence (mainly from mouse models) show that EMT aids
tumour cell dissemination and promotes intravasation into the vascular system (CTC forma‐
tion). MDA-MB-468 breast cancer cells that can be driven to undergo EMT by epidermal
growth factor (EGF) exposure were used in a severely compromised immunodeficient (SCID)
mouse xenograft model. Xenografts in this model lead to lung and liver metastases, and a peak
in CTC counts coincided with the appearance of cells strongly staining for the EMT marker
vimentin in the initial xenograft. Vimentin was also expressed in CTCs and CTC clusters,
suggesting that EMT promoted CTC formation [13]. Another study, in which KRAS-pancreatic
tumour model mice were treated with cerulein to induce pancreatitis and EMT changes in the
cancer cells, showed significant increases in CTC counts [14]; however, this finding was not
corroborated in a more recent study involving a similar model [15]. A role for EMT in CTC
formation was further substantiated when a squamous cell carcinoma prone mouse model
with targeted transcription factor Twist1 induction confirmed that Twist1 caused tumour cells
Importance and Detection of Epithelial-to-Mesenchymal Transition (EMT) Phenotype in CTCs
http://dx.doi.org/10.5772/64342
243
to undergo EMT, and this was associated with a doubling of CTC counts as well as increased
metastasis [16]. Recently, an innovative model of endothelial cells that form vascular-like
structures in vitro was used to show that SW620 colorectal cancer cells could migrate into these
‘vessels’, especially when hypoxia-induced EMT was triggered [17]. A concept supporting the
notion that mesenchymal properties afford cancer cells some protection in circulation suggests
that any cells shedding from a tumour without undergoing EMT might undergo stressful,
traumatic events required for the interruption of the strong epithelial cell-cell interactions
resulting in reduced viability [18]. Additionally, EMT-phenotype changes are generally
thought to reduce sensitivity to stress signals that would normally lead to apoptosis [8]. Taken
together, these observations underpin the emerging opinion that EMT-CTCs may comprise a
more viable, aggressive tumour cell population than epithelial CTCs, and go some way to
explain the association of EMT-CTCs and increased metastasis. In that regard, it is worth noting
that transforming growth factor β (TGFβ), which is commonly released by platelets, may
promote or maintain EMT in CTCs while in the circulation and promote extravasation [19].
The current understanding of the role of CTCs in establishing distant metastatic sites was
recently reviewed and is beyond the scope of this chapter [2, 20].
3. EMT phenotypes in CTCs isolated by EpCAM targeting
It is important to emphasise that, despite the epithelial nature of EpCAM, CTCs isolated by
EpCAM targeting can display markers of EMT. This is due to the fact that changes between
epithelial and mesenchymal phenotypes are dynamic, and cells can be found in intermittent
stages and express mesenchymal as well as epithelial markers at the same time. Accordingly,
mesenchymal markers have been successfully detected in CTCs after EpCAM-based isolation.
For instance, intermittent EMT phenotype characterised by co-expression of mesenchymal
proteins vimentin, N-cadherin and CD133 with epithelial markers EpCAM, CK and E-cadherin
was shown in breast cancer and prostate cancer CTCs isolated by EpCAM targeting [21].
EpCAM-based breast cancer CTC isolation also yielded cells with common gene expression
of the EMT markers TGFβ1, FOXC1, CXCR4, NFKB1, VIM and ZEB2 [22]. Moreover, higher
breast cancer staging correlated with mesenchymal vimentin and fibronectin expression in
EpCAM-enriched CTC samples. Interestingly, vimentin and fibronectin expression was also
detected in 31 of 92 (34%) of patient samples, which were CTC negative according to the
common CTC definition (DAPI+, CK+, CD45-) but not in samples from healthy control indi‐
viduals, suggesting the presence of CTCs lacking CK in some patients [23].
4. EMT phenotype in CTCs isolated with alternate strategies
The inability of EpCAM-based CTC isolation to optimally account for EMT-CTCs with EpCAM
loss has led to the targeting of alternative, EMT-associated cell-surface markers, for CTC
enrichment, or by avoiding these methods altogether and focussing on CTC enrichment due
to physical cancer cell properties, mainly size exclusion. Not surprisingly, when EpCAM-
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based immunomagnetic CTC isolation was directly compared with size exclusion CTC
enrichment of parallel blood samples from 40 NSCLC patients, CTCs were isolated from a
higher proportion of patients (80 vs 23%) by size exclusion, and as expected the isolated cells
tended to lack EpCAM; however, they expressed CK and had elevated levels of the EMT-
associated epithelial growth factor receptor (EGFR) and thus likely were tumour cells [24].
An elegant approach to account for the CTCs missed during EpCAM-based capture in HER2-
positive breast cancer patients utilised CD45 immunomagnetic depletion of blood cells after
an initial EpCAM-based CTC capture, to further enrich the remaining EpCAM-negative CTCs.
The EMT-linked transcription factors SNAI1 and ZEB1 were more commonly expressed in
these EpCAM-negative cells that were likely tumour-derived cells compared to the EpCAM-
isolated counterparts [25]. Vimentin, best known for its functions as a cytoskeletal support
protein, can also be present on the cell surface of mesenchymal cells and has been successfully
targeted in immunomagnetic isolation of CTCs from colorectal cancer patients and breast
cancer patients. After CD45 immunodepletion, CTCs were positively selected with cell-surface
vimentin (CSV) targeting. The authors suggest that CSV expression is restricted to cancer cells,
and CSV targeting isolates significantly more CTCs from colorectal cancer patients with
progressive disease than those with stable disease; moreover, higher CSV-CTC counts were
more commonly found in therapy-resistant patients. In a direct comparison of CSV- and
EpCAM-based CTC isolation (CellSearch CTC platform) in breast cancer patients, CTCs
isolated with CSV targeting were a more reliable marker for progressive disease compared to
stable disease. In both CSV-isolated breast and colorectal cancer CTCs, the EMT markers
FOXC2, SNAIL, Twist-1 and Slug tended to be highly expressed while E-cadherin and EpCAM
levels were low. The CSV antibody is currently not commercially available, thus limiting its
Figure 2. EMT analysis in isolated CTCs. Quadruple staining to detect CTCs with EMT phenotype according to levels
of the EMT marker vimentin. (A) CTCs were identified by nuclear Hoechst staining ‘Ncl’ (blue, Fluxion enumeration
kit) and cytokeratin (CK) staining (green; FITC-conjugated anti-cytokeratin antibody: clone c-11, Sigma-Aldrich) as
well as exclusion of CD45 expression (red, antibodies: CTC enumeration kit, Fluxion). Vimentin staining, ‘Vim’ (or‐
ange, AF647-conjugated anti-vimentin antibody: clone V9, Abcam), in CTCs, was scored as indicated: Staining of a rep‐
resentative cell for each category, negative (−), weak (+), positive (++) and strongly positive (+++), is depicted. (B) Cell
counts for vimentin-positive EMT-CTCs isolated from a representative patient sample using EpCAM- versus N-cad‐
herin- ‘N-cad’-based isolation of CTCs using the quadruple staining assay. CTCs were isolated with the IsoFlux CTC
isolation platform using EpCAM-based or N-cadherin-based immunomagnetic isolation with the Rare Cell Isolation
Kit, Fluxion.
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EMT markers Main finding/clinical correlation [reference]
EpCAM-based immunomagnetic isolation:
EpCAM, CK, E-cadherin,
vimentin, N-cadherin, CD133
CTCs with intermittent EMT phenotype are common in advanced prostate- and
breast cancer [21]
CK Low CK level CTCs were correlated with receptor negative metastatic breast cancer
and with poorer OS [30]
Vimentin Vimentin expression in prostate cancer CTCs is associated with decreased OS [31]
TGFß1, FOXC1, CXCR4, NFKB1,
VIM, ZEB2
Gene expression of EMT markers shown in CTCs [22]
HER2, VIM, FN1 Presence of EMT-CTCs correlates to disease stage [23]
CK, VIM, FN1 The presence of EMT-CTCs correlates to shorter PFS [32]
EpCAM-based isolation combined/compared with other methods:
Cell-surface vimentin (CSV) EMT-CTC numbers were a more reliable progressive disease marker for breast can‐
cer patients when isolated targeting CSV versus EpCAM [27]
Vimentin, twist, ZEB1, ZEB2,
snail, slug and E-cadherin
The expression of both twist and vimentin in CTCs was significantly correlated with
portal vein tumor thrombus in liver hepatocellular carcinoma [33].
CK, EpCAM Most CTCs from metastatic breast cancer patients showed intermittent phenotype
while 16% of patients had EpCAM- only CTCs and 33% EpCAM-null CTCs [34]
CK, EpCAM, CDH1, FN1, CDH2 Combined EpCAM/EGFR/Her2-based CTC isolation was linked to
increased EMT-CTC numbers in metastatic breast
cancer patients with disease progression [35]
TWIST1, SLUG, SNAIL1, ZEB1,
FOXC2
EMT-CTCs were more common in primary breast cancer
patients with poorer prognostic markers (ie
needed neoadjuvant treatment) [36]
Targeted immunomagnetic isolation (non-EpCAM):
Cell-surface vimentin (CSV) >5 >5 EMT-CTCs more common in progressive colorectal cancer [26]
CD45-based immunomagnetic blood cell depletion:
Vimentin, twist, CK EMT -CTCs more prevalent in CTCs from metastatic breast cancer
patients [37]
EpCAM, CK, VIM CTCs of ‘CTC-negative’ NSCLC patient by EpCAM based isolation
were tumorigenic in mice [29].
Isolation by cell size:
Vimentin, CK Pancreatic cancer CTCs without CK or vimentin are more commonly in
patients with lymphnode metastasis [38].
CK, EpCAM,VIM, TWIST Proportion of EMT-CTCS is linked to response to therapy in gastric cancer [39]
EpCAM, CK, VIM, TWIST Intermittent phenotype and EMT CTCs were predominant in hepatocellular
carcinoma and correlated with metastasis [40]
OS: overall survival, PFS: progression-free survival. Dependent on their nature, EMT markers follow protein or gene
nomenclature
Table 1. Detection of EMT biomarkers in CTCs.
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use and confirmation of the data by others [26, 27]. A study that investigated gene expression
in ovarian cancer CTCs showed the expression of EMT markers in most individual CTCs from
three patients, while only 30% of these cells also expressed epithelial CK5 or CK7. However,
all CTCs expressed epithelial MUC1 [28]. In a patient with non-small cell lung cancer who was
CTC-negative according to EpCAM-based (CellSearch) enrichment, it is worth noting that
CTCs enriched by CD45 depletion were tumourigenic in mice and CTCs isolated from the
same patient by size exclusion showed predominant EMT or intermittent phenotype [29].
In our laboratory, we embarked on the isolation of CTCs from advanced ovarian cancer
patients using N-cadherin-based immunomagnetic isolation and captured approximately
three times more CTCs- when using N-cadherin-based versus EpCAM-based CTC isolation
(data not shown). We also developed an assay to probe CTCs for vimentin as marker of EMT,
which showed that N-cadherin-based CTC isolation from advanced ovarian cancer patients
increased the capture of EMT-CTCs (Figure 2). Studies that investigated EMT markers in CTCs,
isolated by various strategies, are compiled in Table 1.
5. The pitfalls of non-EpCAM-based CTC isolation
The clear advantage of EpCAM-based CTC isolation is the observation that EpCAM is only
rarely found on cells circulating in the blood stream of healthy individuals, resulting in a
limited number of false-positive ‘CTCs’. In our hands, using the IsoFlux CTC platform and
EpCAM-based enrichment, the average Hoechst+, CK+, CD45−-false positive ‘CTCs’, obtained
from 10 healthy blood donors is 1.8 per 9 ml of blood with a range of 0–5 cells. By contrast, the
greatest problem with the use of EMT markers for CTC isolation or CTC identification, or with
CTC isolation techniques relying on physical cell properties such as size and plasticity, is the
increased risk of detecting false-positive ‘CTCs’. This is the case because some rare cells found
in normal blood can express a number of epithelial and mesenchymal markers. For instance,
circulating endothelial cells (CECs) can be found at varying numbers in blood samples of
healthy individuals (0–29/ml blood) [41] and increased numbers in cancer patients [42]. CECs
do not only express cytokeratin, but typical EMT markers such as N-cadherin, EGFR, vimentin
and fibronectin [43–48]. Moreover, circulating endothelial cells tend to be above 10 μm in
diameter [49], and some endothelial cells might therefore not be excluded from size-based CTC
enrichment. There are currently limited data evaluating potential CEC contamination in either
filter-enriched CTC samples or samples enriched by positive or negative immunotargeting.
However, it is likely that the inclusion of CECs in CTC counts in the literature (i.e. false-positive
CTCs) has inadvertently led to overestimation.
A particularly interesting approach to avoid the issues surrounding EpCAM is the use of
CD146 (MCAM)-based immunomagnetic CTC isolation. Elevated expression of CD146 has
been reported for melanoma, breast-, ovarian- and prostate cancer [50], and CD146-based
immunomagnetic CTC isolation was reported for breast cancer and melanoma patients [44,
51]. However, CD146 is also an endothelial marker used to define and target CECs [41]. Thus,
CD146-based CTC isolation needs to be complemented by cancer-specific CTC identification,
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such as Melan-A for melanoma CTCs, for example. Alternatively, there is a need to distinguish
co-purified CECs from CTCs using specific endothelial markers not expressed on cancer cells.
The endothelial marker CD34 has been used to distinguish CD146-enriched breast cancer CTCs
from CECs [44]. Whether CD34 is the most reliable or specific marker to distinguish true CTCs
from false positives still needs to be confirmed.
Our preliminary data suggest that the accumulation of false positives, most likely endothelial
cells, is also an issue when using N-cadherin-based immunomagnetic CTC isolation. While
CTC numbers isolated from advanced ovarian cancer patients were approximately four times
higher than EpCAM-isolated CTC numbers, we also detected more Hoechst+, CK+, CD45− false-
positive ‘CTCs’ in the blood from seven individuals without any history of cancer (data not
shown). N-cadherin, EGFR and cytokeratin expression of endothelial cells suggest that
targeting these proteins in CTC isolation or identification might lead to similar problems.
Moreover, other cells in the circulation, such as monocytes, macrophages and neutrophils, also
express the EMT markers EGFR, vimentin and N-cadherin. Further, tumour-associated
macrophages of breast cancer and prostate cancer patients were also shown to express
cytokeratin and therefore could be confused with CTCs [52–55]. Thus, while non-EpCAM-
based CTC isolation techniques appear to produce higher CTC counts and favour isolation of
CTCs with EMT features, they also may enrich for false-positive cells, and as long as identifi‐
cation solely relies on CK and CD45 staining of nucleated cells, these cannot be sufficiently
well discriminated from CTCs. Advances in identifying CTCs and distinguishing them from
false positives, in particular endothelial cells, will refine CTC detection and help avoiding
diagnostic errors when progressing CTC-based assays into the clinic.
6. EMT-phenotype CTCs, do they have clinical relevance?
Circumstantial evidence linking EMT changes to advanced disease and increased metastasis
is strong. EMT phenotype in patient tumour tissue is often prognostic and correlates negatively
to overall survival and disease progression. Most notably, a switch from the expression of the
epithelial cell-cell adhesion molecule E-cadherin to the mesenchymal N-cadherin is thought
to be central to EMT, and it is commonly found in association with disease progression in
various cancers including melanoma, pancreatic-, bladder- and colorectal cancer (reviewed by
Cavallaro et al. [56]). Other studies found elevated expression of a number of E-cadherin
transcriptional repressors such as Twist, Slug, ZEB1/2 and Snail1 linked to poorer prognosis
in endometrial-, colorectal-, hepatocellular-, bladder-, gastric- and lung cancer [57–63].
Equally, increased expression of vimentin was associated with poorer outcomes for patients
with gastric-, colorectal-, bladder- and breast cancer [58, 64–66]. However, the correlation of
EMT with poorer overall or disease-free survival is not universal. A recent study, which
established a comprehensive EMT gene expression signature in tumour tissue, found that
poorer disease-free survival was associated with an EMT gene expression pattern in ovarian
and colorectal cancer but not in breast cancer; therefore, it will be important to better define
the context in which EMT gives cancer cells a selective advantage [67]. As detailed above, EMT
marker gene or protein expression has also been studied in CTCs, and the overall emerging
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evidence suggests that increased EMT-phenotype detection in CTCs correlates with more
advanced disease stages and is the predominant phenotype found in the blood of patients with
metastatic disease (see Table 1).
Cancer cells frequently undergo EMT when exposed to stress, and this makes them signifi‐
cantly more resistant to a variety of therapies. However, it is not well understood whether the
range of phenotypic EMT changes that cause increased mobility and metastasis is instrumental
in resistance or merely associated with it. Mounting in vitro evidence suggesting that EMT
confers drug resistance has been thoroughly reviewed previously [8]. More recently, in vivo
data reaffirm the link between EMT and therapy resistance. For instance, the loss of E-cadherin
expression in erlotinib-treated non-small cell lung cancer tumour tissues correlated with
poorer progression-free patient survival [68], and EMT gene expression signatures in ovarian
or prostate cancer patient tissue were associated with resistance to platinum therapy or
docetaxel and androgen deprivation, respectively [69, 70]. Interestingly, two recent studies
suggested that in breast- and pancreatic cancer mouse models, the majority of cells that
metastasised to the lungs did not undergo EMT. Nevertheless, EMT was involved in drug
resistance and conditional metastatic outgrowth when mice were treated with the drugs
cyclophosphamide and gemcitabine, respectively [15, 71]. These data add to the controversy
regarding the role of EMT in the metastatic process and warrant further research. The data do
support the survival/therapy resistance functions associated with EMT and it is plausible that
cancer cells may ‘escape into EMT’ to render themselves resistant to drug treatment. Data are
starting to emerge suggesting these changes might be detectable by CTC analysis as subtyping
CTCs as possessing epithelial, intermittent or mesenchymal characteristics showed that gastric
cancer CTCs of a patient progressing on therapy were all of EMT phenotype. However, and
confusingly, any remaining CTCs detected in gastric cancer patients that responded to therapy
were more epithelial in nature [39].
Regardless, it is possible that therapy inadvertently induces cells that survive drug exposure
to change into more mobile, viable and aggressive clones. Due to their EMT phenotype, these
cells may be ideally equipped to leave the primary tumour, become CTCs, prevent anoikis and
potentially form distant metastases sites. Additionally, the survival advantage of EMT cancer
cells might allow time to acquire alternative resistance mechanisms such as mutations. In turn,
that would allow EMT-CTCs to undergo MET after extravasation to enable the resettling and
formation of proliferating metastases. The underlying mechanisms need to be more thorough‐
ly investigated, and the ability to accurately isolate EMT-CTCs will prove central to clarifying
the role of EMT in therapy resistance, disease relapse and metastatic processes. Efficient EMT-
CTC isolation and identification may also allow the development of diagnostic tests that
monitor escape into EMT as part of therapy response to inform improved patient management.
7. Conclusion
Despite open questions regarding how EMT contributes to cancer progression and drug
resistance, there is strong evidence that EMT changes, per se, are useful prognostic markers.
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Consequently, EMT-CTC isolation and analysis have the capacity to progress EMT research
and importantly allow the development of feasible, non-invasive diagnostic tests to predict
and monitor the effectiveness of specific therapies. More reliable identification of these cells
will permit the translation of EMT and CTC research into clinically relevant tests to guide
therapy.
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Abstract
Epithelial cell adhesion molecule (EpCAM)-targeted capture remains the most common isolation strategy for circulating
tumor cells (CTCs). However, epithelial-to-mesenchymal transition (EMT) leads to decreased epithelial EpCAM
expression affecting the optimal CTC capture. In this study, we tested a cohort of ovarian cancer cell lines using flow
cytometry to identify N-cadherin as the additional immunomagnetic cell surface target for ovarian cancer cell isolation.
Combined immunomagnetic targeting of mesenchymal N-cadherin and epithelial EpCAM enriched CTCs from advanced
ovarian cancer patient blood approximately three times more efficiently than targeting of EpCAM alone. We also show
that more EMT-phenotype CTCs are captured by including N-cadherin targeting into CTC isolation protocols. However,
after N-cadherin-based CTC isolation, in some blood samples of healthy individuals, we also observed the presence of
cells expressing markers common to CTCs. Our data show that these “false positives” can be largely distinguished from
CTCs as circulating endothelial cells (CECs) by vascular endothelial–cadherin co-staining. CEC counts are highly variable
in patients and healthy controls. Our data demonstrate that a combination of EpCAM with N-cadherin-targeted isolation
can improve CTC detection and widen the EMT-phenotype spectrum of captured CTCs.
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Introduction
Ovarian cancer is the fifth leading cause of cancer in
women and the leading cause of gynecological cancer
death worldwide. While 70–80% of patients initially
respond to first-line platinum-based chemotherapy, others
have intrinsically resistant tumors. Further, the majority
(70%) of advanced-stage patients will eventually develop
treatment resistance.1,2
The analysis of circulating tumor cells (CTCs) is emer-
ging as a promising way to monitor cancer progression and
the effectiveness of therapy. CTCs are cells that have shed
from the primary or metastatic tumor and intravasated into
the blood stream. CTC isolation and analysis can give an
insight into the disease biology and its behavior. Expect-
edly, high CTC counts have been correlated with disease
progression and poorer prognosis in colorectal, breast, and
prostate cancers (reviewed by Caixeiro et al.3). A compre-
hensive study in ovarian cancer patients (n ¼ 216) showed
that CTC counts above two at therapy commencement cor-
related with poorer progression-free and overall survival.4
Another study found that enhanced CTC counts predicted
relapse or progression in 31 epithelial ovarian cancer
patients.5 Although some smaller studies found no correla-
tion of CTCs with disease progression, four recent meta-
analyses showed that CTC positivity in ovarian cancer
patients was significantly associated with shorter overall,
disease-free, and progression-free survival as well as
advanced stage in ovarian cancer.6–9
Potential diagnostic application of ovarian cancer
patient CTCs include CTC ERCC1 transcript detection
associated with platinum resistance, detection of CTC clus-
ters associated with platinum resistance, and in vitro assay-
ing of platinum sensitivity in cultured CTCs which
correlated with patient response.10–12 Thus, although CTCs
are often considered of minor relevance in ovarian cancer
because it metastasizes mainly throughout the peritoneum,
a view that was challenged by data using an elegant para-
biosis mouse model, ovarian cancer CTCs appear to have
value as biomarkers.13,14
Currently, the most common method of CTC isolation
relies on immunomagnetic cell capture by targeting the
epithelial cell adhesion molecule (EpCAM). However,
with EpCAM expression lost or reduced, CTC detection
may be difficult,15,16 and there is evidence for EpCAM
heterogeneity in ovarian cancer cells.17 Moreover, EpCAM
is downregulated during epithelial-to-mesenchymal transi-
tion (EMT), a process that is implicated in the metastatic
spread of cancer and especially the egress of CTCs into the
circulation.18 A recent study evaluating epithelial and
mesenchymal gene expression of ovarian cancer patient
CTCs before and after chemotherapy suggested that
platinum-based therapy enriches EMT-like CTCs.19 Simi-
larly, EMT-phenotype changes may be a marker of resis-
tance to platinum therapy as shown for ovarian cancer cell
lines,20 and gradual change towards EMT gene expression
signatures in ovarian cancer tissue during progression to
platinum resistance was correlated with poor prog-
nosis.21,22 Quite contrary, another study indicates that the
epithelial cell phenotype combined with high nuclear factor
kB activity is associated with ovarian cancer platinum
resistance.23 Taking the evidence together, liquid biopsies
and CTC analysis may provide important predictive and
prognostic information, and heterogeneity in resistance
mechanisms suggest that both epithelial and mesenchymal
cells need to be investigated to follow changes of disease
progression biomarkers in a representative population of
CTCs.
A well-characterized central step during EMT is the
expression switch of the epithelial cell–cell adhesion mole-
cule E-cadherin to the mesenchymal cell–cell adhesion
molecule N-cadherin (reviewed by Lamouille et al.24), and
an E-cadherin-to-N-cadherin switch was shown in ovarian
cancer tissue at progression from stage II to stage III.25
Therefore, in this study, we assessed E-cadherin, EpCAM,
and N-cadherin expression on the surface of ovarian cancer
cell lines to identify N-cadherin, in addition to EpCAM, as
a useful target for immunomagnetic CTC isolation. We
demonstrate that additional CTCs are isolated by combin-
ing EpCAM with N-cadherin-targeted CTC isolation by
establishing a method to identify EMT-phenotype CTCs.
Materials and methods
Patients
Patients were recruited from Liverpool Cancer Therapy
Centre and The Crown Princess Mary Cancer Centre West-
mead. Clinical information was sourced from patient med-
ical records. Information at the time of blood sampling was
collected including age and primary cancer site. Treatment
information was collected including chemotherapy regi-
men, previous lines of therapy prior to CTC isolation,
serum CA-125 levels, and radiological assessments (Online
Supplementary Table S1). Blood samples from healthy
individuals were analyzed as controls.
Cell culture
Ovarian cancer cell lines A2780, CAOV3, COLO316, ES2,
OVCAR3, PEO1, PEO4, PEO14, SKOV3, and the WME-
099 EBV-transformed human B-lymphocyte cell line were
maintained in RPMI 1640 media (Lonza, Basel, Switzer-
land) supplemented with 10% fetal bovine serum (FBS)
(Interpath, Melbourne, Australia) in a humidified incubator
with 5% atmospheric carbon dioxide at 37C. All cell lines
were authenticated by Short Tandem Repeat (STR) Profil-
ing (Australian Genome Research Facility, Melbourne,
Australia) and tested negative for mycoplasma. Cells were
seeded at 15–20% confluency and cultured for 3 days.
Adhered cells were harvested with 0.2 mM ethylenediami-
netetraacetic acid (EDTA) in phosphate-buffered saline
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(PBS) at 37C to maintain cell surface protein integrity.
Cell scrapers were used to help detach any cell adhering
beyond 5–10 min of PBS/EDTA incubation.
Flow cytometry
Detached cells were pelleted, resuspended, and aliquoted at
1–5  105 cells. Cells were blocked with 10% FBS in PBS
and probed sequentially with primary and secondary anti-
bodies for 30 and 20 min, respectively (Online Supplemen-
tary Table S2) and resuspended in 300 ml of PBS for
fluorescence-activated cell sorting (FACS) analysis (FACS
Canto II Cell Analyzer, BD Biosciences, North Ryde, Aus-
tralia). Flowing Software 2.5.1 was used for analysis
(Turku Centre for Biotechnology, Turku, Finland).
Immunocytostaining
Cells were seeded on sterile 18-mm diameter coverslips in
12-well plates at 2.5 104 cells/well and grown for 3 days.
Non-fixed cells were blocked with 10% FBS in PBS for 10
min and sequentially incubated with primary and second-
ary antibodies for 45 and 30 min, respectively (Online
Supplementary. Table S2). ProLong Gold Antifade
reagent with 40,6-diamidino-2-phenylindole (DAPI) (Life
Technologies, Melbourne, Australia) was used for mount-
ing. Fluorescent microscopy cell images were taken with a
BX53 microscope (Olympus, Notting Hill, Australia) with
20 objective using the CellSens Dimension imaging
software.
CTC capture
Immunomagnetic beads, Rare Cell Isolation Kit (Fluxion,
San Francisco, California, USA), were incubated with anti-
EpCAM or anti-N-cadherin antibodies for conjugation
according to the distributer’s protocol (Online Supplemen-
tary Table S2). Conjugated beads were stored at 4C and
used within 4 weeks.
At each blood collection, three 9 ml peripheral blood
tubes were drawn per patient into EDTA vacutubes (Grei-
ner Bio-One, Frickenhausen, Germany) and processed
within 24 h. A total of 26 blood collections from 22 patients
were analyzed.
Lymphoprep and Sepmate tubes (Stemcell Technolo-
gies, Vancouver, Canada) were used to separate the periph-
eral blood mononuclear cells (PBMCs), containing CTCs,
according to the manufacturer’s instructions. PBMCs
derived from 9 ml blood each were washed once in PBS
and resuspended in 800 ml binding buffer; then, 40 ml FC
buffer (Fluxion) and either 30 ml anti-EpCAM antibody-
coupled beads or 30 ml anti-N-cadherin antibody-coupled
beads or 30 ml of each were added. Cells were incubated for
90 min at 4C on a rotating platform and then loaded into
primed IsoFlux cartridges for CTC enrichment using the
IsoFlux standard isolation protocol (Fluxion). Enriched
CTCs samples were fixed with 3.7% formaldehyde in PBS
before immunocytostaining.
CTC immunocytostaining
Enriched CTC samples were washed with binding buffer
and blocked with 25 ml of 10% FBS in binding buffer,
followed by 15-min incubation with 25 ml of anti-CD45
antibody (Fluxion), 1:100 in 10% FBS/binding buffer.
After a binding buffer wash, cells were incubated with
25 ml Cy3-conjugated donkey anti-rabbit immunoglobulin
G (IgG) antibody (Fluxion), 1:200 dilution in 10% fetal calf
serum (FCS)/binding buffer for 15 min, washed again, then
permeabilized with 25 ml 0.2% Triton X-100, and incubated
with 25 ml of fluorescein isothiocyanate (FITC) conjugated
anti-cytokeratin antibody diluted in 10% FCS/binding buf-
fer (Online Supplementary Table S2) for 30 min. After
final wash steps, samples were transferred to glass slides
and mounted with ProLong Gold Antifade reagent with
DAPI (Life Technologies, Melbourne, Australia). Cells
were imaged as outlined above. Initially, CTCs from the
blood samples of 10 patients and 10 healthy blood donors
were detected and enumerated in this standard way by
establishing nuclear DAPI (Nucþ), cytokeratin (CKþ),
and CD45 cells.
VE-cadherin quadruple immunocytostaining
For quadruple staining, enriched CTC samples were pre-
blocked with mouse immunoglobulins as above. After fix-
ing in 3.7% formaldehyde, the CTC immunocytostaining
protocol was followed by the Cy3-conjugated donkey anti-
rabbit IgG antibody probing. Sample was then washed in
binding buffer and incubated with VioBlue-conjugated
antihuman vascular endothelial (VE) -cadherin (cad) anti-
body for 30 min (Online Supplementary Table S2), fol-
lowed by cytokeratin probing. Sample mounting media
included DRAQ5 nuclear dye (Abcam, Melbourne, Austra-
lia) instead of DAPI. Imaging was performed as outlined
above. VioBlue VE-cad staining was scored immediately
in Nucþ/CKþ/CD45 cells to avoid background associ-
ated with slide storage. Blood samples from six patients
and nine healthy donors were analyzed this way.
Finally, blood samples from six patients were com-
pared using quadruple staining with either antihuman
vimentin or VE-cad antibodies (as described above) ana-
lyzing CTC isolations based on targeting either the cell
surface marker EpCAM or the combination of EpCAM
and N-cadherin.
Vimentin quadruple immunocytostaining
For quadruple CTC and vimentin staining, enriched CTC
samples were preblocked in 25 ml mouse immunoglobulins
(Abacus, Brisbane, Australia) at a final concentration of
1.2 mg/ml in binding buffer for 20 min to saturate any
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remaining free anti-mouse antibody present on magnetic
beads. Samples were then washed briefly in binding buffer
and fixed in 3.7% formaldehyde for 10 min. Initially, the
CTC immunocytostaining protocol was followed. After the
cytokeratin probing, samples were washed in binding buf-
fer and incubated with Alexa Fluor 647-conjugated mouse
antihuman vimentin antibody for 1 h at room temperature
(Online Supplementary Table S2). After three washes (2
PBS, 1 H2O) mounting media included Hoechst nuclear
dye, and cells were observed and images were captured as
mentioned earlier. Nucþ/CKþ/CD45 cells were scored
as EMT-CTCs when showing strong vimentin reactivity
(Vimþ).
N-cadherin quadruple immunocytostaining
For N-cadherin quadruple CTC staining, enriched CTC
samples or PBMCs were preblocked with mouse immuno-
globulins and then washed, fixed, and blocked as
mentioned earlier. Samples were then incubated with
FITC-conjugated anti-CD45 (Biolegend, San Diego, CA,
USA) and FITC-conjugated anti-CD144 (Miltenyi Biotec,
NSW, Australia) for 30 min. Samples were washed in bind-
ing buffer and probed with rabbit anti-N-cadherin (Novus,
Biologicals, Litleton CO, USA) for 60 min and then its
AlexaFluor647-conjugated secondary donkey anti-rabbit
IgG antibody (Jackson ImmunoResearch, West Grove,
PA, USA) for 30 min. After permeabilization with
0.2% Triton-X in PBS, samples were probed with
AlexaFluor555-conjugated pan-cytokeratin (Cell Signaling
Technology, Beverly, MA, USA) for 30 min (see Online
Supplementary Table S2, for antibody dilutions). After
three washes (2 PBS, 1 H2O), cells were observed and
images captured as mentioned earlier.
Compliance with ethical research standards
The study was conducted in accordance with the Declara-
tion of Helsinki and approved by the South Western Syd-
ney Local Health District Ethics Committee (Ref: HREC/
13/LPOOL/158). All patients and healthy controls included
in this study gave informed written consent for blood col-
lection and subsequent CTC analysis.
Results
Epithelial and mesenchymal cell surface proteins on
ovarian cancer cells
To identify suitable ovarian cancer cell surface proteins for
evaluating immunomagnetic CTC isolation, a heterogene-
ity representative cohort of nine different ovarian cancer
cell lines was analyzed by FACS and immunocytostaining
for the expression of E-cadherin, EpCAM, and N-cadherin.
A human B-lymphocyte cell line (WME-099) was included
in the analysis to rule out antibody interaction with lym-
phocytes. As expected, EpCAM was heterogeneously
expressed and was never found on the entire cell population
of any ovarian cancer cell line. In all, 60–85% of cells
expressed detectable EpCAM levels, while in two cell
lines, ES-2 and A2780, EpCAM was undetectable.
E-cadherin expression was found in the same cell lines that
expressed EpCAM, although the proportion of cells expres-
sing detectable E-cadherin tended to be slightly lower,
ranging from 30% to 80%, again ES-2 and A2780 lacked
E-cadherin. N-cadherin expression, on the other hand,
tended to be inversely related to EpCAM expression, with
EpCAM-negative ES-2 cells expressing detectable
N-cadherin in approximately 80% of cells. Exceptions were
EpCAM and E-cadherin-positive PEO14 cells that also
expressed high N-cadherin levels in approximately 75%
of cells, while EpCAM/E-cadherin-negative A2780 cells
also lacked detectable N-cadherin in the majority (>60%)
of cells (Figure 1). Overall, N-cadherin emerged as a pos-
sible target for EMT-CTC isolation.
N-cadherin-targeted CTC isolation from advanced
ovarian cancer patients
CTC isolation was performed using the Isoflux microflui-
dic CTC isolation instrument. We confirmed in initial
experiments that the GC-4 anti-N-cadherin antibody is suit-
able for immunomagnetic cell capture of ES-2 cells (data
not shown). To validate that N-cadherin in addition to
EpCAM targeting improves CTC isolation, we compared
CTC isolation in 20-patient blood collections from 18
advanced ovarian cancer patients when analyzed according
to standard CTC identification (Nucþ/CKþ/CD45).
CTCs were captured in 90% (18 of 20) of the patient sam-
ples when EpCAM and N-cadherin were targeted together,
and slightly fewer (80%, 16 of 20) by directing isolation at
EpCAM alone (Figure 2(a), Table 1). CTC counts showed
high intra-patient variability in all antibody groups (0–376
for EpCAM, 0–853 for N-cadherin, and 0–1300 for
combined targeted isolation). N-cadherin-directed CTC
isolation outperformed EpCAM-based isolation by 2.1-
fold, based on median fold change of CTC capture, while
combined targeting of N-cadherin and EpCAM increased
CTC capture 3.0-fold (Table 1). In 10 healthy blood donor
control samples, we also observed a background of cells
that met the staining criteria for CTCs when N-cadherin
alone or in combination with EpCAM was targeted for
isolation. Importantly, these “false-positive CTCs” were
highly variable in number, and most healthy individuals
had only moderate counts. Howver, 40% (4 of 10) of
healthy individuals had >10 cells in 9 ml blood meeting
the CTC definition of Nucþ/CKþ/CD45 (Figure 2(b)).
Distinguishing CECs from CTCs
Circulating endothelial cells (CECs) are rare cells in the
circulation, expressing N-cadherin and cytokeratin28 and
thus are likely to be co-enriched with our assay as “false-
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Figure 1. Cell surface proteins on ovarian cancer cells and lymphocytes. The nine indicated ovarian cancer cell lines and the
lymphocyte line WMM-099 were tested for the expression of EpCAM, E-cadherin (E-cad), and N-cadherin (N-cad) by FACS analysis
and immunocytostaining. (a) Representative FACS histograms and immunocytostaining for mesenchymal ES-226 and epithelial PEO1
cells27 are depicted. (b) The proportion (gray columns) of cells from the indicated cell lines expressing the designated proteins with
mean expression level (red bars) is graphed (mean+ SEM. n  2). FACS: fluorescence-activated cell sorting; SEM: standard error of
mean.
Table 1. Comparative CTC isolation approaches with indicated antibodies presented by common CTC identification (Nucþ/CKþ/
CD45).
Patient EpCAM N-cadherin Fold change Combination Fold change
Pt 1 20 38 1.9 24 1.2
Pt 2 0 17 — 2 —
Pt 3 0 0 — 0 —
Pt 4 19 25 1.3 58 3.1
Pt 5* 8 288 36.0 82 10.3
Pt 6 48 82 1.7 125 2.6
Pt 7 376 853 2.3 1300 3.5
Pt 7a,* 236 307 1.3 697 3.0
Pt 8 8 24 3.0 42 5.3
Pt 9* 16 162 10.1 68 4.3
Pt 10 4 7 1.8 9 2.3
Pt 11 0 0 — 0 —
Pt 12 51 530 10.4 465 9.1
Pt 13 7 47 6.7 29 4.1
Pt 13a 20 38 1.9 74 3.7
Pt 14 6 46 7.7 8 1.3
Pt 15 0 2 — 1 —
Pt 16 5 21 4.2 8 1.6
Pt 17 4 6 1.5 9 2.3
Pt 18 4 3 0.8 1 0.3
Median fold change 2.1 Median fold change 3.0
CTC counts per 9 ml blood. Data from 20 blood collections (18 patients) with CTCs stained by the common identification stain (Nucþ/CKþ/CD45)
(n ¼ 10) or relevant data from common stain plus Vim (n ¼ 4) or VE-cadherin (n ¼ 6) are combined. Pt: patient; EpCAM: epithelial cell adhesion
molecule; CTCs: circulating tumor cells.
aRecollection post >3 months.
* <9ml blood available, data normalised to 9ml.
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positive CTCs” when isolation is directed at EMT markers.
To identify CECs, a quadruple-staining identification strat-
egy, including probing for the endothelial marker VE-cad,
revealed that isolated CECs (Nucþ/CKþ/VE-cadþ/
CD45) were enriched in blood collections from our
patients and healthy controls with comparable distribution
to the cells we identified as “false-positive CTCs” (Figure
2(b) and (c)). To help estimate how much of an issue false
positive (non-CTCs) are for this assay, we spiked SKOV3
cells into healthy donor blood and compared a small pro-
portion of pre-enrichment PBMCs with the major propor-
tion of blood after CTC enrichment using the same
staining. Mimicked CTCs (SKOV3) were found in the
pre-enrichment sample, consistent with the minor propor-
tion of PBMCs analyzed. Importantly, more cells met the
CEC criteria in the pre-enriched sample (5 from 1 ml blood
vs. 1 after N-cadherin-based CTC enrichment from 8.7 ml
blood). Together with the fact that no CECs were detected
after EpCAM or combined targeted CTC enrichment, this
indicates that the healthy donor had relatively low overall
CEC counts (Online Supplementary Figure S1).
The prevalence of CECs in ovarian cancer patients and
healthy controls confirmed that CEC co-isolation by
EpCAM targeting is rare, while N-cadherin targeting is
associated with increased identification of co-isolated
CECs. CEC counts are highly variable between individ-
uals and low (<5) in approximately 60% of assayed
healthy controls and patient samples. Strikingly though,
in patient 14, CECs (44 of 46) outnumbered CTCs
(2 of 46) (Figure 3(a)), highlighting the value of CEC
co-staining during CTC identification.
EMT-CTC detection and discrimination from CECs
To confirm that we can detect EMT-CTCs, we developed
another quadruple stain for Nucþ/CKþ/CD45 CTCs by
including the EMT marker vimentin (Vim) into our immu-
nomagnetic CTC isolation method. Due to limitations of
our microscope (four-color detection only), we were unable
to include Vim and VE-cad detection in the same assay.
To determine whether contaminating CECs will affect
EMT-CTC detection, we decided to focus on CTCs isolated
by either EpCAM alone or in combination with N-cadherin
targeting. We performed a quadruple stain for VE-cad or
for Vim in CTCs of parallel samples from six patients, five
positive for CTCs (Figure 3(b)). EMT-CTCs were observed
at higher counts than CECs in the majority of patient sam-
ples regardless of isolation method. Only patient 22 dis-
played higher CEC counts than EMT-CTC counts
associated with CTC isolation by combination targeting.
Importantly, regardless of varying CEC co-purification,
true EMT-CTC counts were always higher in
combination-based CTC isolates in comparison to
EpCAM-alone–based isolation (Figure 3(b)).
To estimate how prevalent rare blood cell expression of
N-cadherin is and how well we are able to distinguish
EMT-CTCs from potential false positives, we took 27ml
blood from one patient. We then kept a small proportion of
the PBMCs pre-CTC enrichment to compare immunostain-
ing with staining after CTC enrichment using our different
Figure 2. Cell isolation from advanced ovarian cancer patients.
(a) Data from 20 blood collections (18 patients) are presented to
compare EpCAM, N-cadherin (N-cad), or the combination
(Combi) targeted CTC isolation efficiencies when applying the
standard CTC identification (Nucþ, CKþ, and CD45). (b)
False-positive “CTCs” in 10 healthy donor blood samples, when
using the standard CTC identification (Nucþ, CKþ, and CD45).
(c) CECs in healthy individuals and patients: the same cell isolation
method using a VE-cadherin (VE-cad) CEC staining protocol
identified co-isolated CECs in patients (n ¼ 6) and healthy con-
trols (n ¼ 9). Red symbols: patient-derived CTCs (a) or CECs (c);
black symbols: healthy control-derived false positive “CTCs” (b)
or CECs (c). All counts are presented as cells per 9 ml blood.
EpCAM: epithelial cell adhesion molecule; CTCs: circulating
tumor cells; CECs: circulating endothelial cells.
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isolation strategies. To also evaluate N-cadherin expression
in that setting, we combined CD45 with VE-cad probing in
the green fluorescent channel. The patient evidently had
very low CTC numbers (Online Supplementary Table
S3). Thus, not surprisingly, we did not detect any CTC in
the pre-enriched sample from 1 ml blood but detected four
non-CTCs (Nucþ/(CD45, VE-cad)þ/CKþ). In total, more
non-CTCs were detected in the enriched CTC samples,
indicating that the patient had high CEC counts which
could be appropriately distinguished from CTCs (Online
Supplementary Table S3). However, normalized on the
blood volume (8.7 ml) only N-cadherin-alone isolation pro-
duced similarly high non-CTC numbers, further evidencing
that this enrichment strategy may also enrich potential false
positives most effectually (Online Supplementary Table
S3). The detected non-CTCs might be CECs, although with
some uncertainty, due to CD45 and VE-cad detection in the
same fluorescent channel in these experiments. Of note, N-
cadherin was detected in some but not all of these cells
(Online Supplementary Figure S2).
We set out to demonstrate increased isolation efficiency
with our method, and blood collections were not restricted
to specific time points throughout treatment. Thus, not
unexpectedly, no significant correlation between CTC
numbers and disease parameters was observed (data not
shown).
Discussion
The aim of this study was to establish a method to improve
immunomagnetic CTC isolation from ovarian cancer
patients by capturing both CTCs with epithelial and
mesenchymal phenotype. The EMT-phenotype change is
characterized by an E-cadherin-to-N-cadherin switch
(reviewed by Lamouille et al.24), while expectedly the two
epithelial markers EpCAM and E-cadherin are closely co-
expressed in our large ovarian cancer cell line cohort. Thus,
well-established EpCAM-based CTCs isolation is likely
adequate to isolate epithelial cells. As expected, we con-
firmed increased levels of N-cadherin in our ovarian cancer
cell lines with low EpCAM levels, and these flow cytome-
try data informed our decision to add N-cadherin to our
immunomagnetic targeting assay using the Isoflux plat-
form. However, it is worth highlighting that N-cadherin
was not expressed on approximately 75% of EpCAM-
negative A2780 cells, implying that A2780-like CTCs are
likely to remain as poorly detectable with our method as
with established EpCAM-based CTC isolation methods.
Figure 3. CEC and EMT-CTC capture by immunomagnetic isolation (a) top: representative quadruple staining of a CTC (VE-cad,
CKþ, CD45, and Nucþ) and CEC staining (VE-cadþ, CKþ, CD45, and Nucþ). Bottom: ovarian cancer patient cells were isolated
by EpCAM, N-cadherin (N-cad), or combined targeting as indicated. The proportion of total CTCs and CECs captured with each
isolation strategy is displayed. All counts are presented as cells per 9 ml blood. (b) Top: representative quadruple staining of an epithelial
(EPI) and an EMT-phenotype CTCs. Bottom: comparison of EMT-CTC and CECs isolated from advanced ovarian cancer patients by
EpCAM or combined EpCAM plus N-cadherin (Combi) targeting. All counts are presented as cells per 9 ml blood. CECs: circulating
endothelial cells; EMT: epithelial-to-mesenchymal transition; CTCs: circulating tumor cells; CECs: circulating endothelial cells; EpCAM:
epithelial cell adhesion molecule.
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Notably, A2780 ovarian origin has been questioned previ-
ously as genetic clustering puts these cells closer to intest-
inal or lung cancer cells.25,29
Our data show that targeting the EMT marker
N-cadherin with a commercially available anti-N-
cadherin antibody isolates 2.1-fold more CTCs from
advanced ovarian cancer patients than EpCAM-alone-
based isolation and 3.0-fold more when used together with
EpCAM targeting. Our CTC isolation efficiencies from 80%
to 90% of patients are comparable to other ovarian cancer
studies that detected CTCs from 14% to 85% of patients
dependent on disease stage and CTC detection methods.4,5
Notably, CTC counts when targeting EpCAM alone were
similar to those reported in a recent ovarian cancer study
using the Isoflux platform (range 0–1208; median 55).30 In
comparison to EpCAM-alone–targeted CTC isolation, CTC
counts were always higher when N-cadherin was targeted
alone or in combination with EpCAM, although some
co-purification of CECs was observed when including
N-cadherin targeting into isolation strategies.
In our study, N-cadherin-alone–based isolation of CTCs
always improved on EpCAM-alone–based isolation. Also,
the combined targeting always improved on EpCAM-alone
targeting; however, the combination strategy was only
superior to N-cadherin-alone–based CTC isolation in about
half of the samples. We speculate that immunomagnetic
beads with different antibodies in the same admixture can
cause interference with cell capture if only one of the tar-
geted antigens is predominantly expressed. Thus, an EMT-
CTC population predominantly expressing N-cadherin
would be expected to be more efficiently isolated with
N-cadherin-only targeting than by adding potentially inter-
fering beads coupled to, in the context less relevant, anti-
EpCAM antibodies. We, therefore, propose that antibody
cocktails used in CTC isolation should be considered
with caution, as antibodies that might only aid in excep-
tional cases to isolate relatively rare cells may interfere
in the appropriate isolation of the intended common cell
population. Nevertheless, we propose that combining
EpCAM with N-cadherin-based ovarian cancer CTC isola-
tion will ultimately be a more successful strategy, particu-
larly if also investigating early-stage patients, who would
be expected to have more epithelial CTC phenotypes.
Our data confirm that, similar to size filtration-based
CTC enrichment methods, CTC isolation strategies focus-
ing not only on EpCAM expressing CTCs lead to higher
total CTC counts.31,15 However, we confirm that EpCAM-
only–based CTC isolation yields purer CTC populations as
contamination with false positives is rare in comparison to
N-cadherin-based CTC isolation. Our data also confirm,
importantly, that CECs are an important cause of false-
positive CTC identification and are not distinguished by
the common CTC identification (Nucþ/CKþ/CD45).
Moreover, CECs not only express N-cadherin but also a
number of other markers that have been previously pro-
posed for CTC isolation, such as Epidermal growth factor
receptor (EGFR), vimentin, and fibronectin. With a cell
size ranging up to around 10 mm, they may also not be
filtered out sufficiently by size exclusion methods of CTC
isolation. Our data agree with studies that specifically tar-
geted CECs for isolation, where CEC counts were highly
variable in healthy individuals (0–29/ml blood) and tended
to be increased in some disease states including cancer
(reviewed by Po et al.28). Therefore, it is important to
account for CECs when using any non-EpCAM-based CTC
isolation method. We developed quadruple-stain CTC
identification (Nucþ/CKþ/CD45/VE-cad) that largely
diminishes the identification of false-positive CTCs by dis-
tinguishing them from co-isolated CECs. Importantly,
regardless of whether CECs might make up a varying pre-
dominantly smaller proportion of cells in a CTC isolate,
parallel samples confirmed that immunomagnetic CTC iso-
lation based on EpCAM plus N-cadherin does isolate more
EMT-phenotype CTCs than EpCAM targeting and any
CEC can be readily distinguished. This indicates that
although CECs can be considerable for a few individuals,
when isolating CTCs by other than EpCAM-based meth-
ods, they play mostly a minor role especially if a study only
analyses CTC numbers.
Our study was aimed to improve immunomagnetic CTC
isolation by also targeting EMT-CTCs, and we confirmed
our isolation strategy in predominantly advanced disease
ovarian cancer patients. Our patient recruitment did not
require liquid biopsies at specific times during a patient’s
disease progression or with regard to timing before and
after treatment cycles. In our small heterogeneous cohort
used for method validation, we, therefore, did not observe
any obvious correlation of CTC counts with disease stage
or outcomes. We did, however, capture a larger number of
CTCs in a higher proportion of advanced ovarian cancer
patients by combined targeting of EpCAM and N-cadherin
for immunomagnetic isolation. Therefore, our data also
support the notion that ovarian cancer CTCs are more het-
erogeneous with regard to EMT status, which agrees with
the findings that emerging EMT-phenotype CTCs might be
associated with response to therapy.19.
In conclusion, we established a combined EpCAM and
N-cadherin immunomagnetic targeting strategy to improve
on the overall CTC isolation. We suggest that non-
EpCAM-based CTC isolation methods should employ a
quadruple staining method to avoid false positives. The
significance of detecting more and a wider range of CTC
phenotypes is that they are more likely to accurately rep-
resent the biology of a patient’s ovarian cancer at that point
in time, thus improving their value as potential tumor bio-
markers. Finally, our combined antibody targeting
approach may also be useful in improving CTC capture
in other cancer types.
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Abstract
Personalised medicine targeted to specific biomarkers such as BRAF and c-Kit has radically
improved the success of melanoma therapy. More recently, further advances have been
made using therapies targeting the immune response. In particular, therapies targeting the
PD-1/PD-L1 or CTLA-4 axes alone or in combination have shown more sustained responses
in 30–60% of patients. However, these therapies are associated with considerable toxicities
and useful biomarkers to predict responders and non-responders are slow to emerge. Here
we developed a reliable melanoma circulating tumor cell (CTC) detection method with PD-L1
evaluation on CTCs. A set of melanoma cell surface markers was tested as candidates for tar-
geted melanoma CTC isolation and a melanoma specific immunostaining-based CTC identifi-
cation protocol combined with PD-L1 detection was established. In vitro testing of the effect of
exposure to blood cells on melanoma cell PD-L1 expression was undertaken. Immunomag-
netic targeting isolated melanoma CTCs in up to 87.5% of stage IV melanoma patient blood
samples and 3 8.6% of these had some PD-L1 expressing CTCs. Our in vitro data demon-
strate PD-L1 induction on melanoma cells in the blood.This study established a robust, reli-
able method to isolate melanoma CTCs and detect expression of PD-L1 on these cells.
Introduction
Improved technology for the capture of circulating tumor cells (CTCs) is increasing the utility
of CTCs to predict prognosis and patient survival. CTCs are a non-invasive biosource for
molecular biomarker detection that can inform precision therapy and together with analysis of
circulating tumor nucleic acids (ctRNA and ctDNA) are emerging with high potential for
widespread clinical utility (reviewed by [1–3]).
One challenge for biomarker testing from common tissue biopsies is tumor heterogeneity.
It is now widely accepted that a single tissue biopsy is poorly representative for a patient’s can-
cer. This is particular relevant in advanced malignancies, where biopsies of the primary tumor
provide limited information at a time of therapy resistance and tumor progression [4]. CTCs
have been shown to accurately reflect tumor heterogeneity [5, 6]. Since blood draws can be
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performed repeatedly during disease progression, they are well suited to identifying emerging
resistance mechanisms and monitor treatment response. Blood biopsies offer the opportunity
to analyse both ctDNA and CTCs for biomarkers. ctDNA analysis is more sensitive for muta-
tion analysis and easier to perform; CTC analysis provides characterisation of cellular hetero-
geneity and cell specific expression of RNA or proteins [5, 7–10].
In keeping with this paradigm, CTC isolation should be efficient and include heterogenous
populations of cancer cells. Currently most carcinoma CTCs are isolated using capture and
identification methods targeted to the epithelial cells. However, these CTC detection strategies
cannot be utilized for certain malignancies including melanoma [11–14].
A challenge in melanoma is marked heterogeneity in gene expression leading to altered
expression of proteins targetable for CTC isolation or identification. Thus, targeting multiple
cell surface proteins for isolation and identification may be better suited for optimal melanoma
CTC detection [15, 16].
Systemic treatment of melanoma, has recently undergone revolutionary changes with the dis-
covery of predictive tumor biomarkers, such as BRAF, which predict the efficacy of targeted ther-
apy with small molecule inhibitors such as vemurafinib, or dabrafenib. Remarkable responses are
restricted to tumors with the relevant mutations and limited, with resistance inevitably develop-
ing with only 6–7 month progression free survival [17, 18]. More recently, immune checkpoint
inhibition (ICI) using antibodies directed at either the programmed cell death protein 1 (PD-1),
its ligand (PD-L1) or CTLA-4, alone or in combination, has dramatically improved the outcome
of metastatic melanoma. Approximately 30–60% of patients respond to drugs like nivolumab
alone or in combination with ipilimumab [19, 20]. Combination immunotherapy enhances
response rates but results in greater systemic toxicity. In the Checkmate 067 trial combining nivo-
lumab with ipilimumab resulted in 59% grade 3–4 toxicity compared with 21% nivolumab and
28% with ipilimumab alone [19]. Hence, it is highly important to develop mechanisms to identify
likely responders to these efficacious but toxic therapies. While expression of PD-L1 in the tumor
tissue is currently employed as biomarker for predicting patient response to PD-1 inhibition, it
remains controversial and is not part of routine testing in melanoma as significant proportions of
patients with PD-L1 negative melanomas have shown treatment response [21–23]. In addition,
testing for PD-L1 requires tumor samples, which should ideally be taken shortly before therapy
commencement and be longitudinally available to monitor changes and response. While this is
challenging for tumor tissue biopsies it is realistic for CTCs.
The aim of the current study is to demonstrate that screening PD-L1 from liquid biopsies
(CTCs) is feasible with the use of an efficient protocol to isolate melanoma CTCs. We also
present in vitro data suggesting that melanoma cell PD-L1 levels are increased when these cells
are in blood.
Materials and methods
Patients
Fourteen patients with stage IV metastatic melanoma were recruited from Liverpool and Wol-
longong Hospitals, Australia (Table 1). The study was undertaken with written patient consent
and approval of the South Western Sydney Biosafety Committee (HREC/13/LPOOL/158). Per
blood draw, 3x 9ml EDTA vacutube (Greiner Bio-One, Frickenhausen, Germany) blood sam-
ples were taken.
Cell lines
SkMel28, A375 (ATCC, in Vitro Technologies, Lane Cove West, Australia), 501mel (kindly
provided by Colin Goding), WMM1175 (kindly provided by Graham Mann), MelRM,
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NM176, MelMS (kindly provided by Peter Hersey) and M230 (kindly provided by Antony
Ribas) melanoma cells were maintained in DMEM / 10% FCS, WME-099 lymphocytes were
maintained in RPMI / 10% FCS at 37C with 5% CO2 enriched atmosphere (S1 Table). All cell
lines were small tandem repeat (STR) authenticated (AGRF, Melbourne, Australia).
Cell surface marker immunocytostaining on cultured cells
Melanoma cells were seeded at 3x104 cells per well in 12-well plates on sterile cover slips. 24h
post seeding attached cells were fixed and probed with primary antibody (S2 Table) and Alexa-
Fluor488 conjugated goat-anti-mouse secondary antibody (Life Technologies, Mulgrave, Austra-
lia, 1:3000) and mounted with Prolong Antifade containing DAPI (Invitrogen, Carlsbad, USA).
Flow cytometry
Approximately 5x104 cells were pelleted after detachment from tissue culture flasks using 0.2mM
EDTA in PBS to preserve cell surface proteins. Cells were washed with PBS, blocked with 10%
FCS/PBS and incubated with the relevant primary antibodies or matched IgG controls (S2 Table)
in 10% FCS/PBS. After PBS washes the cells were probed with AlexaFluor488 goat-anti-mouse
secondary antibody (1:3000, Life Technologies), washed once before suspension in 300μl PBS.
Cells were detected using a FACS-Canto II (Becton Dickinson, North Ryde, Australia).
Melanoma cell identification antibodies
Initial testing was performed by immunocytostaining as outlined above using the rabbit
derived antibodies against human Melan A (clone EP1422Y, LSBio, Seattle, USA, 1:300),
S100-β (clone EP1576Y, Abcam, Melbourne, Australia, 1:300) and Gp100 (clone Ep4863(2),
Abcam, 1:600) with secondary FITC anti rabbit antibody. Inclusion of healthy donor periph-
eral blood mononuclear cells (PBMCs) discounted antibody interactions with blood cells.
Table 1. Patient cohort.
Clinical Characteristic n %
Patient Median Age� 63 (47–88) 14 100
Gender
Male 9 64%
Female 5 36%
Stage IV subclass�
M1a/M1b 6 43%
M1c 7 50%
Unknown 1 7%
Prior Therapies
0–1 13 93%
�2 1 7%
Treatment #
ICI 10 71%
Targeted therapy (BRAF/MEK) 4 29%
Other/Unknown 1 7%
ICI = immune checkpoint inhibitors,
� at diagnosis,
# at time of CTC sample
https://doi.org/10.1371/journal.pone.0211866.t001
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Fluorescently conjugated anti-human GP100 [AlexaFluor488] (clone DT101/BC199/HMB4,
Novus Biologicals, Littleton, USA; 1:100), anti-human Melan-A [AlexaFluor488] (clone
SPM555, Novus Biologicals, 1:100), anti-human S100-β [FITC] (clone 4C4.9+S100B/1012,
Novus Biologicals, 1:500) were obtained for ease of CTC identification staining, throughout
the manuscript referred to as Mel-ID staining.
Spiking of cultured melanoma cells
Cultured cells were detached using 0.2mM EDTA in PBS, counted using a hemocytometer and
a suspension of 5x103 cells per ml was prepared. Cell concentration was confirmed by counting
cells in 4 independent 5 μl aliquots placed on a slide. 20 μl cell suspension was spotted on an
input control slide as well as independently spiked into 3 parallel 9 ml blood (or pre-enriched
PBMC) samples per healthy donor and cell line, followed by another input control slide. Input
control slides were air-dried and cells counted after Hoechst staining. Only experiments with
less than 5% deviation between first and second input control cell numbers were included in
the analysis with the input number defined as the average of both input control counts.
Melanoma cell isolation
Selected antibodies were conjugated to immunomagnetic beads (IsoFlux rare cell enrichment
kit, Fluxion, San Francisco, USA) according to the supplier’s instruction (S2 Table). Magnetic
beads conjugated to individual (30μl per sample) or a combination of antibodies (30μl each per
sample) were used to capture cultured melanoma cells spiked in defined numbers into 106
healthy donor PBMCs. Cells were recovered using the IsoFlux CTC isolation platform (Fluxion)
with the standard isolation protocol. After immunostaining for CTC (Mel-ID), CD45 (Alexa
Fluor 647 conjugated anti-CD45 clone HI30, Novus Biologicals; 1:200) and Hoechst (Fluxion),
imaging was performed using the IX71 fluorescent microscope (Olympus, Tokyo, Japan).
Immunodetection of melanoma CTCs
Melanoma CTCs from 3x9ml metastatic melanoma patient blood samples were captured in
the same way and first probed for CD45 and with the rabbit anti-human-PD-L1 PD-L1 anti-
body (clone: E1L3N, Cell Signalling Technology, Massachusetts, USA; 1:50), then with Alexa
Flour 555 conjugated goat-anti-rabbit secondary antibody (Life Technologies; 1:2000), fol-
lowed by permeablisation with 0.2% Triton X-100 and Mel-ID probing. Hoechst dye was
included in the mounting media.
PD-L1 modulation on melanoma cells in blood
MelRM, NM176 and SkMel28 cells were spiked into 3x 9ml blood samples from the same
blood draw of 3 (for MelRM) or 6 (for NM176 and SkMel28) healthy donors and on input
control slides as described above. Cells from blood samples were recovered by using combined
targeting of MCAM and MCSP for immunomagnetic “CTC” isolation after 0, 24 and 48 hour
storage at room temperature. Samples were stained as per immunodetection of melanoma
CTCs including PD-L1 detection. Cells were enumerated by fluorescent microscopy.
Results
Cell surface proteins for melanoma CTC isolation
We tested expression of a range of cell surface antigens on a cohort of eight heterogeneous
melanoma cell lines to identify possible targets for immunomagnetic cell isolation of mela-
noma CTCs (S1 Table).
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All but two c-Kit mutant cell lines expressed MCAM strongly on 70–100% of cells, irrespec-
tive of the anti-MCAM antibody used. MCSP expression was even more pronounced on the
melanoma cell lines. Five of eight cell lines expressed MCSP strongly in nearly 100% of the cell
populations. However, the BRAFV600E mutant 501mel cells, and both c-Kit mutant lines, were
MCSP negative (Fig 1). None of the other cell surface antigens remained convincing candi-
dates for cell isolation due to inadequate expression on the majority of cells. (S1 Fig).
Melanoma markers for CTC identification
The combination of three antibodies, anti-Melan A, -S100β and -Gp100 detected all melanoma
cell lines well (S3 Table) and showed negligible interaction with PBMCs. Directly fluorescently
conjugated antibodies against these markers confirmed adequate detection in representative
cell lines (Table 2).
Isolation of melanoma cells
Initially it was confirmed that both MCAM antibody clones (P1H12 and F4-35H7) behaved
similar in isolating MelRM from healthy donor PBMCs (Fig 2A). Comparison of melanoma
cell capture using anti-MCAM (clone P1H12), anti-MCSP (clone 9.2.27) revealed cells
expressing both proteins (SKMel28) were isolated with either antibody. Combining the two
antibodies for isolation improved cell recovery. Expectedly, 501mel cells, which do not express
MCSP, were only isolated by MCAM targeting (Fig 2B).
Fig 1. MCAM and MCSP are the dominant melanoma cell surface markers. (A) Representative FACS histograms and immunocytostaining for
MCAM and MCSP presented for MelRM (left panel) and 501mel (right panel) cells. (B) Compiled data for all indicated cell lines showing proportion of
cells expressing MCAM and MCSP as detected with the indicated antibodies, data and error bars are derived from three independent experiments.
Mean fluorescence (by FACS analysis) is included as a red bar and indicates the antigen expression level on positive cells.
https://doi.org/10.1371/journal.pone.0211866.g001
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Melanoma CTC detection from advanced melanoma patients
When comparing CTC isolation from three parallel 9ml blood samples per patient, immuno-
magnetic targeting of MCAM isolated melanoma CTCs from 62.5% (10/16), MCSP from
81.3% (13/16) and combined MCAM and MCSP targeting from 87.5% (14/16) of samples with
median CTC counts of 2.5, 9 and 16 respectively (Table 3 and Fig 2C).
Detection of PD-L1 on melanoma CTCs
As shown in Fig 3A, PD-L1 immunodetection is compatible with melanoma CTC identifica-
tion probing. Since tissue based cancer cell PD-L1 expression tends to be associated with
tumor infiltrating lymphocytes (TILs) [21, 24], we postulated that cancer cell exposure to lym-
phocytes in the blood, as is the case for CTCs, may trigger adaptive PD-L1 expression in mela-
noma CTCs.
MelRM and SKMel28 cells, known to be IFN-γ inducible for PD-L1 expression [25]
as well as NM176 melanoma cells without previously reported data regarding PD-L1
inducibility, were spiked into healthy donor blood and recovered using the melanoma CTC
isolation protocol after room temperature storage for 0, 24 or 48 hours. While for MelRM
longer delay until CTC isolation, as expected, reduced melanoma cell recovery, a higher
proportion of melanoma cells had detectable PD-L1 after storage. After 24 hours, average
cell recovery had dropped by about 50%, but the total number of PD-L1 positive cells had
increased and made up about a third of recovered MelRM cells. Although this increased to
approximately 50% by 48 hours, overall MelRM recovery was unacceptably low by then.
For SKMel28 and NM176 cells no PD-L1 was expressed at baseline, but was detected on
>10% of cells after 24 or 48 hours in blood. Interestingly for both these cell lines total cell
recovery seemed to slightly, but not significantly increase post 24, while only dropping
after 48 hours (Fig 3B).
Finally, we probed for PD-L1 on melanoma CTCs isolated from melanoma patients. For
this measure, CTCs, isolated using the various antibodies from the three parallel bloods, were
considered as one 27ml blood draw. PD-L1 positive CTCs were detected in 38.6% (5/13) of
CTC positive blood draws. In total 1.5–60% of detected CTCs were PD-L1 positive (range of
0–13) (Table 3).
Most of the patients analysed in this study were already on ICI treatment for various cycles
and the small, heterogeneous patient cohort, although sufficient for CTC isolation method val-
idation, showed no association of CTC or PD-L1+ CTC counts with clinical parameters,
including response, stable disease or disease progression (Table 3).
Table 2. Melanoma CTC identification marker detection in cell lines.
Cell Line Melan-A � S100β # GP100 � All
SkMel28 + +++ ++ +++
501Mel ++ +/- +++ +++
WMM1175 + +/- ++ ++
MelRM +/- ++ ++ ++
PBMCs - - - -
+++ very strong in all cells, ++ strong in�85% of cells, + clearly detectable in most cells, +/- clearly detectable in
�40% of cells, - undetectable
� AF488,
# FITC conjugated antibodies.
https://doi.org/10.1371/journal.pone.0211866.t002
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Fig 2. Immunomagnetic melanoma cell isolation. The indicated melanoma cells (n = 100) were spiked into pre-
enriched PBMCs in triplicate experiments and then recovered using immunomagnetic beads (Rare Cell Kit, Fluxion)
coupled to either (A) anti human MCAM antibody clone H1P12 or F4-35H7 or (B) to anti human MCAM antibody
clone H1P12 (αMCAM) or anti human MCSP antibody clone 9.2.27 (αMCSP) or with the combination of both. The
proportion of isolated melanoma cells is presented. (C) 14 advanced melanoma patients (16 blood draws, 3x9ml each)
were compared for CTC counts after αMCAM (H1P12) based, αMCSP (9.2.27) based or combination based CTC
isolation. CTC counts are graphed as box blot.
https://doi.org/10.1371/journal.pone.0211866.g002
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Discussion
Melanoma CTC isolation
The most comprehensive previous investigation of melanoma antigens suitable for immuno-
magnetic isolation of melanoma CTCs was reported by Freeman et al. Their study chose anti-
gens either relatively highly expressed on melanoma cells (MCAM and MCSP) or expressed
on subpopulations of melanoma cells proposed to be particularly aggressive and competent to
initiate metastasis (CD271 and ACBC5). Dynabeads mediated isolation was validated with one
melanoma cell line (A2058) known to express the relevant antigens, spiked into blood. Recov-
ery efficiency was 35% with either MCAM or MCSP antibodies, with no significant increase in
recovery rates by combining both antibodies. Nevertheless the authors suggest combination
might still be advantageous for heterogeneous patient samples [26].
Our study revisits the same antigens, but to potentially improve on melanoma CTC isola-
tion, tested three additional antibodies against cell surface proteins either commonly upregu-
lated during melanoma progression (N-cadherin), or promising antigens with common
membrane staining of melanoma cells (KBA.62, LHM3). To predict suitability as isolation tar-
get we analysed a cohort of eight melanoma cell lines with various genetic backgrounds and
phenotypes to account for heterogeneity.
Our data confirms heterogeneous levels of MCAM expression in 6 melanoma cell lines, which
is in keeping with MCAM expression in tissue of 68% of primary melanoma and 89% of mela-
noma lymph node metastases [27]. Very high detectable levels of MCSP were observed in 5 of 8
melanoma cell lines throughout the entire cell population, while the remaining 3 lines (501mel,
MelMs and M230) lacked detectable MCSP. Targeting MCAM alone has previously shown to
Table 3. Melanoma CTC counts and PD-L1 positive CTCs.
Isolation antibodies
Patient Gender Age# Stage# Therapy Status αMCAM (PD-L1+) αMCSP (PD-L1+) αMCAM / αMCSP (PD-L1+) combined
(27ml blood draw)
1 F 53 M1a Targeted N/A 13 (�) 0 (�) 17 (�) 30 (�)
2 M 47 M1c Immuno N/A 0 (�) 0 (�) 0 (�) 0 (�)
3 M 56 M1a Immuno PR 40 (0) 43 (2) 146 (0) 229 (2)
32 M 56 M1a Immuno PR 0 (0) 23 (0) 9 (0) 32 (0)
4 M 60 M1a Targeted CR 10 (2) 18 (1) 25 (10) 53 (13)
42 M 60 M1a ImmunoC CR 0 (0) 61 (0) 85 (0) 146 (0)
5 M 55 M1c Targeted N/A 2 (0) 8 (0) 15 (0) 25 (0)
6 F 62 M1c Immuno PR 0 (0) 5 (0) 4 (0) 9 (0)
7 F 70 M1c Immuno Prog 7 (0) 9 (0) 48 (0) 64 (0)
8 M 61 M1b Immuno PR 25 (0) 67 (1) 59 (0) 151 (1)
9 M 88 M1c Immuno S 26 (0) 8 (0) 49 (0) 83 (0)
10 F 64 M1c Immuno CR 10 (0) 18 (0) 9 (2) 37 (2)
11 M 78 M1a Targeted Prog 2 (0) 9 (0) 43 (0) 54 (0)
12 F 75 M1c Immuno Prog 0 (0) 0 (0) 0 (0) 0 (0)
13 M 85 M1a Immuno Prog 3 (0) 17 (0) 8 (0) 28 (0)
14 M 64 N/A N/A N/A 0 (0) 2 (1) 5 (3) 7 (4)
# At diagnosis, PR: partial response, CR complete response, Prog: progression, S: stable, N/A: data not available,
� no PD-L1 staining done,
Immuno: PD-1/PD-L1 inhibitor, ImmunoC: PD-1 combined with CTLA-4 inhibitor, superscript2: repeat sample at later treatment timepoint, αMCAM: anti MCAM
antibody [P1H12]; αMCSP: anti-MCSP antibody [9.2.27]
https://doi.org/10.1371/journal.pone.0211866.t003
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satisfactorily recover SkMel-28 melanoma cells (74–88% recovery) spiked into blood with the
CellSearch isolation platform. In those studies the anti-MCSP antibody clone we used here for
cell isolation, was not used for isolation but for identification of MCAM isolated CTCs [28, 29].
Sakaizawa et al targeted MCSP for melanoma CTC isolation with the efficiency tested on three
melanoma cell lines preselected to express MCSP (888mel, 928mel or MMG1). 1–24% recovery
was achieved when cells were spiked into blood of healthy donors [30]. Our data confirms that
combined targeting of both MCAM and MCSP for melanoma CTC isolation using the IsoFlux
CTC isolation platform improves cell isolation from cultured cells and patient blood samples.
Our cultured cell isolation data also suggests that from patients with “501mel-like” CTCs,
MCAM targeting would isolate CTCs. However, if in this instance relying on MCSP probing for
identification, these CTCs would be missed. Importantly, in our hands the anti-MCAM antibody
clone (F4-35H7) used in the CellSearch studies was similarly effective in binding melanoma cells
(FACS, immunostaining and spiked cell isolation) as the more readily commercially available
clone P1H12. Therefore we relied on the latter to isolate melanoma CTCs from patient blood.
Fig 3. PD-L1 on melanoma CTCs. (A) Representative melanoma CTC identification staining with PD-L1 detection of
a patient derived CTC surrounded by lymphocytes. (B) MelRM, NM176 or SKMel28 cells were spiked into blood
samples of healthy donors and isolated immediately or after room temperature blood storage for the indicated time
before recovery using our melanoma CTC isolation and immunostaining protocol including PD-L1 probing. Data
from three to six experiments (different healthy donors) were analysed per cell line. Mel-ID: probed with cocktail of
three fluorescently conjugated melanoma identification antibodies.
https://doi.org/10.1371/journal.pone.0211866.g003
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Our small patient cohort includes two patients with CTCs that behaved like 501mel cells as
they were not (patient 1) or relatively poorly (patient 9) isolated by MCSP but well by MCAM
targeting (Table 3). More patient samples showed the opposite with higher CTC counts found
with MCSP compared with MCAM based isolation. These findings support our melanoma CTC
isolation strategy and combined targeting of MCAM and MCSP. This is in line with our study
detecting CTCs in 87.5% of stage IV patients, while a recent study reported detection of mela-
noma CTCs in 42% of stage IV patients using the CellSearch strategy [31]. It should however be
noted, that the combination of both antibodies not always increased CTC counts. Previously
published work in ovarian cancer suggests that the presence of magnetic beads conjugated to an
antibody against an antigen of minor abundance may interfere with optimum isolation of CTCs
lacking the antigen [32]. Hence, use of multiple isolation antibodies for immunomagnetic cell
capture, especially targeting relatively rare markers, needs careful consideration.
Regarding the other potential targets, we tested for immunomagnetic melanoma CTC isola-
tion: N-cadherin positivity correlated with MCSP detection for all cell lines. This is not surpris-
ing since MCSP is proposed to induce epithelial to mesenchymal (EMT) like changes in
melanoma cells and N-cadherin is an important EMT marker [33]. However, in all cases, a sig-
nificantly lower proportion of cells (25–75%) interacted with the anti-N-cadherin antibody.
Thus, although we successfully validated this antibody for isolation of EMT-CTCs from ovar-
ian cancer patients, we disregarded it for melanoma CTC isolation in favour of the anti-MCSP
antibody [32]. All tested antibodies, other than anti-MCAM and anti-MCSP, failed as relevant
isolation tools for melanoma cells due to poor interaction with melanoma cells. Although
some of the correlating target cell surface markers may still be expressed in some melanoma
cells, since our data supports careful rationalisation of isolation antibodies, we consider target-
ing both MCAM and MCSP is the most viable immunomagnetic melanoma CTC isolation
strategy. This is supported by other studies identifying MCAM and MCSP as dominating mel-
anoma cell surface proteins [16].
Interestingly, disregarding marginal MCAM and LHM3 expression, both tested c-Kit
mutant cell lines (MelMS and M230) were, negative for all the tested cell surface markers. This
finding suggests that isolation of CTCs from c-Kit mutant melanoma patients may need fur-
ther refinement. This should be kept in mind when managing patients with acral or mucosal
melanomas, which have significantly higher rates of c-Kit mutation [34]. Isolation of mela-
noma CTCs using size-based spiral microfluidics may provide an alternative, but it is limited
to cells larger than average blood cells [6].
Detection of PD-L1 on CTCs
There is some debate regarding PD-L1 antibodies as certain antibody clones are less reliable, and
others are recommended for companion diagnostics and PD-L1 detection [35]. We chose the
anti-human PD-L1 rabbit monoclonal antibody (clone E1L3N), because PD-L1 positivity in tis-
sue detected with this antibody correlates well with other anti-PD-L1 antibodies [35–37]. This
antibody was also previously successfully used for PD-L1 probing in bladder cancer CTCs [38].
Although PD-L1 expression in melanomas correlates with good response to PD-1 inhibi-
tory therapy it is not strictly required with a significant proportion of patients responding to
ICI despite the lack of detectable PD-L1 in their tumor tissue [21–23]. Since PD-L1 expression
in tumor tissue appears to be induced by TILs, it has been proposed that this so called adapt-
able PD-L1 expression in tumor cells could be the key to its value as a therapy response bio-
marker and adaptable PD-L1 might be missed in TIL deficient tumors [21, 35]. As predicted,
our data suggest that melanoma cells in blood can show increased PD-L1 expression. Interest-
ingly, for both BRAF mutant cell lines, recovered cell numbers did not decline but slightly
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increase after 24 hour storage in blood at room temperature. This might be due to effects of
blood based cytokine exposure on levels of MCAM and MCSP expression, in turn improving
cell isolation, combined with effective protection from anoikis by oncogenic BRAF signalling
[39]. Regardless, induction of PD-L1 on melanoma cells in the blood implies that PD-L1
screening of CTCs may detect adaptable PD-L1 even when the tumor tissue exhibits no or low
counts of TILs. Whether such adaptable PD-L1 on CTCs correlates with ICI response needs to
be tested in suitable patient cohorts.
Unfortunately, for our proof of concept study to validate the effectiveness of our MCAM
and MCSP based melanoma CTC isolation method, we had predominantly access to blood
draws of patients already on ICI therapy. Nevertheless, we found overall 38.6% (5/13) of
patients whose blood draws were probed for PD-L1 had some PD-L1 positive CTCs with the
proportion of PD-L1 positive CTCs varying between 1.5–60%. Interestingly, although the
patient cohort size is too small for any firm conclusions, there appears to be an association of
PD-L1 positivity with the isolation of CTCs by targeting MCSP either alone or in combination
with MCAM. This does highlight that different targeting indeed captures different populations
of melanoma CTCs. If this MCSP-PD-L1 association can be confirmed in a larger patient
cohort, it would be interesting to study the mechanism of presenting these two antigens
together and the implication for melanoma cell recognition by immune cells.
Ideally PD-L1 assaying in CTCs should be done prior as well as during the course of treat-
ment to evaluate their value as predictive biomarker. One would expect a higher proportion of
PD-L1 positive CTCs before commencement of treatment as these cells should loose protec-
tion upon PD-1/PD-L1 inhibition and be rapidly targeted by blood based immune cells upon
therapy. However, in melanoma tissue there is evidence that ISI causes increase of PD-L1
expression [40] and with CTCs being regularly replenished from tumour tissue, testing of
PD-L1 on CTCs longitudinally during therapy is needed to fully understand the relationship.
Nevertheless, our PD-L1 detection on CTCs is similar to studies in other cancers. A breast
cancer study using the mouse monoclonal antibody 130021 to detected PD-L1 found 69% (11/
16) hormone sensitive breast cancer patients positive for CTCs (defined as�1 CTCs per 7.5ml
blood, CellSearch) of those 72% (8/11) had PD-L1 positive CTCs with a range of 0.2–100% being
PD-L1 positive [41]. With the same antibody in a non small cell lung cancer (NSCLC) study, at
baseline 80% (20/25) of patients had 1–20 CTCs (Cellsearch) and of those 95% (19/20) had some
CTCs with detectable PD-L1 ranging from 25–100% of the CTCs [42]. A study into PD-L1 detec-
tion on bladder cancer CTCs used the same antibody clone (E1L3N) we employed in our study.
That study found CTCs in 80% of patient samples and PD-L1 positive CTCs in 35% of CTC pos-
itive patient samples. Proportion of PD-L1 positive CTCs varied between 0.9–67% [38].
Two of the mentioned studies, appraised the correlation of presence of PD-L1 positive CTC
detection and ICI therapy response. In the NSCLC study by Nicolazzo et al. patient attrition
meant that only 10 patients were analysed at 6 month into nivolumab treatment. There was a
trend towards worse response with retention of PD-L1 positive CTCs at this time point. PD-L1
CTC detection at baseline was not response related. This was consistent with the finding that
some tissue PD-L1 positive NSCLC patients were not responding to ICI [42]. Anantharaman
et al’s study assessed the relationship between PD-L1 on CTCs and ICI response in only four
bladder cancer patients finding progressive disease on ICI regardless of CTC PD-L1 status [38].
To our knowledge, there are no melanoma studies investigating the relationship of the pres-
ence of PD-L1 on CTCs and response to PD-1 inhibitor therapy. This is despite the widespread
and expanding use of PD-1 inhibitor in melanoma therapy, currently without testing a clini-
cally approved biomarker to predict response. More comprehensive studies are required to
delineate whether PD-L1 detection on CTCs could be a suitable biomarker of ICI therapy out-
comes in melanoma.
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Conclusion
We were able to develop an efficient isolation and identification protocol for melanoma CTCs
which included PD-L1 detection on CTCs. Our in vitro data suggest that CTCs with adaptable
PD-L1 may increase PD-L1 expression in the blood. Whether that makes CTCs a good bio-
source to screen for PD-L1 and how levels of PD-L1 on melanoma CTCs, measureable with
this relatively fast and easy detection assay, correlate to patient response needs to be investi-
gated in larger scale studies.
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